Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Surgical implant or material

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

424422000 - Implant or insert

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424426000 Errodable, resorbable, or dissolving 213
424424000 Membrane or diffusion barrier 68
Entries
DocumentTitleDate
20110177151IMPLANTABLE MATERIAL AND A METHOD FOR THE PREPARATION THEREOF - A method for the preparation of a regenerated silk fibroin solution comprises the steps of: treating silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C.; and subsequently degumming the treated silk or silk cocoons; or alternatively, degumming silk or silk cocoons; and subsequently treating the degummed silk or silk cocoons with an ionic reagent comprising an aqueous solution of monovalent cations and monovalent anions, the cations and anions having ionic radii of at least 1.05 Angstroms and a Jones-Dole B coefficient of between −0.001 and −0.05 at 25° C. The invention also extends to fibroin solution, a fibroin material and an implant useful for cartilage repair.07-21-2011
20090004242Coatings and Biomedical Implants Formed From Keratin Biomaterials - Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.01-01-2009
20090214615LAYER - BY - LAYER STEREOCOMPLEXED POLYMERS AS DRUG DEPOT CARRIERS OR COATINGS IN MEDICAL DEVICES - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and atherosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned.08-27-2009
20090123519Swellable hydrogel matrix and methods - The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a macromer and photo-polymer combination. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area.05-14-2009
20090123516DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS - Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.05-14-2009
20090123515POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY - A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.05-14-2009
20090123514Electropolymerizable Monomers and Polymeric Coatings on Implantable Devices Prepared Therefrom - Conductive surfaces of e.g., implantable devices, coated with electropolymerized polymers having active substances attached thereto are disclosed. Electropolymerizable monomers designed and used for obtaining such conductive surfaces and processes, devices and methods for attaching the electropolymerized polymers to conductive surfaces are also disclosed. The polymers, processes and devices presented herein can be beneficially used in the preparation of implantable medical devices.05-14-2009
20090123513Antimicrobial Biguanide Metal Complexes - A compound comprising a metal species and a biologically acceptable ligand, wherein the biologically acceptable ligand comprises a biguanide moiety, and wherein the biologically acceptable ligand forms a complex with the metal species in which the metal species is stabilised in an oxidation state greater than 1+. Compositions and medical devices comprising the compound. A method for the treatment or prophylaxis of microbial, including bacterial, infections, comprising the use of such compounds, compositions or medical devices.05-14-2009
20090123512Quorum Sensing Modulators - Compounds described herein are useful in modulating bacterial quorum sensing.05-14-2009
20100119573ENDOTHELIUM MIMICKING NANOMATRIX - Disclosed herein are peptide amphiphiles for use in producing a natural endothelium mimicking nanomatrix. The disclosed natural endothelium mimicking nanomatrix can be used to coat medical devices such as vascular stents to promote endothelializaiton and inhibit restenosis and thrombosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.05-13-2010
20100119580SUSTAINED RELEASE DRUG DELIVERY DEVICES, METHODS OF USE, AND METHODS OF MANUFACTURING THEREOF - A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.05-13-2010
20090196903DRUG DELIVERY DEVICES, KITS AND METHODS THEREFOR - Implantable drug delivery devices, and kits and methods incorporating them are described. The devices may, for example, be configured for implantation into an ocular region of a subject. The drug delivery devices may comprise multiple, selectively-triggerable drug reservoirs for administration of sequential or concomitant drug regimens. Some variations of devices may comprise one or more reservoirs that may be triggered by an optical stimulus, e.g., light having a wavelength within a certain wavelength range. The devices, methods, and kits may be useful in the treatment chronic ocular conditions, such as age-related macular degeneration.08-06-2009
20090196902BIOGENERATOR CONSTRUCTED USING LIVE CELL CULTURES - An apparatus (or a biogenerator) is disclosed which utilizes the electrochemical polarization of epithelial cells to generate electricity. The apparatus employs living cells to convert chemical energy into electricity. The biogenerator is capable of supplying electricity to other devices continuously for extended periods of time. Because the apparatus may be made sufficiently small for implantation into the body of an animal or a human, such an apparatus is particularly useful for powering devices that require implantation into the host body.08-06-2009
20090196899Controlled Alloy Stent - A method of manufacturing a stent includes determining a porosity characteristic and combining at least two predetermined alloy constituents based on the porosity characteristic. The method further determines a solidification profile based on the porosity characteristic and combined alloy constituents and solidifies the combined alloy constituents based on the solidification profile. In addition, the method includes forming a stent framework from the solidified alloy constituents, removing at least a portion of at least one of the alloy constituents, and forming pores within the stent framework based on the removal and consistent with the porosity characteristic.08-06-2009
20110182961OSTEOGENIC CELL DELIVERY MATRIX - Compositions and methods for augmenting bone formation by administering isolated human mesenchymal stem cells (hMSCs) within a matrix provided. By adding calcium and/or phosphate ions to the matrix, one may foster greater bone regeneration.07-28-2011
20090130169STERILIZING COMPOSITIONS COMPRISING PHOSPHORS FOR CONVERTING ELECTROMAGNETIC RADIATION TO UVC RADIATION AND METHODS FOR USING THE SAME - There is disclosed a composition for converting electromagnetic energy to ultraviolet C (UVC) radiation or radiation of a shorter wavelength, the composition comprising at least one phosphor capable of converting an initial electromagnetic energy (A) to an electromagnetic energy (B) comprising UVC radiation or radiation of a shorter wavelength, and an organic or inorganic media containing said phosphor. There is also a method of sterilizing an article by exposing it to UVC radiation or radiation of a shorter wavelength for a time sufficient to deactivate or kill at least one microorganism and/or for a time sufficient to inhibit abnormal cell growth within the body, when said composition is in an implantable medical device. A method of coating an article with such compositions is also disclosed.05-21-2009
20100129414Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment - Described herein are methods for treating aneurysms, vascular occlusions, and vascular lesions. The methods comprise the use of an implantable medical device which includes a bioactive agent substrate associated with its surface. Liposomes are used to encapsulate the bioactive agent and are delivered either systemically or locally to the bloodstream. A means for liberating the bioactive agents from the liposomes is used once an appropriate location is chosen and the liposomes have distributed themselves through the vasculature. Once liberated, the bioactive agent can be sequestered by the bioactive agent substrate associated with the implantable medical device, and slowly released to impart a therapeutic effect on the surrounding tissues.05-27-2010
20080260797METHODS OF TREATING DISEASE WITH NITRIC OXIDE (NO)-RELEASING POLYMERS AND SOLUBLE NO-RELEASING NITROSAMINES - The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release of NO for the treatment of diseases and disorders associated with NO-deficiency, wherein the treatment includes systemic or local administration of the NO-releasing polymers or the low molecular weight NO-releasing compounds.10-23-2008
20080260796REDUCTION OF INFECTION ASSOCIATED WITH MEDICAL DEVICE - Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.10-23-2008
20080260794COLLAGEN PRODUCTS AND METHODS FOR PRODUCING COLLAGEN PRODUCTS - Medical implants and methods for forming a medical implant blends a dispersion of human collagen fibers and/or threads and optionally a volume between about 2 to about 15% of an alcohol and forms medical implants by removing a liquid component of the collagen dispersion. Medical implants formed include collagen films, coatings, threads, patches, tubes, plugs, scaffolds, injectable collagen, and collagen for in vitro applications.10-23-2008
20090022773POROUS AND BIOCOMPATIBLE CARRIER MATERIAL FOR TREATING BONE AND/OR CARTILAGE DEFECTS - A porous and biocompatible carrier material for treating bone and/or cartilage defects, including a collagen of animal origin that has an active substance complex.01-22-2009
20100092538Nucleic Acids Encoding Spider Glue Proteins and Methods of Use Thereof - Nucleic acids encoding spider glue proteins and methods of use thereof are disclosed.04-15-2010
20100055146CYCLIC ANGIOTENSIN ANALOGS - The invention relates to analogs of angiotensins, in particular to cyclised analogs having Ang(1-8) agonistic or antagonistic activity and to cyclised Ang(1-7) analogs with agonistic or antagonistic activity and displaying improved proteolytic resistance compared to their linear counterparts. Provided is a cyclic angiotensin peptide analog comprising a thioether-bridge linkage between the amino acids corresponding to positions Tyr03-04-2010
20100034863Delivery Devices Containing Encapsulated and/or Particle-Bound Active Pharmaceutical Ingredients - Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.02-11-2010
20100086578FISTULA PLUG COMPRISING ECM - The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell morphology and distribution.04-08-2010
20110195107METHOD FOR MANUFACTURING A POROUS THREE-DIMENSIONAL SCAFFOLD USING POWDER FROM ANIMAL TISSUE, AND POROUS THREE-DIMENSIONAL SCAFFOLD MANUFACTURED BY SAME - The present invention provides a method for manufacturing a porous three-dimensional scaffold using animal tissue powder, comprising powdering an animal-derived tissue, decellularizing the animal-derived tissue before or after powdering it, or simultaneously with powdering it, and forming the decellularized animal-derived tissue powder into a porous three-dimensional scaffold by a particle leaching method.08-11-2011
20110195106Decorin and Gliosis and Related System and Method - Brain stimulators are used to treat a variety of disorders, and their range of uses continues expand. However, one problem with long-term stimulation of neural tissue is the need to increase the stimulation parameters to continue to maintain the same clinical effect. This is thought to be due to local tissue reaction to the implanted foreign body. Because the implanted stimulator functions by means of contact with functional cells within the tissue, prevention of tissue reaction to the stimulator would make a significant improvement to the device's performance and longevity.08-11-2011
20090191254INHIBITION OF BIOFILM FORMATION USING BACTERIOPHAGE - Disclosed herein are indwelling medical devices suitable for introduction into the body of a subject, wherein the indwelling medical devices comprise one or more surfaces on which a bacterial biofilm can form, and an effective amount of a bacteriophage composition carried by one or more of the surfaces, wherein the bacteriophage composition inhibits formation of the bacterial biofilm on the indwelling medical device. Also disclosed herein are methods of inhibiting the formation of bacterial biofilms on indwelling medical devices.07-30-2009
20090191253Use of K-252a and Kinase Inhibitors for the Prevention or Treatment of HMGB1-Associated Pathologies - The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis. 07-30-2009
20100150981SUSTAINED RELEASE SYSTEMS OF ASCORBIC ACID PHOSPHATE - A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention.06-17-2010
20100158978BIOACTIVE SPRAY COATING COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF - Described herein are spray coating compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods.06-24-2010
20090214617IMMOBILISATION AND STABILISATION OF VIRUS - The present invention relates to a method for immobilization and optional stabilization of viruses whilst retaining the viral biological activity and the use of immobilized virus in therapy. In particular, the immobilized virus relates to immobilized bacteriophage and their use as an antibiotic or bacteriostatic agent and in the treatment of antibiotic-resistant infections.08-27-2009
20080317811Treatment of Cancer Using Tlr3 Agonists - The present invention relates generally to the fields of genetics and medicine. More specifically, the present invention relates to improved methods of treating cancers using a TLR3 agonist, by assessing the expression of TLR3 receptor by cancer cells.12-25-2008
20090280155Coating systems for the controlled delivery of hydrophilic bioactive agents - Described are coating systems for the controlled delivery of hydrophilic bioactive agents, for example, from implantable medical devices. The coating systems of the invention comprise (a) a polymeric basecoat layer containing one or more hydrophilic bioactive agents; and (b) an elution-controlling topcoat layer that comprises a poly(ethylene-co-vinyl acetate) copolymer. The elution rate of the hydrophilic bioactive agent can be controlled by varying the vinyl acetate concentration in the elution-controlling topcoat layer.11-12-2009
20090238852METHODS FOR CONTROLLING INTRACELLULAR CALCIUM LEVELS ASSOCIATED WITH AN ISCHEMIC EVENT - Described herein are methods for controlling the intracellular calcium concentration in a subject prior to experiencing an ischemic event, while experiencing an ischemic event, or while suffering from ischemia. The methods comprise administering an effective amount of O-desulfated heparin to the subject. The methods described herein are also useful in treating the symptoms associated with ischemic events or ischemia.09-24-2009
20090060970Compositions and methods of administering paclitaxel with other drugs using medical devices - Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.03-05-2009
20100074940LINEAR POLYESTERAMIDES FROM AMINOPHENOLIC ESTERS - The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by03-25-2010
20100074938IMMOBILISED BIOLOGICAL ENTITIES - There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which entity is covalently attached to said surface through a link comprising a 1,2,3-triazole.03-25-2010
20100074937POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS - An aromatic polyanhydride comprising a repeating unit having the structure03-25-2010
20100074939HARMINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.03-25-2010
20100074936Repair of larynx, trachea, and other fibrocartilaginous tissues - Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.03-25-2010
20100129418METHOD OF INDUCING NEGATIVE CHEMOTAXIS USING AN ELLAGITANNIN OR GALLOTANNIN - The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of an ellagitannin and a gallotannin. In one embodiment, the compound is ellagic acid or a pharmaceutically acceptable salt thereof.05-27-2010
20100136083Metal Implants - An implant with a metal structure for use in a surgical procedure, in which at least part of the metal structure is coated with a biocompatible metal such as titanium by plasma spraying of the metal powder. Biocidal metal cations are then absorbed by ion exchange into the coating, so that after being implanted the biocidal ions gradually leach out into the surrounding body fluids and suppress infection. The ion exchange properties of the coating may be modified by pretreatment with dilute phosphoric acid.06-03-2010
20080311169Composition Comprising Ginsenosides for Treating or Preventing Angiostenosis and Restenosis - The present invention relates to use of ginsenoside Rg3, Rg5 or Rk1, or extract of ginseng, red ginseng or processed ginseng comprising the ginsenosides; a composition for preventing or treating angiostenosis and restenosis comprising the ginsenosides or extracts; a method for preventing or treating angiostenosis and restenosis by administrating the ginsenosides or extracts comprising the ginsenosides; and a preparation method of agents for preventing or treating angiostenosis and restenosis. The present composition can effectively prevent or treat angiostenosis and restenosis.12-18-2008
20080206304Medical devices having polymeric regions based on styrene-isobutylene copolymers - According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes a styrene monomer and an isobutylene monomer. Moreover, the styrene monomer content of the copolymer typically ranges from 25 to 50 mol %.08-28-2008
20100098740METHOD OF CONTROLLING A DRUG RELEASE RATE - A method of controlling the drug release rate of a drug coated endovascular stent by depositing a drug material layer on the stent and then modifying the drug material using gas cluster ion beam irradiation to create a carbon matrix with interstices containing the original drug. The rate at which the drug elutes through the interstices can be controlled by processing parameters. Multiple layers may be employed to create time varying release rates.04-22-2010
20100098741METHOD OF INCORPORATING CARBON NANOTUBES IN A MEDICAL APPLIANCE, A CARBON NANOTUBE MEDICAL APPLIANCE, AND A MEDICAL APPLIANCE COATED USING CARBON NANOTUBE TECHNOLOGY - A method of coating an article is provided. The method includes: preparing a solution including a bioactive agent and a carbon nanotube precursor; treating the solution to form carbon nanotubes; and applying the solution to the article. A method of producing a medical device is provided. The method includes: forming a core of the medical device with a pattern on a surface of the core and assembling a multi-walled carbon nanotube array on the pattern on the surface. The pattern on the surface may determine an orientation of the multi-walled carbon nanotube array. A method of manufacturing a medical appliance is provided. The method includes creating a mixture of a carbon nanotube precursor and a polymer and injecting the mixture into a mold. The mold forms the mixture into a shape of the medical appliance. A method of forming a nanotube tissue scaffold is provided. The method includes forming a nanotube precursor and treating the nanotube precursor to form the nanotube tissue scaffold. The nanotube tissue scaffold is electrically conductive.04-22-2010
20100112031Compositions And Methods For Regulating Extracellular Matrix Production In Adipose Derived Cells - The present application provides compositions and methods for regulating ECM production in ASCs and for isolating and using the various ECM molecules. The present application further provides methods for inducing various growth factors, cytokines and stem cell markers.05-06-2010
20100112030ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE - The present invention provides methods and related compositions for treating or preventing cardiovascular diseases, including, e.g., atherosclerosis, using an oxysterol. In addition, the present invention provides novel methods and related compositions for treating or preventing cardiovascular diseases, including, e.g., atherosclerosis, using a hedgehog protein, or a biologically active fragment or variant thereof.05-06-2010
20100322994PARTICULATE CARTILAGE SYSTEM - The present invention is directed to compositions having at least one neocartilage particle, juvenile cartilage particle or a combination thereof and a matrix, and methods and devices that include the compositions.12-23-2010
20100150983OUTER LAYER HAVING ENTANGLEMENT OF HYDROPHOBIC POLYMER HOST AND HYDROPHILIC POLYMER GUEST - An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation. Intermingling may be performed by producing a mixture of guest and host (whether in solution, powdered, granular, etc., form); next, a crosslinking of the guest with itself is performed; then, the mixture is molded into the outer layer.06-17-2010
20090155334IMPLANT FOR TISSUE ENGINEERING - The invention provides a process for the production of a monolithic implant for use in tissue engineering, the process comprising the steps of plasticising at least one biocompatible material into a paste, extruding the paste through a die, and drying the extruded material to eliminate an aqueous and/or non-aqueous component. The invention also relates to a monolithic implant as thereby manufactured, and the use of such an implant as a scaffold for tissue-engineering and as a transplant tissue in reconstructive or replacement surgery.06-18-2009
20090155333Dermis-Derived Cells for Tissue Engineering Applications - Methods for inducing differentiation of dermis-derived cells to serve as a source of chondrocytes and associated methods of use in forming tissue engineered constructs. One example of a method is a method for inducing differentiation of cells into chondrocytes comprising providing aggrecan sensitive isolated dermis cells and seeding the cells onto an aggrecan coated surface.06-18-2009
20090155336NEUROMODULATORY METHODS FOR TREATING PULMONARY DISORDERS - A method for treating a pulmonary disorder in a subject includes inserting a therapy delivery device into a vessel of the subject, advancing the therapy delivery device to a point adjacent an intraluminal target site of the autonomic nervous system, and activating the therapy delivery device to delivery a therapy signal to the intraluminal target site to treat the pulmonary disorder. The intraluminal target site is in electrical communication with nervous tissue selected from the group consisting of a spinal nerve, a postganglionic fiber of a spinal nerve, a sympathetic chain ganglion, a thoracic sympathetic chain ganglion, a cervical ganglion, a lower cervical ganglion, an inferior cervical ganglion, an intramural ganglion, a splanchnic nerve, an esophageal plexus, a cardiac plexus, a pulmonary plexus, an anterior pulmonary plexus, a posterior pulmonary plexus, a celiac plexus, a hypogastric plexus, an inferior mesenteric ganglion, a celiac ganglion, and a superior mesenteric ganglion.06-18-2009
20100104617GRAFT PROSTHESIS, MATERIALS AND METHODS - A graft prostheses (04-29-2010
20100104618POLYMER-BASED SURGICALLY IMPLANTABLE HALOPERIDOL DELIVERY SYSTEMS AND METHODS FOR THEIR PRODUCTION AND USE - Surgically implantable drug delivery systems for long-term delivery of haloperidol containing a biodegradable polymer and haloperidol fabricated into the surgically implantable drug delivery systems via solvent casting and compression molding are provided. Also provided are methods for producing the surgically implantable drug delivery systems and methods for using these systems in the treatment of psychotic disorders such as schizophrenia.04-29-2010
20090155332REPLACEMENT BONE TISSUE - Bone replacement tissue suitable for bone grafting procedures, said bone replacement tissue being grown in a host until suitable for translocation into a desired position in a patient, and methods for manufacturing said bone replacement tissue.06-18-2009
20100040661Materials and methods for cell growth - Nanopatterned surfaces which provide for improved cell growth including improved stem cell differentiation. The patterned surfaces can comprise an array of fields of biologically active moieties and can be controlled by parameters which include the pitch between the fields and the size of the fields. Nanopatterning can be carried out with use of dip pen nanolithographic printing, microcontact printing, and nanoimprint lithography.02-18-2010
20100040665METHOD FOR OBTAINING THREE-DIMENSIONAL STRUCTURES FOR TISSUE ENGINEERING - The present invention belongs to the field of tissue engineering and specifically relates to a method for obtaining three-dimensional structures for tissue engineering and to the structures obtained by said method. The invention also relates to an ex vivo method for regenerating a tissue using the three-dimensional structures of the invention and to the use of the structures thus treated for their transplanting to the area to be regenerated of the patient.02-18-2010
20100040664AABB-POLY(DEPSIPEPTIDE) BIODEGRADABLE POLYMERS AND METHODS OF USE - The invention provides AABB-poly(depsipeptide)s (AABB-PDPs), a class of biodegradable polymers composed of α-amino and α-hydroxy acids with material properties suitable for biomedical applications. These AABB-PDPs belong to the family of amino acid-based poly(ester amide)s (PEAs), which are characterized by the presence of alternating ester and amide functionalities. Containing four ether groups per basic unit, these polymers degrade rapidly by biotic or abiotic hydrolytic action to release dispersed bioactive agents at a controlled delivery rate, are non-toxic, produce digestible breakdown products, and are easy to fabricate by solution polycondensation.02-18-2010
20100040663Arterial Implants - The technology described herein generally relates to the field of tissue engineering and treatment of cardiovascular disease by endovascular repair. The technology more particularly relates to devices and methods to produce a tissue-based implant that can be used for abdominal aorta aneurysm, thoracic aorta aneurysm, or other cardiovascular repair.02-18-2010
20100040660DEVELOPMENT OF A TISSUE - ENGINEERED SCAFFOLD FOR NERVE REGENERATION USING A BIOCOMPATIBLE AND INJECTABLE HYDROGEL - The present invention relates to a tissue-engineered scaffold prepared by using a biocompatible and injectable hydrogel, and particularly to a tissue-engineered scaffold capable of regenerating or recovering an injured spinal nerve for central nervous system after being implanted to connect neurons, prepared by combining an adult stem cell or a nerve cell with a physiologically active material on tissue-engineered carriers comprising biocompatible and temperature-sensitive polyethylene glycol/polyester block copolymer or biocompatible and injectable hydrogel made of small intestinal submucosa tissue powder with sol-gel phase transition behavior.02-18-2010
20100143442GROWTH FACTOR COMPLEXES AND MODULATION OF CELL MIGRATION AND GROWTH - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.06-10-2010
20100143438BIOMOLECULES - A substrate is provided having a biomolecule immobilised thereon, wherein the biomolecule is connected via an enzyme-cleavable link to a blocking moiety such that cleavage of the link causes removal of the blocking moiety and activation of the biomolecule.06-10-2010
20090098184PROCESSES AND SYSTEMS FOR LOADING MEDICAL IMPLANTS WITH SIMULATIVE GROWTH AGENTS - Methods and systems for providing an improved apparatus and packaging system to more expeditiously hydrate or reconstitute medical grafts and to effectively and uniformly seed the medical grafts with biological components and cells. The systems generally comprise a container comprising entry port, at least one substrate cavity, and top, side and bottom walls defining an inner surface. The entry port is configured to receive the biological solution. The cavity is in communication with the entry port and includes the porous substrate maintained under negative pressure. The container volume is substantially the same as a volume of the porous substrate. The side and bottom walls are configured to promote a laminar flow of the biological solution received through the entry port.04-16-2009
20100092537SURGICAL IMPLANT COMPOSITE MATERIALS AND KITS AND METHODS OF MANUFACTURE - A surgical implant composite material comprises a surgical implant substrate and a thin film coating deposited on the substrate, the thin film coating comprising TiO04-15-2010
20090317446Calcium Phosphate Nanofibers - Calcium-phosphate nanofiber matrices comprising randomly dispersed crystalline calcium-phosphate nanofibers are provided. The nanofibers are synthesized using sol-gel methods combined with electrospinning. The nanofibers may be hollow, solid or may comprise a calcium-phosphate shell surrounding a polymer containing inner core to which biologically functional additives may be added. The nanofiber matrices may be used to culture bone and dental cells, and as implants to treat bone, dental or periodontal diseases and defects.12-24-2009
20090053283Compositions And Methods For Treating Diseases - This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.02-26-2009
20130089594MACROPOROUS BIOENGINEERED SCAFFOLDS FOR CELL TRANSPLANTATION - The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.04-11-2013
20100003300INJECTABLE DELIVERY OF MICROPARTICLES AND COMPOSITIONS THEREFORE - Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation.01-07-2010
20080305147Drug Delivery System For The Prevention Of Cerebral Vasospasm - The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.12-11-2008
20090324672Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices For Controlled Release Of A Protein Or Peptide And A Hydrophobic Drug - This invention is generally related to coatings for implantable medical devices, such as drug delivery vascular stents. The coating includes a drug reservoir layer above the outer surface of the device body, the drug reservoir layer with a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons. A preferred polymer is a poly(ester amide) polymer.12-31-2009
20090311302HYDROPHILIZED ANTIMICROBIAL POLYMERS - A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing.12-17-2009
20090311298Antimicrobial Collagenous Constructs - Bioengineered collagen constructs with antimicrobial properties are provided. The bioengineered collagen constructs comprise a sheet-like layer of purified collagenous tissue matrix derived from a tissue source, such as the tunica submucosa of small intestine or a processed intestinal collagen layer derived from the tunica submucosa of small intestine, treated with an antimicrobial agent. The constructs are biocompatible. The present invention has a variety of applications, including wound dressing and surgical repair devices. Methods for treating a damaged or diseased soft tissue are provided. Methods for treating a wound in need of care and treatment are also disclosed.12-17-2009
20090304773SURGICAL ADHESIVE AND USES THEREFORE - The present invention provides a liquid polymer composition which can be implanted into a living mammal and which forms a solid hydrogel by in situ polymerization upon contact with body fluid and tissue. The composition also can be used as a coating on a medical device, or for the formation of a medical device. Formation of a solid implant or coating involves crosslinking of the adhesive with itself and with surrounding tissue. The liquid implant, by itself or in conjunction with various prostheses, can be used for many purposed, including fixation of the urethra for providing treatment for incontinence, and repair of herniations in the abdominal cavity, including rectocele, cystocele, enterocele, and inguinal hernia. The adhesive may be used to establish adhesion prevention during such repairs, in part by coating or being the material of a repair mesh.12-10-2009
20090304771Local Delivery System for the Chemotherapeutic Drug Paclitaxel - The present invention provides methods for producing a semi-degradable polymeric composite drug delivery device for localized delivery of chemotherapeutic agents to be used in conjunction with total vertebral body replacement surgery that requires placement of a vertebral replacement cage for the treatment of a spinal neoplasm.12-10-2009
20090304772IMPLANTABLE MATERIALS HAVING ENGINEERED SURFACES AND METHOD OF MAKING SAME - Implantable materials having engineered surfaces and method of making same comprising geometric features on at least one surface of the material having at least one of chemical, physiochemical and electrochemical activity different than regions of the at least one surface without the features.12-10-2009
20090304770POLYMER - A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y—B—X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerised form a polymer with a Tg lower than the Tg of a homopolymer of monomer (I) and lower than the Tg of a homopolymer of monomer (ii); and a monomer having a crosslinkable group is described. The invention also relates to a method for producing such polymers, implants coated with the polymers and methods for forming the same.12-10-2009
20090304767Bio-Degradable Block Co-Polymers for Controlled Release - A block or graft copolymer includes a first block, and a second block different from the first block, wherein the first block is a poly(lactide-glycolide) copolymer. The polymers may be formulated in compositions with drug components for use in coating medical devices such as stents. Different blocks of the block or graft copolymer degrade in the body at different rates. The drug release profile from the coating is a combination the individual release rates of the different blocks and so can be controlled by controlling the selection and relative amounts of the respective blocks.12-10-2009
20090304766LOCALIZED DELIVERY OF DRUG COMBINATIONS - Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non-antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed.12-10-2009
20090304768Gastro-Retentive System for the Delivery of Macromolecules - The present invention provides a gastro-retentive delivery assembly (GRDA) comprising a folded multi-layered device comprising a macromolecule-containing compartment bordered by enveloping layers and one or more enforcing strips, the device being adapted to unfold when in a subject's stomach, whereupon unfolding, the macromolecule is released from said device via at least one aperture in an enveloping layer. The invention also provides a method for gastroretentive delivery of macromolecules via the GRDA of the invention; a method of preparing the GRDA of the invention as well as a method for treating a subject for a pathological condition, making use of the GRDA of the invention.12-10-2009
20090304769METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OF RESTENOSIS - Agents that inhibit or prevent restenosis are identified by assaying test agents in a battery of assays to measure the effect of the test agent on cell proliferation, thrombosis, tissue modeling, and inflammation. Treatment for restenosis is provided using compositions of the invention.12-10-2009
20090304765R-RAS ACTIVITY IN VASCULAR REGULATION - The invention provides means and methods for vascular regulation through enhancement or inhibition of R-Ras activity. The invention specifically provides means and methods for promoting a quiescent state of a vascular cell by providing additional R-Ras activity to the cell. The invention further provides means and methods for diagnosing a condition of vasculature of an individual.12-10-2009
20090304764Bone Regeneration Element for Stabilising Artificial Tooth Roots - A bone regeneration element for stabilizing artificial tooth roots (12-10-2009
20090041825Cell culture well-plates having inverted colloidal crystal scaffolds - An artificial bone marrow construct comprising a substrate having at least one well; a three dimensional biocompatible polymer matrix comprising a transparent polymer network containing microspherical voids, wherein the microspherical voids are each connected to at least one other void through inter-connecting pores; at least one LBL coating on a surface of at least one of the polymer network, voids and pores, a population of bone marrow cells comprising stem cells and stromal cells; and at least one bioactive agent. An artificial immune network comprising a polymer matrix with a population of immune cells comprising B-cells and T-cells is disclosed. Methods for testing the toxicity of drugs and other agents against bone marrow cells and methods for making universal blood using the artificial bone marrow constructs are also disclosed.02-12-2009
20090041824METHOD AND APPARATUS FOR COMPOSITE DRUG DELIVERY MEDICAL DEVICES - A medical device and method for drug delivery employing a 3-dimensional pattern of a polymer support material (e.g., that is degradable after implant in a body), a drug associated with the polymer support material, and an adhesive that adheres the polymer support material and associated drug to body tissue. The adhesive may persist to maintain the device in a suitable position for a suitable time (e.g., until after the polymer support material begins to degrade to release the drug), and the drug may be arranged in discrete areas of the 3-dimensional pattern that are separated from each other. The pattern may be produced in whole or in part before deployment at a body site, or may be produced in whole or in part directly at a tissue surface.02-12-2009
20110008407COATING AND COATING METHOD - The present invention discloses a coating for a medical implant, wherein at least a part of said coating contains an osseointegration agent and the same and/or a different part of the coating contains an antimicrobial metal agent.01-13-2011
20130071463IMPLANTS FOR POSTOPERATIVE PAIN - Medical implants and methods useful in treating postoperative pain are described. The implants comprise one or more electrospun drug-loaded fibers, which fibers comprise a drug useful in the treatment of pain. The implants are implanted at sites of interest including joint capsules, bones, and subcutaneous spaces, and are secured with tissue flaps or fasteners.03-21-2013
20090092653REPAIR AND REGENERATION OF RENAL TISSUE USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.04-09-2009
20090092652Method for the inhibition of angiogenesis or cancer using protective antigen related molecules - The present invention is based on the discovery that protective antigen related molecules (PARMs) without anthrax lethal factor have antiangiogenic or anticancer properties. The invention is directed to a method of inhibiting an angiogenic disease/disorder or cancer. Additionally, the invention can be applied to those at risk for developing cancer or an angiogenic disease/disorder comprising administering to a mammal an angiogenesis-inhibiting or cancer inhibiting amount of an PARM (including analogs, or derivative thereof having angiogenesis-inhibiting or anticancer activity, consisting of PA, PA fragment, analog, or derivative that is administered in a composition substantially free of anthrax lethal factor or other toxins).04-09-2009
20110038913Polymeric endoprostheses with modified erosion rates and methods of manufacture - An erodible prosthesis comprising alternate rates of erosion is disclosed, wherein said alternate rates of erosion can be selectively initiated. Some embodiments according to the invention may comprise an agent for initiating an alternative rate of erosion, such as, for example, a sensitizer, dissolution inhibitor, photo-acid generator, biochemically active additive, thermally activated catalyst, light activated catalyst, electromagnetic radiation activated catalyst, hydration activated catalyst, pH activated catalyst, low melting agent, and/or enzyme activated catalyst. One or more of the foregoing agents may be dispersed within one or more layers.02-17-2011
20110059152AUGMENTATION OF ORGAN FUNCTION - The present invention provides methods and compositions for augmenting organ functions using small-scale matrix implants generated by seeding tissue-specific or undifferentiated cells onto a matrix materials (e.g., a wafer, sponge, or hydrogel). The seeded matrix composition can then be implanted and will develop into an organ-supplementing structure in vivo. Continued growth and differentiation of the seeded cells on the implanted matrix results in the formation of a primitive vascular system in the tissue. The primitive vascular system can then develop into a mature vascular system, and can also support the growth and development of additional cultured cell populations. The seeded matrix system can be used to introduce a variety of different cells and tissues in vivo.03-10-2011
20100172953Biopolymer Based Implantable Degradable Devices - Implantable degradable devices for tissue repair or reconstruction comprising biopolymers, as well as to methods of manufacture and use thereof. The implantable device is formed by the application of pressure and the device may include up to about 65% by weight of water, based on the total weight of the implantable degradable fastening device. Methods for making implantable, degradable devices from biopolymers by application of pressure are also disclosed. The invention provides the ability to customize the device in various ways to influence properties such as mechanical strength, degradation rate and swellability.07-08-2010
20100015203BIOCOMPATIBLE FIBRINOGEN MATRIX ON A SOLID SUPPORT - The present invention provides a non-clottable matrix on a solid support comprising immobilized and crosslinked fibrinogen. The matrix may further comprise, in and/or on the matrix, one or several biologically active compound(s) and/or pharmacological substance(s). The matrix may be composed of one or several fibrinogen layer(s). The solid support according to the present invention may be selected from the group consisting of orthopaedic devices, implants, stitches, stents, pins, screws, plates, and sutures.01-21-2010
20110014266EXPANDABLE, POROUS APATITE/COLLAGEN COMPOSITE, AND ITS PRODUCTION METHOD - A expandable porous body constituted by a compressed apatite/collagen composite, which expands by water absorption, and a method for producing an expandable, porous apatite/collagen composite, which expands by water absorption, comprising the steps of freezing a porous apatite/collagen composite impregnated with a liquid in a compressed state, and drying it.01-20-2011
20110014263Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.01-20-2011
20090297582VASCULAR OCCLUSION DEVICES AND METHODS - A device for in situ treatment of vascular or cerebral aneurysms comprises an occlusion device having a flexible, longitudinally extending elastomeric matrix member that assumes a non-linear shape to conformally fill a targeted site. The occlusion device comprises a flexible, longitudinally extending elastomeric matrix member, wherein the device assumes a non-linear shape capable of fully, substantially, or partially conformally filling a targeted vascular site. In one embodiment the vascular occlusion device comprises a first longitudinally extending structural element having a longitudinally extending lumen and an outer surface; a second longitudinally extending structural element extending through the lumen; and an elastomeric matrix member surrounding the outer surface, wherein the second structural member does not engage or attach to the first structural element or the elastomeric matrix.12-03-2009
20090017092Novel Class of Cell-Interactive Material and Process of Preparation of Artificial Tissues of Human and Animal Origin - An artificial extra cellular matrix product and artificial human and animal tissue product comprising tissue specific cells.01-15-2009
20090269387COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells.10-29-2009
20090269385COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells.10-29-2009
20090269388ALLOGRAFT BONE COMPOSITION HAVING A GELATIN BINDER - The invention is directed toward an osteoimplant for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing composition of demineralized allograft bone material mixed with an aqueous phosphate buffered gelatin which when lyophilized to remove water from the composition crosslinks the gelatin to form a solid structure and when rehydrated is flexible10-29-2009
20090269386COMPOSITE IMPLANTS FOR PROMOTING BONE REGENERATION AND AUGMENTATION AND METHODS FOR THEIR PREPARATION AND USE - Collagen based matrices cross-linked by a reducing sugar(s) are used for preparing composite matrices, implants and scaffolds. The composite matrices may have at least two layers including reducing sugar cross-linked collagen matrices of different densities. The composite matrices may be used in bone regeneration and/or augmentation applications. Scaffolds including glycated and/or reducing sugar cross-linked collagen exhibit improved support for cell proliferation and/or growth and/or differentiation. The denser collagen matrix of the composite matrices may have a dual effect initially functioning as a cell barrier and later functioning as an ossification supporting layer. The composite matrices, implants and scaffolds may be prepared using different collagen types and collagen mixtures and by cross-linking the collagen(s) using a reducing sugar or a mixture of reducing sugars. The composite matrices, implants and scaffolds may include additives and/or living cells.10-29-2009
20090269384BIOACTIVE THERMOGELLING POLYMER SYSTEMS AND METHODS OF THEIR USE - Hydrogels comprising poly(N-alkylacrylamide), poly(alkyleneglyco)di-acrylate or methacrylate, cross-linking agent, a source of calcium ions, and water are described, as well as methods of their preparation and use.10-29-2009
20090087472CONTROLLED RELEASE OF BIOPHARMACEUTICAL GROWTH FACTORS FROM HYDROXYAPATITE COATING ON BIORESORBABLE INTERFERENCE SCREWS USED IN CRUCIATE LIGAMENT RECONSTRUCTION SURGERY - Controlled release of biopharmaceutical growth factors from a hydroxyapatite coating on a bioresorbable interference screw used in cruciate ligament reconstruction surgery on a human. Biologically active scaffolds, such as interference bone screws used for ligament fixation, made by growing calcium phosphate-based hydroxyapatite coatings on bioresorbable poly(α-hydroxy ester) scaffolds that provide controlled mineral dissolution and controlled release of bone morphogenetic protein-2. The biologically active scaffold provides improved bioavailability of BMP-2 growth factor that in turn provides enhanced graft-bone healing in the tibial bone tunnel. The coating method uses surface hydrolysis and modified simulated body fluid incubation which does not require solvent or heat and is conducted at room temperature.04-02-2009
20090074834METHOD AND SYSTEM FOR MODIFYING THE WETTABILITY CHARACTERISTICS OF A SURFACE OF A MEDICAL DEVICE BY THE APPLICATION OF GAS CLUSTER ION BEAM TECHNOLOGY AND MEDICAL DEVICES MADE THEREBY - Irradiation of a surface of a material with a gas cluster ion beam modifies the wettability of the surface. The wettability may be increased or decreased dependent on the characteristics of the gas cluster ion beam. Improvements in wettability of a surface by the invention exceed those obtained by conventional plasma cleaning or etching. The improvements may be applied to surfaces of medical devices, such as vascular stents for example, and may be used to enable better wetting of medical device surfaces with liquid drugs in preparation for adhesion of the drug to the device surfaces. A mask may be used to limit processing to a portion of the surface. Medical devices formed by using the methods of the invention are disclosed.03-19-2009
20090060977DEVICES, SYSTEMS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER CONDITIONS - Devices, systems and methods for compressing, cutting, incising, reconfiguring, remodeling, attaching, repositioning, supporting, dislocating or altering the composition of tissues or anatomical structures to alter their positional or force relationship to other tissues or anatomical structures. In some applications, the invention may be used to used to improve patency or fluid flow through a body lumen or cavity (e.g., to limit constriction of the urethra by an enlarged prostate gland).03-05-2009
20080286327THOMBOLYSIS AND CHRONIC ANTICOAGULATION THERAPY - Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a stroke, and a pulmonary embolism, programming the stimulator with the one or more stimulation parameters, delivering with the stimulator via the catheter at least one drug to at least one tissue in accordance with the one or more stimulation parameters, and limiting perfusion of the at least one tissue by delivering electrical stimulation with the stimulator via the at least one electrode to the at least one tissue.11-20-2008
20090246247COMPOSITE ENTEROCYSTOPLASTY - The present invention relates to methods for tissue augmentation or regeneration. More specifically, the present invention provides for a composite enterocystoplasty procedure using a biocompatible scaffold and minced autologous tissue for implantation in a mammalian bladder.10-01-2009
20110020419OSTEOINDUCTIVE CALCIUM PHOSPHATES - The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 μm, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 μm, and having a surface area percentage of micropores in a range of 10-40%.01-27-2011
20090238854PLASTICIZERS FOR COATING COMPOSITIONS - A biocompatible plasticizer useful for forming a coating composition with a biocompatible polymer is provided. The coating composition may also include a biobeneficial polymer and/or a bioactive agent. The coating composition can form a coating on an implantable device. The implantable device can be used to treat or prevent a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.09-24-2009
20090238853Hybrid Biomedical Device Fabricated From Biomaterials and Coated With a Natural Extra Cellular Matrix (ECM) Coating - The present invention relates to a hybrid biomedical device formed from a prefabricated biomedical device and coated with an extracellular matrix coating which is produced by directly culturing mammalian cells on the prefabricated biomedical device. The purposes of applying such an ECM coating is to regulate the biological and cellular responses of a living tissue or a cellular environment that the hybrid biomedical device is intended to interact with. The ECM coating will provide necessary biological cues, biomechanical cues, structural cues, etc to regulate the biological and cellular responses of a living system. The invention further provides methods of making the hybrid biomedical device.09-24-2009
20090232869Filamentous Embolization Device With Expansible Elements - An embolization device for occluding a body cavity includes one or more elongated, expansible, hydrophilic embolizing elements non-releasably carried along the length of an elongated filamentous carrier that is preferably made of a very thin, highly flexible filament or microcoil of nickel/titanium alloy. At least one expansile embolizing element is non-releasably attached to the carrier. A first embodiment includes a plurality of embolizing elements fixed to the carrier at spaced-apart intervals along its length. In second, third and fourth embodiments, an elongate, continuous, coaxial embolizing element is non-releasably fixed to the exterior surface of the carrier, extending along a substantial portion of the length of the carrier proximally from a distal tip, and optionally includes a lumenal reservoir for delivery of therapeutic agents. Exemplary methods for making these devices include skewering and molding the embolizing elements. In any of the embodiments, the embolizing elements may be made of a hydrophilic, macroporous, polymeric, hydrogel foam material. In the second, third and fourth embodiments, the elongate embolizing element is preferably made of a porous, environmentally-sensitive, expansile hydrogel, which can optionally be made biodegradable and/or bioresorbable, having a rate of expansion that changes in response to a change in an environmental parameter, such as the pH or temperature of the environment.09-17-2009
20090232868Nitric Oxide Releasing Polymer Composition - Disclosed herein are biocompatible carbon-based nitric oxide (NO) donating polymers suitable for forming and coating medical devices. These polymers have acrylate backbones and are comprised of substantially hydrophobic monomers. The NO donating polymers are carbon based wherein the diazeniumdiolate group is attached to the acetate group on an acetate based monomer. Incorporating a vinyl acetate monomer into an acrylate based polymer allows diazeniumdiolation of a polymer that would otherwise not accommodate the diazeniumdiolate group.09-17-2009
20090232867Modified conductive surfaces having active substances attached thereto - Novel processes for coating metal surfaces and/or for attaching active substances to metal surfaces, objects having coated metal surfaces and/or active substances attached thereto and uses thereof in the preparation of implantable devices are disclosed.09-17-2009
20090324677POLYMER CONJUGATES OF BOX-A OF HMGB1 AND BOX-A VARIANTS OF HMGB1 - The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.12-31-2009
20090258053MEDICAL STENT PROVIDED WITH A COMBINATION OF MELATONIN AND PACLITAXEL - A stent provided with a composition comprising melatonin and paclitaxel is described. The described stent is useful in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.10-15-2009
20090047322Degradable Hydrophilic Block Copolymers with Improved Biocompatibility for Soft Tissue Regeneration - The present application discloses biodegradable polymers, to porous and other materials comprising such polymers, and to various medical uses of such materials, including use as a scaffold for supporting cell adhesion or the in-growth for regeneration of tissue. The polymer is of the formula A—O—(CHR02-19-2009
20090047320Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions - A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range from about five to seven days. Tests conducted on laboratory rats established that the method reduced the incidences of adhesions from 100 percent (100%) in a test model to near zero percent (0%) in the treated animals. In an alternative embodiment, Andrographalide was delivered through a drug pump with similar results. In still another embodiment, an effective amount of Rapamune was delivered, via a pump, into the abdominal cavity, again with similar results.02-19-2009
20090047319Pharmaceutical composition for obstructive vascular disease - Provided is the excellent prevention or treatment of a vascular occlusive disease such as vascular restenosis. A pharmaceutical composition for a obstructive vascular disease comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference and a collagen molecule. The use of the nucleic acid construct capable of inhibiting the expression of an MK protein through RNA interference in the presence of the collagen molecule can provide an excellent inhibitory effect on the thickened vascular intima.02-19-2009
20090263450ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY DISEASES - Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease.10-22-2009
20090274739METHODS AND COMPOSITIONS FOR TREATING NEOINTIMAL HYPERPLASIA - The present invention relates to compositions containing an mTOR inhibitor, such as rapamycin or a rapamycin derivative, in combination with a PI3 kinase inhibitor and/or a leptin inhibitor, intraluminal devices configured to release such compositions, and methods for the treatment and/or prevention of intimal hyperplasia, vascular stenosis and/or restenosis comprising delivery of such compositions or intraluminal devices to subjects in need thereof. The compositions, intraluminal devices, and methods of the invention are particularly well-suited for the treatment or prevention of vascular stenosis and restenosis in obese and diabetic subjects.11-05-2009
20100040662Fixation Devices For Tissue Repair - Fixation devices for tissue repair, for example sutures, surgical arrows, staples, darts, bolts, screws, buttons, anchors, nails, rivets, or barbed devices comprise at least one of angiogenic material; angiogenic precursor material which is capable of breaking down in vivo to form angiogenic material; or tissue-engineered material, which tissue-engineered material is capable of producing angiogenic material. In a preferred form, the material is incorporated into a polymer matrix having predetermined hydrophobicity to allow controlled release of angiogenic materials such as butyric or hydroxybutyric acid or salts thereof. Polymer matrix compositions comprising angiogenic materials and methods for tissue repair are also provided.02-18-2010
20120114730COMPOSITIONS AND METHODS FOR TREATING PRECOCIOUS PUBERTY - The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).05-10-2012
20120114729SILICONE-PEROXIDE COMPOSITIONS FOR LONG-TERM, CONTROLLED OXYGEN RELEASE - A composite for delivering extended-release of oxygen is disclosed. The composite can include a biocompatible polymeric support having a plurality of solid peroxide particles suspended therein. The polymer support can exhibit an oxygen tension value of at least 40 mmHg for a period of 14 days. The weight ratio of biocompatible polymeric support to solid peroxide particles can range from 1:1 to 99:1. Also disclosed is a method of using the composite to deliver oxygen to cells in both in vivo and in vitro environments.05-10-2012
20090010989Coating For Implants and Implants With Improved Osteointegration, and Manufacturing Method - A coating on an implant, said implant being intended for implantation in/on an implantation area, is provided. The coating comprises nitric oxide (NO) for obtaining an anti-viral, anti-fungal, and anti-bacterial effect, and for promotion of osteo-integration of the implant, bone healing, bone growth, and wound healing at said implantation area. A nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of a therapeutic dosage of nitric oxide (NO). An implant and a kit of implants, comprising said coating are also provided. Furthermore, a manufacturing method for the implant is disclosed.01-08-2009
20090010988COMPOSITION OF BONE FORMATION WITH PHSRN-RGD CONTAINING OLIGOPEPTIDE - A PHSRN-RGD-containing oligopeptide and a composition for promoting bone formation, which contains such oligopeptide as an effective ingredient. The oligopeptide promotes osteoblastic cell adhesion and differentiation and enhances bone regenerative ability, so that the inventive oligopeptide can be effectively used in regenerative treatment of bone tissue and periodontal tissue.01-08-2009
20090010987Methods and Devices for Reducing Tissue Damage After Ischemic Injury - Methods and devices are provided for the local delivery of anti-ischemic agents which reduce myocardial tissue damage due to ischemia or reperfusion, in combination with compounds that sensitize the response of the tissue to the anti-ischemic agent. The therapeutic agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the tissue.01-08-2009
20080305142Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof - The invention provides an improved cell free amplification method capable of producing large quantities of therapeutic-quality nucleic acids and methods of using the synthesized nucleic acid in research, therapeutic and other applications—The methods combine several different state-of-the-art procedures and coordinate their applications to affordably synthesize nucleic acids for therapeutic purposes. It combines in vitro rolling circle amplification, high fidelity polymerases, high affinity primers, and streamlined template specifically designed for particular applications. For expression purposes, the templates contain an expression cassette including a eukaryotic promoter, the coding sequence for the gene of interest, and a eukaryotic termination sequence. Following amplification, concatamers are subsequently processed according to their intended use and may include: restriction enzyme digestion for the production of short expression cassettes (SECs); ligation steps to circularize the SEC (CNAs); and/or supercoiling steps to produce sCNAs. The final product contains nearly non-detectable levels of bacterial endotoxin.12-11-2008
20080305141Freeze-thaw method for modifying stent coating - Methods are disclosed for controlling the morphology and the release-rate of active agent from a coating layer for medical devices comprising a polymer matrix and one or more active agents. The methods comprise exposing a wet or dry coating to a freeze-thaw cycle. The coating layer can be used for controlled delivery of an active agent or a combination of active agents.12-11-2008
20080305140Long-Term Delivery Formulations and Methods of Use Thereof - The present invention provides a method, a kit and compositions for long-term release of a drug at a constant therapeutically effective level for nervous system disorders where adherence to therapeutic regimen is problematic. In particular, to the therapy of psychotic disorders.12-11-2008
20120237586MATERIAL FOR INDUCTION OF HARD TISSUE REGENERATION - The present invention relates to a material for induction of hard tissue regeneration, comprising platelet-rich plasma and gelatin β-TCP sponge, which promotes angiogenesis, osteogenesis, chondrogenesis and the like.09-20-2012
20120237585Adhesive Composition For Carrying Therapeutic Agents As Delivery Vehicle On Coatings Applied To Vascular Grafts - Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site. Methods of forming the adhesive and making the coated vascular grafts are also disclosed.09-20-2012
20100021524PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.01-28-2010
20080248085METHOD OF TISSUE VASCULARIZATION - Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The methods are useful for vascularizing tissue with a compromised blood supply, particularly cardiac tissue with a compromised blood supply due to heart attack or congestive heart failure.10-09-2008
20090010990Process for depositing calcium phosphate therapeutic coatings with controlled release rates and a prosthesis coated via the process - A method of coating a substrate wherein the crystallinity of a calcium phosphate substance in a coating material is controlled, the calcium phosphate substance is loaded with a therapeutic agent, and the loaded calcium phosphate is deposited onto at least a portion of the substrate.01-08-2009
20090191255BMP-1 PROCOLLAGEN C-PROTEINASE FOR DIAGNOSIS AND TREATMENT OF BONE AND SOFT TISSUE DEFECTS AND DISORDERS - Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.07-30-2009
20090098185Method for treating thrombotic disorders using sulfated polysaccharides - Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.04-16-2009
20100112032Bone/Polyurethane Composites and Methods Thereof - Present inventions present composites of bone particles and polyurethane(s), as well as methods of making such composite and uses thereof. A porous composite comprises a plurality of bone particles; and polyurethanes with which the bone particles are combined. To prepare a porous composite, a composition comprise a plurality of bone particles, polyurethane precursors including polyisocyanate prepolymers and polyols, water and catalyst. A composition is either naturally moldable and/or injectable, or it can be made moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shape implantation site while at the same time being settable to provide the mechanical strength for most orthopedic applications.05-06-2010
20080274159DRUG FORMULATIONS FOR COATING MEDICAL DEVICES - The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.11-06-2008
20090004241POLYMER NANOFILM COATINGS - Disclosed herein are nanofilm coatings for implantable medical devices comprising a diblock or triblock copolymer (PEO-PMMA or PMOXA-PDMS-PMOXA, respectively). Such nanofilms, may be used, for example, as amphiphilic supports for therapeutic agents. These materials are conducive towards the formation of active substrates for a suite of biological and medical applications.01-01-2009
20090155335NON-LEACHING NON-FOULING ANTIMICROBIAL COATINGS - Compositions containing one or more types of membrane-targeting antimicrobial agents immobilized on a substrate with activity in relevant biological environments, and methods of making and using thereof, are described herein. The antimicrobial agents retain their activity in the presence of blood proteins and/or in vivo due to improved molecular structures which allow for cooperative action of immobilized agents and hydrophilic chemistries which resist non-specific protein adsorption. Suitable molecular structures include branched structures, such as dendrimers and randomly branched polymers. The molecule structures may also include hydrophilic tethers which provide both flexibility and resistance to non-specific protein adsorption. The membrane targeting antimicrobial agent coatings can be applied to a variety of different types of substrates including medical implants such as vascular grafts, orthopedic devices, dialysis access grafts, and catheters; surgical tools, surgical garments; and bandages. The substrates can be composed of metallic materials, ceramics, polymers, fibers, inert materials such as silicon, and combinations thereof. The compositions described herein are substantially non-leaching, resistant to non-specific protein adsorption, and non-hemolytic.06-18-2009
20090022771BIOMATERIAL - A process for the preparation of a composite biomaterial comprising an inorganic material and an organic material, the process comprising: (a) providing a first slurry composition comprising a liquid carrier, an inorganic material and an organic material; (b) providing a mould for the slurry; (c) depositing the slurry in the mould; (d) cooling the slurry deposited in the mould to a temperature at which the liquid carrier transforms into a plurality of solid crystals or particles; (e) removing at least some of the plurality of solid crystals or particles by sublimation and/or evaporation to leave a porous composite material comprising an inorganic material and an organic material; and (f) removing the material from the mould.01-22-2009
20110142904Methods for the In Situ Treatment of Bone Cancer - The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.06-16-2011
20110020422Hydroxyapatite-Targeting Poly(ethylene glycol) and Related Polymers - Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.01-27-2011
20110117170Controlled Release of Growth Factors and Signaling Molecules for Promoting Angiogenesis - The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purposed promoting angiogenesis in target tissues.05-19-2011
20110280921ANTIBACTERIAL HYDROGEL AND USE THEREOF IN ORTHOPEDICS - The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.11-17-2011
20100183698METHODS FOR PRODUCING BIOMATERIALS WITH VARIABLE STIFFNESS - This invention relates to the production of biomaterials with variable stiffness by subjecting a gel which varies in at least one dimension to plastic compaction. These biomaterials may be useful, for example, for the directional control or guidance of cells within tissue equivalent implants.07-22-2010
20090081273Medical Devices and Methods Including Polymers Having Biologically Active Agents Therein - Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.03-26-2009
20090148492METHOD OF MAKING A VASCULAR CLOSURE DEVICE - A method of making a biocompatible, implantable medical device, including a vascular closure device is disclosed. The method includes forming a biocompatible polymer into at least one fiber and randomly orienting the at least one fiber into a fibrous structure having at least one interstitial spaces. Polymeric materials may be utilized to fabricate any of these devices. The polymeric materials may include additives such as drugs or other bioactive agents as well as antibacterial agents. In such instances, at least one agent, in therapeutic dosage, is incorporated into at least one of the fibrous structure and the at least one fiber.06-11-2009
20100266656Splittable Elastomeric Drug Delivery Device - A system for treating a vascular condition including a catheter and a splittable elastomeric drug delivery device. The splittable elastomeric drug delivery device includes a balloon disposed on the catheter. The balloon includes a first elastic layer and a second elastic layer. A therapeutic agent layer is disposed on at least a portion of the first elastic layer, and the second elastic layer is disposed on the first elastic layer and the therapeutic agent layer. The first elastic layer has a first elongation-at-break percentage and the second elastic layer has a second elongation-at-break percentage.10-21-2010
20080268014Furoxan Compounds, Compositions and Methods of Use - The invention provides novel furoxan compounds, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for (a) treating cardiovascular diseases; (b) inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device; (c) treating pathological conditions resulting from abnormal cell proliferation; (d) treating transplantation rejections, (e) treating autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; (f) reducing scar tissue or for inhibiting wound contraction; (g) treating diseases resulting from oxidative stress; (h) treating endothelial dysfunctions; and (j) treating diseases caused by endothelial dysfunctions.10-30-2008
20090068247BIOCOMPATIBLE DEVICES COATED WITH A TRIBONECTIN AND METHODS FOR THEIR PRODUCTION - The present invention features biocompatible devices having a surface thereof coated with a composition that includes a tribonectin, and methods of making the devices. The tribonectin may, e.g., reduce microbial growth on or attachment to the surface of the biocompatible device.03-12-2009
20100291178Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue of bone - Methods and apparatuses are provided for musculoskeletal tissue engineering. For example, a scaffold apparatus is provided which comprises microspheres of selected sizes and/or composition. The microspheres are layered to have a gradient of microsphere sizes and/or compositions. The scaffold provides a functional interface between multiple tissue types.11-18-2010
20090208551Biological implantation material and method for preparing same - The present invention relates to a biological implantation material and method of preparing the same, which comprises the steps of:08-20-2009
20110081398MULTI-MECHANISM SURGICAL COMPOSITIONS - The present disclosure provides hydrogel compositions having multiple gelation mechanisms. The composition includes at least one component which forms a hydrogel, in combination with a second component which includes a self-assembling peptide capable of forming a self-assembled macromer.04-07-2011
20110111006CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS - This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.05-12-2011
20100266658Osteogenic Implants with Combined Implant Materials and Methods for Same - Described are osteogenic implants that include a first implant material covered at least in part by a second implant material carrying an osteogenic protein such as a bone morphogenic protein. The first implant material can comprise a mineral and provide an inner scaffolding portion for supporting bone ingrowth, and the second implant material can comprise a collagen or other sponge carrier covering the first implant material and having a liquid osteogenic protein formulation imbibed therein. Related implant materials and methods of preparation and use constitute additional aspects of the invention.10-21-2010
20100055145STENT COATINGS FOR REDUCING LATE STENT THROMBOSIS - Devices and methods relate to drug-eluting stents and coatings, thereof, for reduced late stent thrombosis are described.03-04-2010
20090148494EGFR INHIBITORS PROMOTE AXON REGENERATION - Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.06-11-2009
20090169596DEVICE FOR SPINAL CORD NERVE REGENERATION - A method and a mould for manufacturing a nerve regeneration device specifically adapted to an individual injury in the spinal cord are proposed, which will allow axons in the damaged area to regenerate and restore function. The resulting device can be adapted to a specific wound in order to ascertain an exact and reproducible anatomical positioning of the channels. The mould includes a base plate (07-02-2009
20100330144Methods and Apparatus for Fabricating Porous Three-Dimensional Tubular Scaffolds - Disclosed herein are three-dimensional porous tubular scaffolds for cardiovascular, periphery vascular, nerve conduit, intestines, bile conduct, urinary tract, and bone repair/reconstruction applications, and methods and apparatus for making the same.12-30-2010
20090087471METHOD OF TREATING TISSUE - In one embodiment, the method comprises providing tissue, preparing the tissue, and treating the tissue to improve remodeling characteristics of the tissue. The tissue may be, for example, cortical bone. Treating the tissue to improve remodeling characteristics may comprise heating the tissue, treating the tissue with a chemical, or other. Heating the tissue may be done in the absence of oxygen and may comprise heating the tissue in a vacuum, heating the tissue in an inert atmosphere, heating the tissue in a reducing atmosphere, coating the tissue with a protective coating and heating the tissue, or other. Further embodiments comprise treating the tissue in supercritical fluids, for example, to dry or virally inactivate the tissue.04-02-2009
20080213337DRUG IMPLANT CARRIER FOR DRUG DELIVERY - The present invention relates to ceramic precursor material exhibiting injectability arid properties that make the material suitable as a carrier material used in drug delivery. According to the invention this is accomplished by selecting a microstructure based on pre-reacted phases and after injection established phases, which contain anti-infective and/or anti-inflammatory drugs. The present invention also relates to a cured ceramic material and a method of manufacturing said cured material. The precursor and the cured ceramic material according to the present invention can suitably be used for filling orthopaedic cavities and other bone voids.09-04-2008
20090148491Dual-Targeted Drug Carriers - The present invention relates to implantable medical devices containing surface-treated, dual-targeted drug carriers for treating vascular diseases.06-11-2009
20090047324Medical Devices Containing Rapamycin Analogs - A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to Formula (I). This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.02-19-2009
20110300203CARTILAGE REGENERATION WITHOUT CELL TRANSPLANTATION - Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a cartilage defect. Further provided is a tissue scaffold comprising stromal cell-derived factor-1 (SDF-1) and transforming growth factor-β (TGF-β). Additionally, a method of making a tissue scaffold capable of recruiting a cell is provided.12-08-2011
20110300202Medical item for long term durg release - Polymeric articles capable of releasing drugs at therapeutic levels over extended periods of time, and methods for producing the extended release articles.12-08-2011
20110287079SUPPORTING MATERIAL FOR CELL SHEET - Provided in one embodiment is an implantable support material for culturing cells, wherein at least some of the cells substantially maintain at least one of (i) phenotype and (ii) genotype thereof after being cultured on the support material.11-24-2011
20100272779PROGESTERONE-CONTAINING COMPOSITIONS AND DEVICES - Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin E and/or conjugated linoleic acid. Another aspect of the invention provides a drug eluting device, such as a drug eluting stent, with at least one coating layer comprising a progesterone composition that can minimize or eliminate inflammation, thrombosis, restenosis, neo-intimal hyperplasia, rupturing of vulnerable plaque, and/or other effects related to device implantation, treatment, or interaction. Other aspects of the invention provide for methods of using such compositions, formulations, and devices.10-28-2010
20130216601THREE-DIMENSIONAL BONE IMPLANT AND METHOD FOR PRODUCING SAME - A method for ex vivo production of a three-dimensional bone implant adapted for implantation to a patient, implants produced by such a method, and uses of such implants. The method comprises disposing differentiated osteoblasts on a matrix support comprising at least one of collagen, calcium phosphate, calcium sulfate and tricalcium phosphate; contacting the differentiated osteoblasts on the matrix with autologous blood serum from the patient, comprising at least one of a growth factor and a cytokine; and disposing the differentiated osteoblasts on the matrix support and the medium in a bioreactor, in which production of the bone implant is performed.08-22-2013
20110293688HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.12-01-2011
20110293686Anti-viral compositions and methods for administration - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices.12-01-2011
20090280153 TEXT NOT AVAILABLE - Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.11-12-2009
20090104244THERAPEUTIC AGENT-ELUTING MEDICAL DEVICES HAVING TEXTURED POLYMERIC SURFACES - A medical device comprising: (a) a substrate having first and second surfaces, (b) a therapeutic-agent-eluting polymeric layer disposed over the first substrate surface and (c) a textured polymeric layer that is textured to promote cell attachment, cell growth, or both, disposed over the second surface.04-23-2009
20090285874Implantable Devices For Accelerated Healing - Implantable devices (e.g., stent) having a protein patterning or bioactive patterning for accelerated healing and method of forming and using the same are provided.11-19-2009
20110293689IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.12-01-2011
20080268013Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons - Poly(ethylene oxide) (PEO) glycodendrimers can serve as multivalent inhibitors of selectin-mediated leukocyte recruitment regulating inflammatory response. Disclosed are compounds and methods relating to functionalized branched glycopolymers. In embodiments, the compounds are capable of modifying cell adhesion events and inflammatory conditions. In a particular embodiment, a multi-arm PEO polymer with sulfated lactose end groups can specifically inhibit interactions involving L-selectin. Also disclosed are methods of synthetic preparation and use.10-30-2008
20100166821Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles - The present invention provides cerium oxide nanoparticles for use both in therapeutic compositions in vivo and in research in vitro. The cerium oxide nanoparticles are of a known range of sizes having biological properties that are reproducible and beneficial. Pharmaceutical and other compositions are provided, as are methods of treatment.07-01-2010
20080233168Medical Devices And Coatings Therefore Comprising Biodegradable Polymers With Enhanced Functionality - Biodegradable polymers useful for fabricating implantable medical devices and as coatings for medical devices are provided. The biodegradable polymers are biocompatible and can be tuned to provide optimum bioactive agent elution rates as well as degradation rates. Also provided are methods for making medical devices and medical device coatings using the biodegradable polymers.09-25-2008
20100034864STEM CELL CAPTURE AND IMMOBILIZATION COATINGS FOR MEDICAL DEVICES AND IMPLANTS - Constructs and methods for immobilizing stem and other precursor cells, as well as other bioactive materials of therapeutic value on the surfaces of medical devices, such as bone, cartilage, spinal and tooth implants, are described herein. The present invention has broad application in the incorporation of bioactive and therapeutic materials in or on a medical implant or other interventional device, having particular value in enabling the real-time, utilization by medical personnel of bioactive materials extracted from the patient and subsequently reintroduced and immobilized in an implant device.02-11-2010
20100055147ANGIOTENSIN (1-7) ELUTING STENT - Medical devices with polymer coatings designed to control the release of bioactive agents in combination with angiotensin-(1-7) receptor agonists from medical devices are disclosed. Methods for treating or inhibiting post-stent implantation restenosis as well as improving vascular endothelial function in patients are also provided.03-04-2010
20100034862COVALENTLY GRAFTED PHARMACEUTICALLY ACTIVE POLYMERS - The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.02-11-2010
20100034865OSTEOINDUCTIVE CALCIUM PHOSPHATES - The invention relates to a porous osteoinductive calcium phosphate material having an average grain size in a range of 0.1-1.50 μm, having a porosity consisting essentially only of micropores in a size range of 0.1-1.50 μm, and having a surface area percentage of micropores in a range of 10-40%.02-11-2010
20110217352DEVELOPMENT OF A HUMAN COLLOIDAL BONE GRAFT MATERIAL - The present disclosure provides colloidal bone graft compositions comprising a plurality of mineralized three-dimensional bone constructs, a polymerizable biocompatible matrix, an osteoblast differentiation agent, and at least one osteoblast mineralization agent. The colloidal bone graft compositions of the disclosure are used to perform bone grafts in human or animal patients.09-08-2011
20090280152Tropoelastin for Promoting Endothelial Cell Adhesion or Migration - The invention provides methods, compositions, and devices for promoting adhesion or migration of endothelial cells.11-12-2009
20090202607HEPARIN-LIKE COMPOUNDS, THEIR PREPARATION AND USE TO PREVENT ARTERIAL THROMBOSIS ASSOCIATED WITH VASCULAR INJURY AND INTERVENTIONS - Heparin-like compounds inhibit collagen-induced platelet aggregation in flowing whole blood. The compounds share properties displayed by native mast-cell derived heparin proteoglycans (HEP-PG) and/or heparin glycosaminoglycan (HEP-GAG) molecules. The compounds are useful in prevention and treatment of severe vascular disorders including arterial thrombosis.08-13-2009
20090186066METHOD FOR PRODUCTION OF CHITOSAN-BASED FILMS WITH ENHANCED CELL ADHERING CAPACITY, RESULTING PRODUCT AND APPLICATIONS - The method comprises, in general, the formation of a chitosan based film, the stabilization of said film and the activation of the cell adherence capacity by means of drying the stabilized and washed film. Additionally, the film may be biologically activated by means of fixing with a substance with biological activity. The films obtained have an increased cell adherence capacity, and, optionally, are biologically activated. These films may be used to induce a biological activity in a recipient organism, and/or for enhancing the osteointegration of implants of dental or traumatologic use and/or for regenerating osseous tissue.07-23-2009
20110262517CHIRALLY PURE ISOMERS OF ITRACONAZOLE AND INHIBITORS OF LANOSTEROL 14A-DEMETHYLASE FOR USE AS ANGIOGENESIS INHIBITORS - Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.10-27-2011
20090098182LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.04-16-2009
20090098183MICROSPHERE-BASED MATERIALS WITH PREDEFINED 3D SPATIAL AND TEMPORAL CONTROL OF BIOMATERIALS, POROSITY AND/OR BIOACTIVE SIGNALS - A tissue engineering scaffold for growing cells can include a plurality of biocompatible microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have a first characteristic, and a first predetermined spatial distribution with respect to the three-dimensional matrix. The second set of microspheres can have a second characteristic that is different from the first characteristic, and a second predetermined spatial distribution that is different from the first predetermined spatial distribution with respect to the three-dimensional matrix. The first and second characteristics can selected a composition, polymer, particle size, particle size distribution, type of bioactive agent, type of bioactive agent combination, bioactive agent concentration, amount of bioactive agent, rate of bioactive agent release, mechanical strength, flexibility, rigidity, color, radiotranslucency, radiopaqueness, or the like.04-16-2009
20100112028Composite material for use as protein carrier - The present invention relates to a material having osteoinductive and osteoconductive properties in vivo comprising a ceramic carrier, preferably containing calcium phosphate, and an active agent, preferably an osteoinductive protein/peptide or a drug, and a polymer, wherein the active agent is homogeneously coated on the carrier and within the polymer, which is preferably a degradable polymer. Said polymer modulates the release kinetic of the active agent and protects same from degradation to prolong the half-life in vivo. Moreover, the present invention relates to a method for the production of a material having osteoinductive and osteoconductive properties in vivo.05-06-2010
20100112029COMPOSITIONS AND METHODS FOR NUCLEUS PULPOSUS REGENERATION - Compositions for nucleus pulposus regeneration is provided. Such composition may comprise a scaffolding material and a pore creating agent dispersed within the scaffolding material. The pore creating agent is removed from the scaffolding material in vivo, after the composition is administered to a patient. The pore creating agent may include an active agent, such as a growth factor, which may be released as the pore creating agent is being gradually removed from the scaffolding material. In addition, removal of the pore creating agent results in a porous scaffold for cells capable of regeneration of nucleus pulposus, either existing in situ or delivered separately, to attach to for further proliferation and regeneration.05-06-2010
20100215719POLYARYLATES FOR DRUG DELIVERY AND TISSUE ENGINEERING - Biocompatible polyarylates of diphenol compounds and poly(alkylene oxide) dicarboxylic acids, articles formed therefrom and therapeutic uses are disclosed.08-26-2010
20100215718Bone Graft Material Containment Structures - The present invention provides biocompatible, non-resorbable porous containment structures for containment of bone graft material at a desired location for stimulation of bone growth. The porous containment structures have interconnected pores sized to allow fibrovascular integration with surrounding tissue and conduction of vascular tissue through the structure into the bone graft material.08-26-2010
20090098180FUNCTIONALIZED AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM - The present invention relates to compounds of formula I and II, which are functionalized amino acids, and polymers formed from the same.04-16-2009
20090148493METHODS AND DEVICES FOR ENHANCED BIOCOMPATIBILITY - The present invention is directed to devices with enhanced biocompatibility and methods for generating and utilizing such devices. The present invention is further directed to enhanced biocompatibility utilizing oligonucleotide functionalization. In one aspect, a device for implantation and/or prolonged exposure to the body tissues includes a functionalized surface. The functionalized surface generally enhances the biocompatibility of the device with body tissues. In some embodiments, the functionalized surface includes substances for controlling interaction between the device and the body tissues. Substances for controlling interactions may include, but are not limited to, polymeric materials, biomolecules, ions and/or ion-releasing substances, and/or any other appropriate substance or combination thereof. In exemplary embodiments, the functionalized surface includes oligonucleotides for controlling interaction between the device and the body tissues. In some exemplary embodiments, the oligonucleotides are aptamers.06-11-2009
20090053282Bone Grafting Method and Kit - Bone grafting methods involving harvesting at least of the following types of cells: osteoblasts, adult stem cells and primitive mesenchymal cells and applying these cells to a site intended for a bone graft in combination with the application of a suitable matrix material, where the matrix material is an allograft, xenograft or alloplast matrix material or a combination thereof.02-26-2009
20100119577THERAPEUTIC COMPOSITE FOR CARTILAGE DISORDER USING EXTRACELLULAR MATRIX (ECM) SCAFFOLD - The present invention relates to a method for preparing a cell-derived ECM scaffold to which chondrocytes or stem cells are attached, a method for cartilage regeneration by tissue engineering, which comprises using the cell-derived ECM scaffold, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold as an effective component. More specifically, the present invention relates to a method for cartilage regeneration by tissue engineering, which comprises transplanting ECM scaffold, having chondrocytes or stem cells attached thereto, into cartilage defects, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold, having chondrocytes or stem cells attached thereto, as an effective component. According to the present invention, when the inventive ECM scaffold having chondrocytes or stem cells attached thereto is transplanted into a cartilage defect, mature articular cartilage having the same appearance and characteristics as those of natural cartilage tissue, can be regenerated without side effects such as inflammatory responses.05-13-2010
20100266659IMPLANTABLE DEVICES FORMED ON NON-FOULING METHACRYLATE OR ACRYLATE POLYMERS - Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-21-2010
20100266657PREFORMED DRUG-ELUTING DEVICE TO BE AFFIXED TO AN ANTERIOR SPINAL PLATE - A drug-eluting device comprising a drug-eluting matrix containing at least one elutable drug, a method of manufacturing a preformed drug-eluting device, and an implant kit comprising the same.10-21-2010
20080241211DEVICE WHICH ENHANCES THE BIOLOGICAL ACTIVITY OF LOCALLY APPLIED GROWTH FACTORS WITH PARTICULAR EMPHASIS ON THOSE USED FOR BONE REPAIR - This invention provides a novel medical appliance for repairing, regenerating, maintaining, and/or augmenting a bone. The medical appliance generally includes an osteoinductive agent, an osteoinductive enhancer, and a carrier matrix. Also disclosed are methods, compositions, kits, and bone matrix formulations for regenerating, maintaining, and/or augmenting a bone. Exemplary preferred osteoinductive agents include growth factors such as BMP and TGF-β. Exemplary preferred osteoinductive enhancers include phytoestrogens such as naringin.10-02-2008
20100278896SOLID COMPOSITIONS - A solid, implantable dosage form comprising a therapeutically active agent in solid form, optionally with one or more pharmaceutically acceptable excipients, wherein the one or more excipients, when present, do not lead to a significant delay or prolongation of the release of active agent, as compared to an equivalent dosage form containing no excipients when tested in vitro.11-04-2010
20100119574Recombinant Gelatins - The invention concerns a recombinant CBE gelatin and recombinant gelatins having multimers of the CBE monomer sequence that are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety of medical applications.05-13-2010
20100119576USE OF ONE OR MORE OF THE ELEMENTS FROM THE GROUP YTTRIUM, NEODYMIUM AND ZIRCONIUM, AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THOSE ELEMENTS - A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.05-13-2010
20110045052Bioactive Glass Coatings - The present invention relates to bioactive glass coatings. In particular, the present invention relates to bioactive glass coatings for Ti6Al4V alloys and chrome cobalt alloys, wherein the thermal expansion coefficient of the glass coating is matched to that of the alloy. Such coatings have a particular application in the field of medical prosthetics. The bioactive glass comprises (in mol %) 35-53 SiO2; 2-11 Na20; at least 2% of each of CaO, MgO and K20; 0-15 ZnO; 0-2 B202 and 0-9 P205.02-24-2011
20100015200Drug Delivery Medical Device - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.01-21-2010
20100129417Dihydroxybenzoate Polymers and Uses Thereof - The present invention is directed to polyphenolic polymers formed from dihydroxybenzoic acid (DHB) derivatives or from resorcinol derivatives, monomers which form such polymers, blends of the polymers with drugs and/or additional polymers, as well as medical devices formed from, coated with, impregnated by or coverings made with any of the foregoing polymers (with or without drugs) or blends (with or without drugs).05-27-2010
20110135703Antimicrobial Coating for Surgical Implants and Method of Use - A method of treating a surgical incision uses a material coated in an antimicrobial material. The material may be a synthetic mesh, an allograft, or a xenograft. The antimicrobial material is either tryclosan or lysostaphin. The coating of the material is performed either by adsorption or by covalent bonding.06-09-2011
20100158974COATED IMPLANT - The present invention relates to an implant or part thereof coated with a wax or a resin. Especially, the present invention relates to an implant or part thereof coated with shellac.06-24-2010
20100086580MEDICAL DEVICE WITH CONTROLLABLY RELEASABLE ANTIBACTERIAL AGENT - There is disclosed a medical device, such as a urinary catheter, comprising a substrate material, a hydrophilic surface coating, e.g. comprising polyvinylpyrrolidone (PVP), arranged on at least a part of the surface of said substrate material, and an antibacterial layer comprising oligodynamic metal arranged between the substrate material and the hydrophilic surface coating. Further, the hydrophilic surface coating has a thickness large enough to provide a controlled release of oligodynamic metal ions through the hydrophilic surface coating, such as a thickness when dry that exceeds 3 μm. Hereby, the variation in the release of the oligodynamic metal ions is significantly reduced, enabling an improved control of the release. A corresponding method is also disclosed.04-08-2010
20100098737 METHODS AND COMPOSITIONS FOR DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS TO MEDICAL DEVICE SURFACES - The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.04-22-2010
20090060971METHODS OF TREATING A TRAUMA OR DISORDER OF THE KNEE JOINT BY LOCAL ADMINISTRATION AND SUSTAINED-DELIVERY OF A BIOLOGICAL AGENT - Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and/or therapeutic antibodies.03-05-2009
20100080838Reactive Surgical Implant - Biocompatible implants including a polymer substrate and a reactive component for implant fixation in situ. The reactive component in combination with the substrate creates a reactive implant which bonds to a tissue surface in situ.04-01-2010
20120107384APPARATUS FOR FORMING AN IMPLANT - Implants for repairing tissue defects, such as cartilage tissue defects, and methods of their preparation and use are disclosed. A mold of a tissue defect is prepared by pressing upon the defect a substrate having shape memory, such as aluminum foil. The mold, which has contours substantially conforming to those of the defect, is removed from the defect, and tissue particles are added to the mold ex vivo. A biological carrier such as biocompatible glue is also added to the mold. The combination of tissue particles and the biological carrier thereby form an implant, which retains its shape after separation from the mold. The implant can be transferred to the tissue defect, with contours of the mold matching corresponding contours of the defect.05-03-2012
20120107383OSTEOCONDUCTIVE MATRICES COMPRISING CALCIUM PHOSPHATE PARTICLES AND STATINS AND METHODS OF USING THE SAME - Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.05-03-2012
20090263449DELIVERY OF NUCLEIC ACID COMPLEXES FROM MATERIALS INCLUDING NEGATIVELY CHARGED GROUPS - Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of a photoreactive group; the polymeric coating comprising negatively charged species on the surface; and a plurality of nucleic acid delivery complexes disposed on the polymeric coating, the nucleic acid delivery complexes comprising a nucleic acid and a cationic carrier agent complexed to the nucleic acid. Other embodiments are included herein.10-22-2009
20090263452Drug-eluting intravascular prostheses and methods of use - The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention.10-22-2009
20090263451Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain - Effective treatments of myofascial pain and/or inflammation are provided. Through the administration of an effective amount of at least one anti-inflammatory agent and/or analgesic at or near a target site, one can reduce, prevent or treat myofascial pain and/or inflammation.10-22-2009
20090263446METHOD OF MAKING LOAD BEARING HYDROGEL IMPLANTS - Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.10-22-2009
20090263448Clonidine Formulation in a Polyorthoester Carrier - Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days.10-22-2009
20100098739COMPOSITIONS AND METHODS FOR MODULAR SOFT TISSUE REPAIR - Adipose tissue-derived stromal cells induced to form multicellular aggregates can be formed reliably and consistently, they can be maintained for prolonged periods in adherent or suspension culture, and they are able to survive, grow, and/or differentiate in serum-free media conditions. The present invention provides compositions and methods for the use of such aggregates in tissue repair. This culture platform provides a controlled and defined system in which to study and standardize adult stem cell biology, and begets an instinctive “modular” approach to the predictable replacement and regeneration of adipose tissue.04-22-2010
20100092539Fluorinated GHRH Antagonists - Novel fluorinated synthetic analogs of hGH-RH(1-30)NH04-15-2010
20100098738SURFACE BOUND ACTIVES - An implantable metal device having an active biosurface, the device comprising a non-peptide polymer spacer having a plurality of target sites, at least one or more of the target sites binding a biologically active agent, wherein the target sites are derived from a plurality of carbonyl, epoxy, hydroxyl or thiol target reactive groups or a combination thereof or wherein the biologically active agent is any agent which is capable of modifying the behaviour of cells; a process for generating an active biosurface at the surface of the implantable metal device, comprising contacting a non-peptide polymer spacer having a plurality of target reactive groups with a biologically active agent having one or more reactive functional groups and reaction thereof, thereby binding the biologically active agent to the polymer wherein the, polymer is anchored to the surface of the implantable metal device or subsequently anchoring the polymer to the surface of the implantable metal device by means of unreacted target reactive groups; the implantable metal device having a surface which is receptive for tethering the biologically active agent; a chemical intermediate comprising the polymer spacer anchored to the chemical anchor; processes for the preparation thereof; a method of treating an animal comprising inserting the implantable metal device into a site in need thereof on said animal; and uses thereof as an implantable or subcutaneous metal device, or non-surgical device or a coating thereof, preferably any orthopaedic, cardiovascular, circulatory system or dental implant, tissue engineering device, fixation device, reconstructive device or joint member or trauma-related devices or research tools or particles for shaping into such form.04-22-2010
20090186064ANTIMICROBIAL MATERIAL AND METHOD FOR MAKING THE SAME - This invention provides a modified catheter biomaterial that provides both immediate, and long-term microbiocidal effects on otherwise antibiotic-resistant strains of microorganisms. The material, which exhibits good mechanical performance characteristics for medical devices, is composed of a hydrophobic polyurethane (PU), a hydrophilic polyethylene vinyl acetate (PEVA), a soluble silver salt and a sparsely-soluble silver salt. The hydrophobic polyurethane provides the good physical properties, the PEVA the hydrophilicity necessary to allow some water ingress into the catheter, the soluble silver salt for an immediate burst effect, and the sparsely-soluble silver salt for sustained-release over many months postimplantation.07-23-2009
20110200659SYSTEM AND METHOD FOR LOADING A BENEFICIAL AGENT INTO A MEDICAL DEVICE - A system for delivery of a beneficial agent in the form of a viscous liquid or paste allows holes in a medical device to be loaded in a single step process. The loading of a beneficial agent in a paste form also provides the ability to deliver large and potentially sensitive molecules including proteins, enzymes, antibodies, antisense, ribozymes, gene/vector constructs, and cells including endothelial cells.08-18-2011
20100124563Biomatrix Composition and Methods of Biomatrix Seeding - Apparatus and methods are described for generating autologous tissue grafts, the apparatus including a point of care SVF isolation unit that includes a tissue digestion chamber in fluid communication with a lipid separating chamber, whereby SVF cells are isolated without centrifugation; and a cell seeding chamber in fluid communication with the SVF isolation unit, said cell seeding chamber adapted to support a cell scaffold. Methods and materials for cell seeding, including through the provision of micro rough scaffold surfaces, are also provided.05-20-2010
20090274741POLYMERS CONTAINING POLY(ESTER AMIDES) AND AGENTS FOR USE WITH MEDICAL ARTICLES AND METHODS OF FABRICATING THE SAME - Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a polymer comprising a polymeric product of a reaction comprising a polyol, a polycarboxylic acid, an amino acid and an agent.11-05-2009
20090274738IMPLANTABLE DEVICES FOR PROMOTING REENDOTHELIALIZATION AND METHODS OF USE THEREOF - An implantable device for the controlled delivery of an estrogen receptor agonist to an injured site in the lumen of a mammalian blood vessel, wherein the estrogen receptor agonist is present in an amount of at least about 16.7 μg/mm implantable device length. Methods of use thereof.11-05-2009
20090004239Dural repair material - Multilayer structures including a porous layer and a non-porous layer having a reinforcement member are useful as dural repair materials.01-01-2009
20090291113Osteogenic composition comprising a growth factor, a soluble cation salt and organic support - An open implant, and a method for preparing the implant, constituted of an osteogenic composition with at least one osteogenic growth factor, one soluble salt of a cation at least divalent, and one organic support. The organic support has no demineralized bone matrix. In one embodiment, the implant is in the form of a lyophilizate.11-26-2009
20080206307BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising a biologically degradable, biologically erodable, and/or biologically resorbable ABA or AB block copolymer. A biologically active agent can be conjugated to the block copolymer.08-28-2008
20080206298Enhanced biological autologous tissue adhesive composition and methods of preparation and use - The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, comprising: introducing a composition into the disc, wherein the composition comprises autologous fibrinogen and an activating agent, and wherein the composition forms fibrin.08-28-2008
20080206301Bone void fillers and methods of making the same - The invention relates to a material for use as bone void filler comprising soluble keratin protein. The material may be in the form of a putty, gel or emulsion. Additional components may be added to the material to improve handling characteristics and bone enhancement capabilities. The material may be formulated to serve as a suitable carrier for demineralized bone matrix. This invention also describes methods for making the material.08-28-2008
20080206306POLY(ESTER AMIDE) BLOCK COPOLYMERS - Provided herein is a copolymer that includes a soft block (A) and a hard block (B) comprising a tyrosine di-peptide. The copolymer can be any of AB, ABA or BAB type block copolymers. The soft block can include a PEA polymer. A coating formed of the copolymer may also include a bioactive agent. The implantable device can be implanted in a patient to treat, prevent, or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, and/or tumor obstruction.08-28-2008
20080206303Prolonged Release Formulations Comprising Anastrozole - The present invention relates to slow release anastrozole formulations, more particularly to in situ gelling formulations comprising a polylactide polymer or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer, and processes for the preparation of said formulations.08-28-2008
20090291114OSTEOGENIC COMPOSITION COMPRISING A GROWTH FACTOR/AMPHIPHILIC POLYMER COMPLEX, A SOLUBLE CATION SALT AND AN ORGANIC SUPPORT - The invention relates to an open implant constituted of an osteogenic composition comprising at least: 11-26-2009
20090280156BIOIMPLANT - To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 90% or less is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film. If necessary, a metal oxide layer made of a metal oxide having an isoelectric point of less than 7 is formed on the bioimplant thereby suppressing adhesion of bacteria.11-12-2009
20090104245BIODEGRADABLE CARRIER AND METHOD FOR PREPARATION THEREOF - A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.04-23-2009
20090104246 LOCAL ADMINISTRATION OF A COMBINATION OF RAPAMYCIN AND PANZEM FOR THE TREATMENT OF VULNERABLE PLAQUE - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.04-23-2009
20090104242NIOBIUM OXIDE COMPOSITIONS, NANOSTRUCTURES, BIOACTIVE FORMS AND USES THEREOF - Self-organized niobium oxide nanocones with nano-sized tips are prepared by anodization of niobium in the presence of an electrolyte such as hydrofluoric acid (HF) (aq.). Dimensions and integrity of the bulk nanostructures formed are strongly dependent on potential, temperature, electrolyte composition, and anodization times. Accordingly, the morphology, topology, uniformity and bioactivity of the niobium oxide nanostructures formed can be readily adjusted by adjusting these anodization parameters. A bioactive form of crystalline niobium oxide is formed by anodizing niobium metal in the presence of an electrolyte that includes HF and at least one salt such as Na04-23-2009
20090104243Drug cores for sustained release of therapeutic agents - A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.04-23-2009
20090104241RANDOM AMORPHOUS TERPOLYMER CONTAINING LACTIDE AND GLYCOLIDE - The present invention provides an amorphous terpolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same04-23-2009
20090104240Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases - The present invention relates to implantable medical devices coated with the polymer containing at least an olimus and a corticosteroid for the treatment of vascular diseases.04-23-2009
20100278893IMPLANTABLE MATERIAL COMPRISING CELLULOSE AND THE GLYCOPEPTIDE XYLOGLUCAN-GRGDS - Implantable materials for medical or surgical applications comprising specific chemical groups on their surface to alter the physico-chemical properties of said material rendering it suitable implantation or biocompatible properties.11-04-2010
20090291112Allograft osteochondral plug combined with cartilage particle mixture - An allograft osteochondral plug is combined with a mixture that includes freeze-milled cartilage particles, and such combination is used to repair defects in articular cartilage. The plug includes an subchondral bone portion and an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans. At least a portion of the plug has a lateral dimension selected to form an interference fit against a tissue layer exposed as a result of a bore formed in a defect area in articular cartilage of a host. The cartilage particle mixture is placed adjacent at least a portion of the plug for promoting cartilage cell migration into (i.e., from the adjacent host cartilage) and proliferation in the bore, and for enhancing tissue integration between the plug and patient (i.e., host) tissue when the plug is inserted into the bore. Methods for surgical implantation of the plug into a patient are also disclosed.11-26-2009
20110076317Rapid establishment and/or termination of substantial steady-state drug delivery - The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.03-31-2011
20110076316SCALABLE MATRIX FOR THE IN VIVO CULTIVATION OF BONE AND CARTILAGE - The present invention provides implantable receptacle devices (and methods) for use in bone and tissue regeneration which provide immediate structural stability and strength to a zone where tissue regeneration is required. By virtue of their size, shape and construction, the devices are scalable, modular, structurally stable, self-stacking in three dimensions, can be aggregated to an anatomically accurate shape, and hold various materials delivered into the implant area so as to create a highly regenerative micro-environment. They can be implanted via less invasive surgical procedures, and because they act as external scaffolding as well as being imbedded as an integral part of a matrix for the effective and rapid regeneration of bone and cartilage in vivo, they may provide significant advantages to patients or subjects in terms of reduced pain, faster healing and fewer complications.03-31-2011
20110076315Grafts and Stents Having Inorganic Bio-Compatible Calcium Salt - The present application discusses techniques and structures that incorporate calcium salts in the luminal surface of grafts. In an embodiment, a graft, stent-graft or TIPS may incorporate bio-compatible calcium salt, which is essentially non-osteoinductive in nature, on the surfaces of the implantable device.03-31-2011
20090169595Controlled Release Polymeric Compositions of Bone Growth Promoting Compounds - The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of a bone growth promoting compound to certain tissues.07-02-2009
20100129420METHODS AND DEVICES TO ACCELERATE WOUND HEALING IN THORACIC ANASTOMOSIS APPLICATIONS - A long term oxygen therapy system having an oxygen supply directly linked with a patient's lung or lungs may be utilized to more efficiently treat hypoxia caused by chronic obstructive pulmonary disease such as emphysema and chronic bronchitis. The system includes an oxygen source, one or more valves and fluid carrying conduits. The fluid carrying conduits link the oxygen source to diseased sites within the patient's lungs. A collateral ventilation bypass trap system directly linked with a patient's lung or lungs may be utilized to increase the expiratory flow from the diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. The system includes a trap, a filter/one-way valve and an air carrying conduit. In various embodiments, the system may be intrathoracic, extrathoracic or a combination thereof A pulmonary decompression device may also be utilized to remove trapped air in the lung or lungs, thereby reducing the volume of diseased lung tissue. A lung reduction device may passively decompress the lung or lungs. In order for the system to be effective, an airtight seal between the parietal and visceral pleurae is required. Chemical pleurodesis is utilized for creating the seal and various devices and/or drugs, agents and/or compounds may be utilized to accelerate wound healing in thoracic anastomosis applications.05-27-2010
20090297581MEDICAL DEVICES HAVING ELECTRODEPOSITED COATINGS - According to one aspect, the present invention provides implantable or insertable medical devices that comprise a conductive substrate and an electrodeposited coating over the substrate. The electrodeposited coating includes (a) one or more types of inorganic materials, (b) one or more types of polymeric materials and (c) optionally, one or more types of therapeutic agents. Still other aspects of the invention concern methods of making and using such devices.12-03-2009
20090297578BIOSOLUBLE COATING COMPRISING ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY AGENT COMBINATION FOR TREATMENT OF VASCULAR DISORDERS - Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.12-03-2009
20090297577Local Delivery of Apolipoproteins and Their Derivatives - Disclosed are medical devices and methods for the local delivery and treatment of vascular conditions. The methods and treatments involve local delivery of at least one apolipoprotein. The vascular conditions described herein include plaque rupture, aneurysm, stenosis, restenosis, atherosclerosis, ischemic myocardial infarct and combinations thereof.12-03-2009
20090297575Implantable Drug Delivery Devices Having Alternating Hyrdrophilic And Amphiphilic Polymer Layers - An implantable drug delivery medical device with alternating hydrophilic and amphiphilic polymer layers and methods of using for the treatment of vascular disease are disclosed.12-03-2009
20080213334POLYELECTROLYTE MEDIA FOR BIOACTIVE AGENT DELIVERY - The invention provides polyelectrolyte hydrogels, blends, and multilayers for the controlled release of bioactive agents from implantable medical devices coated with or containing such media.09-04-2008
20080213336POLYMETHYLMETHACRYLATE REVISION BONE CEMENT - The invention relates to a PMMA revision bone cement having powder and liquid component, in which the powder component contains two or more granular antibiotics whose grain size distribution is equal in that the main screening fraction each of the individual antibiotics is in the same grain size range, in particular in the range of 100-250 μm or 150-250 μm.09-04-2008
20080213338IMPLANT STENT WITH A RETINOID FOR IMPROVED BIOCOMPATIBILITY - An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.09-04-2008
20080213333Methods and compositions for fostering and preserving bone growth - A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of new bone within the bone interior portion, and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject. The method may further include administering at least one anti-resorptive agent to the subject in an amount sufficient to substantially prevent resorption of new bone growth. In another embodiment, the method may further include a step of mechanically inducing an increase in osteoblast activity in the subject, wherein the elevation in blood concentration of the anabolic agent and the increase in osteoblast activity at least partially overlap in time.09-04-2008
20100278895ANTIOXIDANTS AND ANTIMICROBIAL ACCESSORIES INCLUDING ANTIOXIDANTS - An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer. The antimicrobial accessory may also include a topcoat formed on the sacrificial diffusion layer. The topcoat may include a biodegradable polymer and at least one antioxidant mixed in the biodegradable polymer.11-04-2010
20100278894ANTIOXIDANTS AND ANTIMICROBIAL ACCESSORIES INCLUDING ANTIOXIDANTS - An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer. The antimicrobial accessory may also include a topcoat formed on the sacrificial diffusion layer. The topcoat may include a biodegradable polymer and at least one antioxidant mixed in the biodegradable polymer.11-04-2010
20100291176MANUFACTURING THREE-DIMENSIONAL SCAFFOLDS USING CRYOGENIC PROTOTYPING - The present invention refers to a method of fabricating a three dimensional scaffold suitable for tissue-engineering having a controlled micro- and macroporous structure using cryogenic prototyping. The present invention also refers to scaffolds obtained by the method of the present invention and to their use.11-18-2010
20090169594CARBON NANOTUBE-BASED FIBERS, USES THEREOF AND PROCESS FOR MAKING SAME - A biocompatible and biodegradable carbon nanotube-based fiber capable of stimulating and sustaining cell proliferation and stimulating and sustaining nerve regeneration is disclosed herein. The biocompatible and biodegradable carbon nanotube-based fiber comprising at least one carbon nanotube; a biodegradable copolymer; and a coagulating polymer. The present disclosure also relates to a process fro producing such a fiber.07-02-2009
20100136081HYALURONIC ACID DERIVATIVE AND NEURAL STEM CELLS FOR SCI AND PNT REGENERATION - A biomaterial for the treatment of spinal cord or of peripheral nerve injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from βFGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof.06-03-2010
20080241209System and Method for Forming Bone, Ligament, and Bone-Ligament Constructs - A system and method for forming a bone construct include providing bone marrow stromal cells on a substrate without disposing the cells within an exogenous scaffold, and culturing the cells in vitro in osteogenic media such that the cells form a confluent monolayer and detach from the substrate to form a self-organized three-dimensional bone construct. A system and method for forming a ligament construct using fibrogenic media and a system and method for forming a functionally integrated bone-ligament construct are also provided.10-02-2008
20110206754IMPLANT DEVICE - The present description relates to an implant device, having an improved integration in the tissue of the animal or human body into which it is inserted, when compared to the prior art devices.08-25-2011
20080241208Methods, Compositions and Devices For Promoting Anglogenesis - This disclosure is, at least in part, directed to compositions, devices, and methods of promote angiogenesis.10-02-2008
20090035344MULTI-POLYMER HYDROGELS - The invention provides a multi-polymer hydrogel article having a first polymeric, water-swellable material and a second polymeric material, organized such that a first region substantially comprises the first polymeric, water-swellable material, a second region adjacent the first region comprises a mixture of the first polymeric, water-swellable material and the second polymeric material, and a third region adjacent the second region substantially comprises the second polymeric material. The article exhibits an increasing concentration gradient of the second polymeric material moving from the first region, through the second region, to the third region. The invention also provides methods for forming a multi-polymer hydrogel article by (a) forming a hydrogel structure using a first polymeric, water-swellable material, (b) creating an aerogel structure having a plurality of open pores by dehydrating the hydrogel structure, (c) contacting the aerogel structure with a second polymeric material to incorporate the second polymeric material into at least a portion of the plurality of open pores to form the multi-polymer hydrogel article, and (d) rehydrating the multi-polymer hydrogel article.02-05-2009
20080317814Tube for Connecting Marteriovenous and Interposition for Medical Operation - Disclosed herein are a tube for arteriovenous anastomosis useful in hemodialysis patients and an insert for use in medicinal operation in the body. The tube or the insert are repetitively treated with a medicament on the surface thereof, which provides stable communication between an artery and a vein of a patient under hemodialysis and can greatly reduce stenosis at arteriovenous connections by releasing the medicament at a suitable rate over a prolonged period of time.12-25-2008
20080233166SYSTEMS AND METHODS OF COATING A HYBRID HEMODIALYSIS ACCESS GRAFT OR A HYBRID FEMORAL ARTERY BYPASS GRAFT IN A MAMMAL - Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop subsystem is capable of adjusting at least two dynamic conditions in the specimen holder or a diameter of a specimen in the specimen holder. Embodiments of methods can coat a hybrid graft with a confluent monolayer of endothelial cells by immobilizing stem cells on a hybrid hemodialysis access graft or a hybrid femoral artery bypass graft, and placing the hybrid graft in a system embodiment according to the invention under conditions effective to promote the stem cells to form a confluent monolayer on the hybrid graft and in an environment to promote the stem cells to differentiate into endothelial cells.09-25-2008
200802331694-Aza-Caprolactone-Based Polymeric Compositions Useful for the Manufacture of Biodegradable Medical Devices and as Medical Device Coatings - N-substituted 4-aza-caprolactone biodegradable polymers, including derivatives thereof, useful for making implantable medical devices and coatings therefore are provided. The medical devices and coatings of the present invention can also be used for in situ controlled release drug delivery and are useful for treating or preventing medical conditions such as restenosis, aneurisms and vulnerable plaque.09-25-2008
20080233167UROLOGICAL MEDICAL DEVICES FOR RELEASE OF PROSTATICALLY BENEFICIAL THERAPEUTIC AGENTS - According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.09-25-2008
20100129416BIOACTIVE LOAD-BEARING COMPOSITES - Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described.05-27-2010
20090098179FLUID EQUILBRATED ABSORBENT POLYMERIC MATERIALS, DEVICES INCLUDING SAME AND PACKAGING FOR SAME - Disclosed are methods and devices for the engineering, formation, and post-formation handling of absorbent polymeric materials. Devices intended for use in a fluid environment that include an absorbent polymeric material can be formed and processed to ensure that upon installation of the device, the polymeric material can not only have the desired physical characteristics for the intended use, but can also be pre-equilibrated for the environment in which the device will be utilized. In particular, the polymeric materials can be formed with particular characteristics such that, upon absorption of a fluid, the characteristics will alter in a predetermined way to provide the materials within target specifications during use. In addition, the materials can be stored in a fluid so as to exhibit the desired operating characteristics immediately upon installation. In one particular embodiment, the invention is directed to biocompatible, implantable devices designed for use in vivo.04-16-2009
20080279910Composite Hemocompatible Material and Method for Its Production - According to the invention, the hemocompatible material comprises a strong and leaklight synthetic substrate, to which a biological tissue adheres by virtue of the constituent substance of said substrate dispersing in a solvent.11-13-2008
20080286331COMPOSITION FOR AN INJECTABLE BONE MINERAL SUBSTITUTE MATERIAL - The invention refers to an injectable composition for a bone mineral substitute material, which comprises a dry powder mixed with an aqueous liquid. The powder comprises a first reaction component comprising a calcium sulphate hemihydrate with the capability of being hardened to calcium sulphate dihydrate when reacting with said aqueous liquid; a second reaction component, which comprises a calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with said aqueous liquid; and at least one accelerator for the reaction of said first and/or second reaction component with said aqueous liquid. A method of producing an injectable bone mineral substitute material is also provided, wherein the composition is mixed in a closed mixing and delivery system for delivery.11-20-2008
20080286329Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.11-20-2008
20080286325CYCLODEXTRIN ELUTION MEDIA FOR MEDICAL DEVICE COATINGS COMPRISING A TAXANE THERAPEUTIC AGENT - The present disclosure provides methods of measuring the release of a taxane therapeutic agent from a medical device as a function time in contact with a suitable elution medium. The method preferably comprises the step of contacting a coated medical device comprising a taxane therapeutic agent with an elution medium comprising a cyclodextrin to provide an elution profile indicative of the composition or configuration of a medical device coating comprising a taxane therapeutic agent. The elution profile can provide information about the medical device coating that is useful in lot release testing.11-20-2008
20080286323Human Therapeutic Cells Secreting Nerve Growth Factor - The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer's disease, peripheral neuropathy and other neurological disorders amenable to local and prolonged NGF therapy.11-20-2008
20080286330METHODS AND DEVICE TO NEUTRALIZE SOLUBLE TOXIC AGENTS IN THE BRAIN - Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include Aβ, and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as Alzheimer's disease (AD). Antibodies to Aβ, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral of antibodies to Aβ, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.11-20-2008
20080286328Implant and Production Method for Said Implant - The invention relates to an implant, e.g. a stent, bone replacement material, a prosthesis, a scaffold or similar, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterised in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component. The invention also relates to a method for producing an implant of this type and to a specific composition, which can be used to produce a coating of this type.11-20-2008
20080286326Medical devices having antifouling character - According to an aspect of the invention, medical devices are provided which include (a) a substrate and (b) a coating that includes an antifouling copolymer, an adhesive copolymer, or both. Antifouling copolymers for use in conjunction with the present invention contain (i) at least one antifouling polymer block having multiple pendant alkoxy functional groups along the polymer backbone and (ii) at least one additional polymer block. Adhesive copolymers for use in conjunction with the present invention contain (i) at least one adhesive polymer block having multiple pendant ring-hydroxyl-substituted aromatic groups along the polymer backbone and (ii) at least one additional polymer block.11-20-2008
20080286324MEDIA AND DEVICES FOR COLD STORAGE OF THERAPEUTIC CELLS - The invention provides a composition for cold storage of cells which includes a population of isolated stem cells, a cell medium, and isolated trophic factors, as well as devices having a plurality of the trophic factors.11-20-2008
20080292678MEDICAL ARTICLES HAVING ENZYMATIC SURFACES FOR LOCALIZED THERAPY - An enzymatically active medical article is provided, which comprises a medical article and an enzyme disposed at or near a surface of the medical article such that the medical article is provided with an enzymatically active surface. The enzyme is selected, for example, from the group consisting of protease enzymes, glycosidase enzymes, enzymes that degrade cholesterol esters, enzymes that convert hydrocortisone to cortisone, enzymes that degrade oxalate, and enzymes that generate NO from arginine.11-27-2008
20080305145PROCESS FOR DEMINERALIZATION OF BONE MATRIX WITH PRESERVATION OF NATURAL GROWTH FACTORS - A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process.12-11-2008
20080305146SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.12-11-2008
20080305143Controlled Radical Polymerization-Derived Block Copolymer Compositions for Medical Device Coatings - Controlled radical polymerization-derived biocompatible block copolymer coatings for medical devices are disclosed. Specifically, block copolymer coatings designed to control the release of bioactive agents from medical devices in vivo are disclosed. The present application also discloses providing vascular stents with drug-eluting controlled release block copolymer coatings and related methods for making these medical devices and coatings.12-11-2008
20080311171IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.12-18-2008
20080213335GRAFT PROSTHESIS, MATERIALS AND METHODS - A graft prostheses (09-04-2008
20080206305Implantable barrier device - A barrier device is formed of a barrier component that can exhibit anti-inflammatory properties, non-inflammatory properties, and/or adhesion-limiting properties, as well as generate a modulated healing effect on injured tissue. The barrier component can be a non-polymeric cross-linked gel derived at least in part from a fatty acid compound, and may include a therapeutic agent. The barrier device can have anchoring locations to provide an area on the barrier device to interface with an anchoring mechanism. The anchoring locations can include openings and/or anchor elements. The barrier device can also include truss structures that provide additional strength to the barrier component. The barrier device is implantable in a patient for short term or long term applications, and can include controlled release of the therapeutic agent.08-28-2008
20090246243Carbonaceous Protective Multifunctional Coatings - The present invention relates to Diamond-like Carbon (DLC) coatings on metal substrates and methods of making the same. The invention particularly relates, in a preferred embodiment, to a metallic substrate such as stainless steel or Ti alloy having a silicon material (such as an organosilicone, silicon nitride, silicon carbide or silicon carbon nitride) intermediate layer and a DLC layer, optionally doped with Si, deposited thereon, and a method for making the same.10-01-2009
20090311301COATING CONSTRUCT CONTAINING POLY(VINYL ALCOHOL) - A method of forming a surface layer that includes a hydroxyl polymer on a substrate coating on a medical device is provided.12-17-2009
20120294925BIOMATERIAL - A process for the preparation of a composite biomaterial comprising an inorganic material and an organic material, the process comprising: (a) providing a first slurry composition comprising a liquid carrier, an inorganic material and an organic material; (b) providing a mould for the slurry; (c) depositing the slurry in the mould; (d) cooling the slurry deposited in the mould to a temperature at which the liquid carrier transforms into a plurality of solid crystals or particles; (e) removing at least some of the plurality of solid crystals or particles by sublimation and/or evaporation to leave a porous composite material comprising an inorganic material and an organic material; and (f) removing the material from the mould.11-22-2012
20080206300Shaped Article - The shaped article is obtained via a cementitious reaction of a particulate composition reactive with water, whereby said reaction is obtained between said composition and an aqueous, liquid or gaseous phase. The particles of the shaped article are present in the form of interlocked particles, whereby the interlocking of said particles is obtained in a 100% water-saturated atmosphere.08-28-2008
20080248083METHOD FOR TREATMENT OF TISSUE LESION - Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed.10-09-2008
20100143443Biological artificial ligament and method of making - A prosthesis for implantation into a human body is made by a method that includes the steps of providing a natural animal ligament or tendon that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate to improve its mechanical properties, and coupling an active layer to the substrate.06-10-2010
20100143439Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor - Biomimetic microparticles for generation of tissue includes a biodegradable tissue replacement/repair matrix formed of a cross-linked scaffold material using a non-toxic multi-valent ionic cross-linking agent. One or more bioactive materials can be encapsulated and/or coated onto the biodegradable tissue replacement/repair matrix. The biomimetic microparticles are formed without exposure to high temperatures, high pressures, high voltages, and toxic chemicals.06-10-2010
20100143441NORTRIPTYLINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.06-10-2010
20100136082IN SITU SYSTEM FOR INTRA-ARTICULAR CHONDRAL AND OSSEOUS TISSUE REPAIR - Disclosed is a device and method which provide a surgical therapy for in situ treatment and repair of intra-articular cartilage lesions and/or defects. The device is an implantable laminate cartilage repair patch which is bio-compatible and physiologically absorbable. The cartilage repair patch has a first outer cell occlusive layer; a second outer, cell porous layer adapted to be disposed proximate a subchondral bone wound site; and a cartilagenic matrix disposed between the first and second layers. The cartilagenic matrix is a sink for diffusion of autologous stem cells and includes chemical components promoting generation of hyaline-like cartilage in the presence of the autologous stem cells. The method of the present invention provides the autologous compositions, which when used in combination with the repair patch provides a therapeutic system to regenerate replacement hyaline-like intraarticular cartilage.06-03-2010
20100209474MALLEABLE IMPLANTS CONTAINING DEMINERALIZED BONE MATRIX - Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising a polysaccharide. Also described are methods for making and using such medical compositions.08-19-2010
20100209473INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT - The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device, provided with at least one coating containing a therapeutic agent comprised in a matrix which sticks to the intraluminal device, characterised in that said matrix is formed by a biocompatible oil or fat, which oil or fat is a chemically hardened oil or fat.08-19-2010
20100209469Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers - The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.08-19-2010
20090022769Medical Devices Comprising Polymeric Drug Delivery Systems With Drug Solubility Gradients - Disclosed are drug delivery systems comprising drugs admixed with polymers having drug solubility gradients and methods of making the polymers. Also disclosed are medical devices having coatings thereon comprising the drug solubility gradient-containing polymers and at least one drug.01-22-2009
20090123517MEDICAL DEVICES FOR RELEASING THERAPEUTIC AGENT AND METHODS OF MAKING THE SAME - An implantable medical device for releasing therapeutic agent having a medical device body and a plurality of reservoir-defining structures disposed on a surface of the body. A reservoir can be defined by the reservoir-defining structures and therapeutic agent may be located in the reservoir. A cover may extend over the reservoir so that the therapeutic agent is released from the reservoir when the medical device implanted. Methods for making the medical device may also include providing a medical device body, positioning a plurality of reservoir-defining structures on a surface of the body to form a reservoir, loading therapeutic agent into the reservoir, and covering the reservoir so that the therapeutic agent may release when the medical device is implanted. Alternatively, the reservoir may be covered with a cover and an opening formed in the cover so that the therapeutic agent may release when the medical device is implanted.05-14-2009
20100233236DRUG COATED EXPANDABLE DEVICES - Medical devices may be utilized for local and regional therapeutic agent delivery. These therapeutic agents or compounds may reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including restenosis, vulnerable plaque, and atherosclerosis in type 2 diabetic patients.09-16-2010
20100233235COMPOSITIONS AND METHODS FOR PREVENTING CARDIAC ARRHYTHMIA - Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.09-16-2010
20110268782POLYURETHANES FOR OSTEOIMPLANTS - Biological-based polyurethanes and methods of making the same. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant.11-03-2011
20090162413COMPOSITIONS AND METHODS OF ADMINISTERING RAPAMYCIN ANALOGS WITH PACLITAXEL USING MEDICAL DEVICES - Systems and compositions comprising paclitaxel and a second drug, such as rapamycin, analogs, derivatives, salts and esters thereof are disclosed, as well as methods of delivery wherein the drugs have effects that complement each other. Medical devices comprising supporting structures capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. These compositions and systems can be used in combination with other drugs, including anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these and other drugs.06-25-2009
20090123518Biodegradable implants with controlled bulk density - Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is greater than about 0.244 grams/milliliter-atm. Also disclosed are methods of making and using such solid water permeable implants.05-14-2009
20090028921Electrospun Ceramic-Polymer Composite As A Scaffold For Tissue Repair - The present invention relates to compositions and methods of preparing a three-dimensional matrix of micron sized electrospun fibers, wherein the electrospun fibers are formed from a electrospun composite comprising a bioactive ceramic component and a polymer component. The matrix provides an osteoconductive and osteoinductive scaffold supporting osteogenesis and thereby facilitates bone repair.01-29-2009
20100233234System and method for a hydrogel and hydrogel composite for cartilage repair applications - The embodiments and examples provided herein are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the present invention relates to compositions and methods of preparing a hydrogel comprising a water soluble cellulose compound, as well as preparing a three-dimensional matrix of micron sized electrospun fibers, wherein the electrospun fibers are formed from a electrospun composite comprising a water soluble cellulose compound. The matrix provides a scaffold supporting and promoting cartilage regeneration and repair.09-16-2010
20090162415Gel Scaffolds for Tissue Engineering - The present invention discloses a colloid scaffolds for tissue engineering, comprising collagen and hyaluronic acid (HA). The collagen and the hyaluronic acid (HA) are mixed to form colloidal suspension. The ratio of the collagen and the hyaluronic acid is less than or equal to 300, and the best is less than or equal to 200. The colloidal scaffolds more comprises micro-fibers or nano-fibers which are used to enhance cell attachment and increase the strength of colloid scaffolds and reduce water loss and contraction of colloid scaffolds.06-25-2009
20090142386CONTROL OF DRUG RELEASE BY TRANSIENT MODIFICATION OF LOCAL MICROENVIRONMENTS - Methods, formulations, and devices are provided for enhancing drug delivery from a medical device. The method is provided for increasing the rate or quantity of a drug formulation released from an implantable drug delivery device, which method comprises the step of providing a release-modifying agent within or proximate to the implantable drug delivery device, in a manner effective to inhibit gelation, aggregation, or precipitation of the drug formulation being released from the device. The drug formulation and the release-modifying agent may be stored together in at least one reservoir in the implantable drug deliver device. Alternatively, the release-modifying agent may be stored in one or more reservoirs separate from the drug formulation.06-04-2009
20090186061Composition Comprising Polymeric, Water-Insoluble, Anionic Particles, Processes and Uses - The present invention relates to an injectable composition which comprises polymeric, water-insoluble, non-biodegradable, anionic particles, these particles having an irregular shape and a biocompatible carrier with a lubricated surface, a method for preparing the same, a method for treating a tissue in a patient which comprises injecting into the tissue site the injectable composition as a permanent implant and the use of the injectable composition as a medicament, particularly for bulking a tissue site.07-23-2009
20090130162IMPLANTABLE TISSUE COMPOSITIONS AND METHOD - Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed. 05-21-2009
20090136560COATED MEDICAL DEVICE - A coated medical device (05-28-2009
20090186067MEDICAL DEVICES HAVING IMPROVED MECHANICAL PERFORMANCE - According to an aspect of the present invention, implantable or insertable medical devices are provided that contain at least one covalently crosslinked polymeric region, which contains at least one block copolymer comprising at least one low Tg block and at least one high Tg block.07-23-2009
20090186065ISOLATING AND PURIFYING CELLS FOR THERAPY - The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of circulating the subject's body fluid through an affinity moiety coupled matrix, such that the affinity moiety coupled matrix is capable of binding to and extracting target cells from the body fluid, and then eluting the target cells from the affinity moiety. Another aspect of the invention is directed to the apparatus for isolating cells from a subject, comprising a blood circulation system with an arterial side blood circuit for extracting blood and flowing the blood over an affinity moiety coupled matrix that binds to and extracts target cells and a venous side blood circuit for returning the blood to the patient. The invention is also directed to in vivo seeding of biomatrials by implanting the affinity moiety coupled matrix in a subject to attract and bind the target cells in vivo.07-23-2009
20080317812SPACER WITH A COATING THEREON FOR USE WITH AN IMPLANT DEVICE - The present invention relates to a spacer, such as a polymeric spacer, for use with an implant device, e.g., a bone plate, for splinting a fracture of a bone. The spacer includes a body defining a bone healing surface, wherein at least a portion of the bone healing surface has a coating which includes a therapeutic agent, a polymeric carrier, and a buffer medium to stimulate bone growth and/or promote fracture healing. A kit is also disclosed which includes one or more of the spacers, at least one bone plate, and optionally one or more bone screws for securing he bone plate to bone. A method for promoting fracture healing in bone is further disclosed which includes securely situating a coated portion of the spacer adjacent bone.12-25-2008
20080317810Methods and Compositions for Reducing Oxalate Concentrations - The present invention provides methods and compositions for oxalate degradation. The present invention comprises devices comprising oxalate-reducing enzymes. The enzymes may be directly attached or incorporated in coatings on the devices. Such devices are useful in treatments where oxalate or oxalic acid deposits interfere. Methods for making and using such medical devices are also included.12-25-2008
20080317809Use of K -252a and Kinase Inhibitors for the Prevention or Treatment of Hmgb1-Associated Pathologies - The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or treatment of restenosis.12-25-2008
20080317815Induction of a physiological dispersion response in bacterial cells in a biofilm - One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising:12-25-2008
20090208554Baclofen Formulation in a Polyorthoester Carrier - Effective treatments of pain for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of baclofen formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days.08-20-2009
20090324673METHOD FOR PRODUCING BIOACTIVE COMPOSITES - An object of the present invention is to provide a method for producing bioactive composites having imparted thereto bioactivity, to thereby form and grow in vivo or in vitro a coating layer containing a calcium phosphate compound as the major component with a high adhesion strength on the surface of various types of porous substrates such as a porous shaped body comprising an organic polymer. The means for solving the problem is characterized by comprising at least (1) a step of immersing a porous substrate in a solution containing at least calcium ions and hydrogenphosphate ions, thereby distributing the solution to the inside of at least a part of the pores of the substrate, and (2) a step of depositing fine particles containing a calcium phosphate compound as the major component inside the pores into which the solution is introduced.12-31-2009
20090324678Methods and kits for treating joints and soft tissues - Methods to treat and provide pain relief for damaged and degenerated tissues of a musculoskeletal joint are disclosed. These methods include introducing into, around and/or on the musculoskeletal joint an effective amount of a pharmaceutical composition containing a biocompatible matrix or biocompatible polymeric compound, a pain reliever, and a corticosteroid formulated for extended-release, wherein at least a portion of the biocompatible matrix or biocompatible polymeric compound is activated and polymerized in situ. Also disclosed is a composition for treating a damaged or degenerated joint or soft tissue. The composition contains a polymerizable material capable of forming a biocompatible and biodegradable matrix in situ at a treatment site, a pain reliever; and a corticosteroid formulated for extended-release.12-31-2009
20090324674GENETICALLY MODIFIED HEART VALVE XENOGRAFTS - A method for producing a heart valve xenograft from bovine tissue expressing reduced or undetectable levels of I1-3 galactosyl transferase are provided.12-31-2009
20090324675BIOOCOMPATIBLE POLYMER COMPOSITIONS - The present invention provides a biocompatible prepolymer comprising hydrophilic and hydrophobic segments, wherein the hydrophobic segments have at least one ethylenically unsaturated functional group and at least 5% of the segments have two or more ethylenically unsaturated functional groups and water. The invention further provides a biocompatible prepolymer composition comprising hydrophilic and hydrophobic prepolymers, wherein at least one of the hydrophobic prepolymers has at least one ethylenically unsaturated functional group and at least 5% of the prepolymers have two or more ethylenically unsaturated functional groups and water. The invention further provides use of the prepolymer or prepolymer compositions of the invention in biomedical applications such as tissue engineering, as bone substitutes or scaffolds, and in wound treatment.12-31-2009
20090324679MEDICAL COPOLYMERS - According to an aspect of the present invention, medical copolymers are provided which comprise (a) a polymer backbone comprising (i) a plurality of —C═C— groups within the polymer backbone, (ii) a plurality of -R12-31-2009
20090324676POROUS COATING INCORPORATING FLUID RESERVOIRS - Porous coating for the controlled release of fluids such as drugs comprising a porous structure with internal reservoirs and passages, said reservoirs communicating with the external environment through said passages, in such a way that a fluid can move between the reservoirs and the external environment, characterized by the fact that for at least a group of said passages, each passage contains a restricting element which partially restricts the passage cross section.12-31-2009
20090324671Poly(Amide) And Poly(Ester-Amide) Polymers And Drug Delivery Particles And Coatings Containing Same - The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers.12-31-2009
20090053281EMBOLIZATION - Articles and methods that include a particle having a maximum dimension of at most 5,000 microns, and an embolic coil capable of binding to the particle, are disclosed.02-26-2009
20080268012Activating Extraction Of Demineralized Bone Matrix - Demineralized bone matric (DBM) and native bone morphogenetic protein (nBMP) are complex mixtures of non-collagenous bone proteins. These mixtures contain many of the BMPs that are available as recombinant molecules. Information regarding the presence in these materials of molecules that may affect the availability and activity of the BMPs is very limited. A chemical extraction of DBM, such as using alkali-urea produces a water soluble extractate which inhibits the osteogenic activity of DBM. Noggin, an extracellular BMP ligand antagonist is found in the water soluble extractate from DBM. Differential chemical extraction is a useful means of removing non-osteogenic, or osteogenic inhibitory molecules from DBM and nBMP.10-30-2008
20090053277Cell Sheet Containing Mesenchymal Stem Cells - Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 μm) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells. The engrafted mesenchymal stem cells inhibited thinning of the myocardial wall in the scar area, and improved cardiac function and survival rate in rats with myocardial infarcts. Thus, mesenchymal stem cell sheet transplantation may represent a novel therapeutic approach for myocardial tissue regeneration.02-26-2009
20090053279TISSUE REGENERATIVE COMPOSITION - A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.02-26-2009
20090053278ANTI-MICROBIAL COMPOSITIONS AND DEVICES AND METHODS OF USING THE SAME - Embodiments of the present invention include medical devices that are coated with an antimicrobial peptide-based coating. Further embodiments include methods of coating the devices with the antimicrobial peptide-based coating, and treating a subject with the coated medical devices to prevent or relieve bacterial infections in the subject.02-26-2009
20090053280COATING STENTS WITH CYCLIC RGD PEPTIDES OR MIMETICS - It is an object of the present invention to overcome certain disadvantages of stents, such as drug eluting stents. In particular, it is an object to provide a stent with improved re-endothelialization ability and/or simultaneous reduced rate of restenosis and/or minimal or no inflammatory potential.02-26-2009
20090081272MEDICAL DEVICES HAVING A METAL PARTICULATE COMPOSITION FOR CONTROLLED DIFFUSION - An implantable or insertable medical device is provided which includes as components: (a) a substrate component comprising a depression that is at least partially filled with a therapeutic agent-containing material that comprises a first therapeutic agent, and (b) a particulate composition disposed in the depression such that it regulates transport of chemical species between the depression and the exterior of the device upon implantation or insertion of the device into a subject.03-26-2009
20110229549Methods and Compositions for Enhancing Vascular Access - Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state suitable for dialysis. Additionally, the present invention can promote formation of a functional arteriovenous graft suitable for dialysis as well as promote formation of a functional peripheral bypass graft. Implantable material can be configured as a flexible planar form or a flowable composition with shape retaining properties suitable for implantation at, adjacent or in the vicinity of an anastomoses or arteriovenous graft. According to the methods disclosed herein, the implantable material is provided to an exterior surface of a blood vessel. Certain embodiments of the flexible planar form define a slot. The materials and methods of the present invention comprises cells, preferably endothelial cells or cells having an endothelial-like phenotype.09-22-2011
20110229546TREATMENT OF DISSECTION, ANEURYSM, AND ATHEROSCLEROSIS USING GRANZYME B INHIBITORS - A method of medical treatment or prevention of a vasculopathy, comprising administering a therapeutically effective amount of a granzyme B inhibitor to a subject in need thereof is provided. In other aspects uses of Granzyme B inhibitors for treatment or for preparation of medicaments for treatment of a vasculopathy are provided.09-22-2011
20110229548Implantable Medical Device With Poly(Vinylidene Fluoride-Co-Hexafluoropropylene)/Zotarolimus Drug Layer - This invention relates to an implantable medical device for and method of treating a vascular disease where the device is preferably a stent comprising a drug reservoir layer comprising poly(vinylidene fluoride-co-hexafluoropropylene) and zotarolimus.09-22-2011
20090098178Porous Coating Loaded with a Liquid or a Solid Substance - The present invention relates to a process for manufacturing a porous coating with structures in the micro or nano-size domain characterized by the following steps: -providing a support having a surface, -depositing on said surface one mono-layer of temporary particles, -depositing a coating on said temporary particles in such a way that the thickness of said coating is less than the particle diameter, -eliminating said temporary particles and thereby obtaining a porous coating, the pores of said coating corresponding to the spaces previously occupied by the temporary particles and at least a pail of the pores communicating with the external environment, -applying a coating fixation step, characterized by the fact that it furthermore comprise a filling step where said pores are at least partially filled with a liquid or solid substance. The invention also concerns a coating and an object which can be obtained with this process.04-16-2009
20090081275Durable swellable hydrogel matrix and methods - The invention provides biocompatible polymeric hydrogel matrices having excellent durability and swellability. The matrices are formed from a combination of linear and branched hydrophilic macromer compounds. The matrices can be used in association with a medical device or alone. In some methods the polymeric matrix is placed or formed at a target site in which the matrix swells and occludes the target area.03-26-2009
20090081271MEDICAL DEVICES HAVING A FILTER INSERT FOR CONTROLLED DIFFUSION - An implantable or insertable medical device is provided which includes as components: (a) a substrate component comprising a depression that is at least partially filled with a therapeutic agent-containing material that comprises a first therapeutic agent, and (b) a pre-formed filter insert disposed in the depression such that it regulates transport of chemical species between the depression and the exterior of the device upon implantation or insertion of the device in vivo.03-26-2009
20090081270Biodegradable polyurethane and polyurethane ureas - This invention relates to biocompatible, biodegradable thermoplastic polyurethane or polyurethane/ureas comprising isocyanate, polyol and a conventional chain extender and/or a chain extender having a hydrolysable linking group and their use in tissue engineering and repair applications, particularly as stents and stent coating. 03-26-2009
20090169593METHOD OF USING AND PRODUCING TROPOELASTIN AND TROPOELASTIN BIOMATERIALS - A device implantable within a human body, and a method for producing the device, are provided. The device comprises a biocompatible coating on at least a portion of an outer surface of a substrate. The biocompatible coating comprises tropoelastin. A biocompatible coating is formed in situ on the outer surface of the substrate.07-02-2009
20090004240IMPLANTS WITH A PHOSPHAZENE-CONTAINING COATING - The present disclosure relates to implants with a biocompatible coating having antithrombogenic properties and which also contains a pharmacologically active agent, as well as a process for their production.01-01-2009
20090220565METHOD FOR PRODUCING AUTONOMOUSLY CONTRACTING CARDIAC MUSCLE CELLS FROM ADULT STEM CELLS, IN PARTICULAR HUMAN ADULT STEM CELLS - A method for producing autonomously contractile heart muscle cells by cultivating and differentiating stem cells obtained from differentiated exocrine gland tissue of an organism is described. Various uses of the heart muscle cells, in particular in regenerative medicine, are also described.09-03-2009
20090220563ARTIFICIAL TOOTH MEDICATING APPARATUS FOR CONTROLLING, REGULATING, SENSING, AND RELEASING MEDICAL AGENTS INTO THE BODY - An artificial tooth apparatus for dispensing medicating agents to the body through the patient's jaw bone comprising a mechanical movement and kinetic mainspring winder, a tourbillon mechanism, a electronic regulator, and a pump mechanism arranged and configured to allow any medicating agent to be dispensed from the apparatus in a highly controlled and regulated manner according to input received by the electronic regulator and the patient's specific pharmacokinetic and pharmacodynamic attributes. Multiple artificial teeth or a comprehensive bridge with several chambers may be used in cases where a polypharmaceutical approach is needed.09-03-2009
20110142905COATED TABLETS WITH REMAINING DEGRADATION SURFACE OVER THE TIME - The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet, preferably obtainable by compression, said tablet comprising said at least one active ingredient and optionally excipients; and a coating, applied on said tablet, said coating covering at least part of said tablet to impede the release of said at least one active ingredient from at least part of the surface of said tablet, said coating being applied in a manner allowing the release of said at least one active ingredient from said tablet after contacting said pharmaceutical composition with said aqueous phase, establishing one or more degradation surfaces of said tablet; wherein the first derivative of the area of each degradation surface with respect to time is larger than or equal to zero.06-16-2011
20090220566BIOIMPLANTS FOR USE IN TISSUE GROWTH - Disclosed herein is an implant for use in stimulating tissue growth. The implant comprises a body with a body core and a body surface. The body is made from a non-hydrogel polymer material. A tissue growth stimulating material is disposed within the body core or deposited onto the body surface, in an amount which is sufficient to stimulate tissue growth within the body core or adjacent to the body surface. Also disclosed are implant bodies made from ceramic, metallic materials, and non-copper containing hydrogels.09-03-2009
20100003299RNAi Methods and Compositions for Stimulating Proliferation of Cells with Adherent Functions - Described herein are methods and compositions for stimulating proliferation of cells that express adherent junctions and cease proliferation, for example, human corneal endothelial cells, by downregulation of certain cell-cell junctions. In one embodiment, downregulation is achieved using RNA interference, and contacting the cells with mitogenic growth factors and an agent that elevates intracytoplasmic cAMP. Furthermore, described herein are methods of isolating human corneal endothelial cells from keratocytes, and methods of preserving and maintaining viability of human corneal endothelial cell aggregates. Also described are surgical grafts comprising human corneal endothelial cells that have been isolated, optionally stored, and transiently contacted with an agent that downregulates expression of p 120, and a biocompatible support. The methods and compositions described herein can be used in novel therapies to help expand human corneal endothelial cells during in vitro tissue engineering and for in vivo treatment of corneal endothelial dysfunction.01-07-2010
20090220562Osteogenic and anti-adipogenic oxysterols - The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed.09-03-2009
20090220568METHODS FOR TREATING A STRICTURE WITH A BOTULINUM TOXIN - Methods of treating a urethral stricture in a patient. The methods can include the step of administering an therapeutically effective amount of a botulinum toxin directly to a urethra of the patient, for example by use of a stent from which the botulinum toxin can elute or diffuse, thereby treating the urethra stricture.09-03-2009
20090220561COMPOSITIONS COMPRISING NANOSTRUCTURES FOR CELL, TISSUE AND ARTIFICIAL ORGAN GROWTH, AND METHODS FOR MAKING AND USING SAME - The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and/or nanotubes.09-03-2009
20090232866Oligopeptides as coating material for medical products - The present invention relates to a pharmaceutical composition comprising a caspase inhibitor and/or a compound of the general formula R-Lys-X, methods for coating medical products using said caspase inhibitors and/or said compounds of general formula R-Lys-X and medical products coated with said caspase inhibitors and/or said compounds of general formula R-Lys-X.09-17-2009
20090220569Prevascularized Constructs for Implantation to Provide Blood Perfusion - This application discloses methods and materials for preparing functional microvascular beds in the laboratory. These prevascularized constructs can be used to vascularize engineered tissue constructs or to revascularize damaged or diseased tissues or organs following implantation. The prevascularized constructs may also deliver genetically engineered gene products to the bloodstream.09-03-2009
20080260795STRONG REVERSIBLE HYDROGELS - The present invention relates to improved hydrogel materials using water gellants that are comprised of polymer backbones P to which hydrogen bonding 4H-units are covalently attached via a hydrophobic linker L. Optionally, the hydrogel contains additional ingredients or additives. These new reversible hydrogels can easily be fine-tuned in their mechanical performance and function and are especially suitable for biomedical applications.10-23-2008
20090258048Self-Assembling Monomers and Oligomers as Surface-Modifying Endgroups for Polymers - Polymers having the formula R(LE)10-15-2009
20100015204CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS - The present invention relates to a device comprising a cell carrier portion containing regenerative cells, e.g. stem and progenitor cells, and a cell carrier containment portion. The device is useful for the treatment of bone related disorders, including spinal fusion related disorders and long bone or flat bone related defects. The device may be used in conjunction with disclosed automated systems and methods for separating and concentrating regenerative cells.01-21-2010
20090252778METHODS AND DEVICES FOR REDUCING TISSUE DAMAGE AFTER ISCHEMIC INJURY - Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. The anti-restenotic agents are delivered over an administration period sufficient to reduce the re-narrowing of a blood vessel following a cardiac procedure such as implantation of a device. Preferred anti-restenotic drugs are those that do not reduce the beneficial effects provided by the anti-ischemic drug, such as drugs that do not act on the mammalian target of rapamycin (mTOR).10-08-2009
20090252780COATINGS FOR IMPLANTABLE MEDICAL DEVICES - Coatings for implantable medical devices comprising non-fouling moieties or polymers chemically bonded to the surface of the device via chelating structures, and methods of fabricating the coatings are disclosed.10-08-2009
20090274740DRUG-LOADED MEDICAL DEVICES AND METHODS FOR MANUFACTURING DRUG-LOADED MEDICAL DEVICES - Drug-loaded medical devices such as stents and methods for manufacturing them are provided. In certain embodiments, the therapeutic agent is loaded only in or on areas of the medical device that do not undergo substantial deformation during expansion. The medical device may be provided with reservoirs in or on the first portions of the medical device that do not undergo substantial deformation during expansion, and the therapeutic agent may be loaded in these reservoirs. The reservoirs may be covered with a porous coating which may be a non-polymeric coating. In other embodiments, a non-polymeric coating is provided in a discontinuous manner in or on the medical device. A method includes the steps of providing a transfer member that includes a translucent substrate and a layer of transfer material such as a film or foil; attaching reservoirs to the transfer material; positioning the transfer member with the reservoirs adjacent a medical device, such as a stent, with the reservoirs facing the medical device; and directing a laser beam at the transfer member such that the laser beam passes through the translucent substrate to vaporize a portion of the transfer material, creating a pocket of trapped gas between the translucent substrate and reservoir, thereby forcing the reservoir from the transfer member to the medical device. The reservoirs may be formed of a non-polymeric material.11-05-2009
20090324670Polyester Implantable Medical Device With Controlled In Vivo Biodegradability - This invention relates to blends of high, optionally medium, and low molecular weight polyesters where at least the low molecular weight polyester is substituted with an acidic moiety, the biodegradation of the blends being controllable by selection of the mean molecular weigh of each fraction, the quantity of each fraction in the blend and the amount and pKa of the acidic moiety(ies).12-31-2009
20090258055Heparin Prodrugs and Drug Delivery Stents Formed Therefrom - A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-15-2009
20090258051Microbes Encapsulated Within Crosslinkable Polymers - The invention relates to porous films comprising crosslinked electrospun hydrogel fibers. Viable microbes are encapsulated within the crosslinked electrospun hydrogel fibers. The crosslinked electrospun hydrogel fibers are water insoluble and permeable. The invention also relates to methods of making and using such porous films.10-15-2009
20090258052COMPOUNDS AND METHODS FOR ALTERING BONE GROWTH - The present invention provides compounds, compositions and methods for promoting bone growth. Compounds useful in the methods of the present invention include the following:10-15-2009
20090258049DRUG ELUTING EXPANDABLE DEVICES - The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.10-15-2009
20080311170IMPLANT DEVICE RELEASE AGENTS AND METHODS OF USING SAME - Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm12-18-2008
20080317808Hyarulonic Acid Derivative Based Three Dimensional Matrix - Use of a biological material containing: e) a three-dimensional matrix based on a hyaluronic acid derivative and optionally f) chondrocytes and/or mesenchymal cells partially or completely differentiated towards chondrocytes for the preparation of a graft to be surgically implanted into a joint cartilage damaged by or to be protected against a degenerative and/or inflammatory pathology.12-25-2008
20100178312System And Method For Attaching Soft Tissue To An Implant - One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface, and a biocompatible polymer matrix coating the nano-textured surface. The polymer matrix coating comprises a naturally occurring extracellular matrix with biocompatible inorganic materials distributed within the matrix, or a biocompatible polymer and an osteoinductive agent.07-15-2010
20100183700IMPLANTABLE PUMP FOR PROTEIN DELIVERY FOR OBESITY CONTROL BY DRUG INFUSION INTO THE BRAIN - Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor on a neural cell in the central nervous system and modifies the receptor function to suppress appetite.07-22-2010
20100183696Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists - The present invention provides novel agents, expression constructs, compositions and methods useful for treating an ocular disease associated with unwanted PPARδ activity through the modulation of PPARδ expression The PPARδ interference RNA (iRNA) agents, expression constructs encoding such agents, and compositions comprising such agents or constructs are directed against RNA molecules encoding PPARδ The methods comprise treating an ocular disease associated with unwanted PPARδ activity in a patient in need thereof by administering an effective amount of a pharmaceutical composition comprising a PPARδ iRNA agent or expression construct encoding such agent to the patient to reduce a symptom associated with unwanted PPARδ activity in the patient.07-22-2010
20090117168Device and method for attaracting diseased cells and foreign substances - An implantable device for attracting diseased cells or foreign substances circulating within bodily fluid channels is disclosed. The device comprises a frame, an attachment means for maintaining the frame in a localized position in a body vessel, and at least one attractant on the frame, where the attractant is capable of attracting a diseased cell or a foreign substance. The device may also include a therapeutic agent The device may be used for diagnosis, disease containment or treatment. The device may also be used for attracting and localized treatment of diseased cells and foreign substances.05-07-2009
20110104227ABSORBABLE POLYETHYLENE DIGLYCOLATE COPOLYMERS TO REDUCE MICROBIAL ADHESION TO MEDICAL DEVICES AND IMPLANTS - The present invention is directed to absorbable polyether esters that have been found to reduce bacterial adhesion to materials such as medical devices and implants. More specifically, the invention is directed to novel amorphous co-polymers comprising polyethylene diglycolate (PEDG) copolymerized with lactide-rich monomers.05-05-2011
20100183697TISSUE-SEPARATING FATTY ACID ADHESION BARRIER - Exemplary embodiments of the present invention provide adhesion barriers having anti-adhesion and tissue fixating properties. The adhesion barriers are formed of fatty acid based films. The fatty acid-based films may be formed from fatty acid-derived biomaterials. The films may be coated with, or may include, tissue fixating materials to create the adhesion barrier. The adhesion barriers are well tolerated by the body, have anti-inflammation properties, fixate, well to tissue, and have a residence time sufficient to prevent post-surgical adhesions.07-22-2010
20100166824EXTRACELLULAR MATRIX COMPOSITIONS - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.07-01-2010
20120195951Therapeutic Inhibitor of Vascular Smooth Muscle Cells - Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.08-02-2012
20110059153USE OF ANTI-CYTOKINE AGENTS FOR TREATING CARPAL AND TARSAL TUNNEL SYNDROME - Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors, IL-10, Interferon-gamma (IFN-?) act to prevent further inflammation initiated by cytokine factors. One embodiment includes, adding with the anti-cytokine agent one or more of an antibiotic or analgesic. Delivery of the anti-cytokine agent may be provided to the inflamed tissue of the carpal or tarsal tunnel by injection, implantation, or a transdermal patch. These agents, individually or in combination, directly address the underlying inflammation that causes the discomfort, pain, and restricted movement associated with carpal and tarsal tunnel syndrome.03-10-2011
20110059151POROUS BIOMATERIAL ON HYDROPATITE - The present invention provides a synthetic non-resorbable silicon-containing calcium phosphate biomaterial having a microporosity of 23% by volume or greater, wherein the surface free energy of the biomaterial is 19 mJ/m03-10-2011
20110059150COATING METHOD - A method of coating a material onto projections provided on a patch. The method includes applying a coating solution containing the material to at least the projections and drying the coating solution to at least the projections using a gas flow.03-10-2011
20110059149Process for depositing calcium phosphate therapeutic coatings with different release rates and a prosthesis coated via the process - A method of coating a substrate including loading a calcium phosphate substance at a first crystallinity with a therapeutic agent; depositing the loaded calcium phosphate substance at the first crystallinity onto a least a portion of the substance; loading a calcium phosphate substance at a second, lower, crystallinity with a therapeutic agent; and depositing the loaded calcium phosphate substance at the second crystallinity onto the deposited loaded calcium phosphate substance at the first crystallinity to control and sustain a long-term osseointegration response and to control the release rate of the therapeutic substance from the calcium phosphate substance.03-10-2011
20110059148Flexible Drug Delivery Chip, its Fabrication Method and Uses Thereof - Nanodevice and method for in vivo monitoring and release of drugs are provided. The disclosed nanodevice is characterized in having a drug-loaded nanosphere that is capable of releasing the encapsulated drugs upon magnetically stimulation. The nanodevice may also be used as a contrast agent for in vivo imaging and monitoring the concentration and distribution of the released drugs and/or active compounds injected separately into a target site of a subject.03-10-2011
20090252779AZAINDAZOLE COMPOUNDS AND METHODS OF USE - Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.10-08-2009
20100255055GOLD-COATED STENT COATED/PLATED THE CHEMICALS AND OLIGONUCLEOTIDE BINDING GOLD-COATED STENT AND PROCESS FOR PRODUCING THE SAME - The present invention relates to a gold-plated stent and its preparation method. More specifically, it relates to a gold-plated stent that is coated with various chemical materials such as 2-aminoalkanethiol, epihalogenhydrin, and diamine compounds in a sequence and also oligonucleotide gold-plated stent, which is prepared by binding oligonucleotide, a biomaterial, to the gold-plated stent coated with said chemicals. The oligonucleotide gold-plated stent of the present invention has an advantages of raising the local concentration in injured parts and minimizing the toxicity overall the body, so it can be used for prevention of restenosis after angioplasty.10-07-2010
20100255053MEDICAL IMPLANT WITH BIOACTIVE MATERIAL AND METHOD OF MAKING THE MEDICAL IMPLANT - Embodiments of the invention include a medical device and a method of manufacturing a medical device having a porous scaffold in combination with a bioactive material. In some embodiments, particularly limited thicknesses of the bioactive material are applied within pores of the porous structure.10-07-2010
20100226955POLYMER FOR CREATING HEMOCOMPATIBLE SURFACE - A polymer comprising a phosphoryl choline moiety(ies), a composition comprising the polymer and optionally a bioactive agent, an implantable device such as a DES or a non-implantable device such as an angioplasty balloon comprising thereon a coating comprising the polymer and optionally a bioactive agent, and a method of using the device for the treatment of a disorder in a human being are provided.09-09-2010
20090311300Stent With a Coating or a Basic Body Containing a Lithium Salt and Use of Lithium Salts for Prevention of Restenosis - The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.12-17-2009
20100239635DRUG DELIVERY MEDICAL DEVICE - Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on said substrate, wherein said coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of said medical device in the body of said subject a portion of said pharmaceutical agent and/or active biological agent is delivered at said intervention site along with at least a portion of said polymer and/or a at least a portion of said pharmaceutical carrying agents.09-23-2010
20100239634COMPOSITIONS AND METHODS FOR PROMOTING BONE FORMATION - A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided.09-23-2010
20100239636Methods and Devices for Delivering Therapeutic Agents to Target Vessels - Methods of preparing devices for delivering at least one therapeutic agent to a target vessel in a mammal, the devices prepared by such methods, and uses of such devices for delivering a therapeutic agent, such as an antiproliferative agent, to a target vessel.09-23-2010
20100239633IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS - IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.09-23-2010
20100255054PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS - Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.10-07-2010
20100255058BIOCOMPATIBLE POLYACRYLATE COMPOSITIONS FOR MEDICAL APPLICATIONS - A composition comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety is disclosed. A medical article comprising the composition in the coating thereof and a method of fabricating the medical article are also disclosed.10-07-2010
20080260798ALIGNED SCAFFOLDS FOR IMPROVED MYOCARDIAL REGENERATION - The present invention relates to a biocompatible, three-dimensional scaffold useful to grow cells and to regenerate or repair tissue in predetermined orientations. The scaffold is particularly useful for regeneration and repair of cardiac tissue. The scaffold contains layers of alternating A-strips and S-strips, wherein the A-strips within each layer are aligned parallel to each other and preferentially promote cellular attachment over attachment to the S-strips. Methods of producing and implanting the scaffold are also provided.10-23-2008
20100233233TENOCYTE CONTAINING BIOSCAFFOLDS AND TREATMENT USING THE SAME - The present invention relates to methods for preparing bio scaffolds useful in the repair of tears. More specifically, the invention relates to a method of treating rotator cuff tear in a mammalian subject in need thereof comprising the steps of: (i) selectively expanding tenocytes in vitro in culture medium comprising insulin or a functional derivative and a glucocorticoid or a glucocorticoid-like molecule to produce a culture of expanded tenocytes; (ii) seeding a bioscaffold with said expanded tenocytes to produce a tenocyte seeded bioscaffold; and (iii) implanting said tenocyte seeded bioscaffold proximal to the rotator cuff tear. The present invention also relates to a bioscaffold comprising cells, wherein more than 80% of said cells are tenocytes.09-16-2010
20090047321ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS - Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.02-19-2009
20100247603ARSENIC TRIOXIDE MEDICAL ELUTION SCAFFOLD - An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement.09-30-2010
20100129419METHODS AND COMPOSITIONS FOR BLOCKING PLATELET AND CELL ADHESION, CELL MIGRATION AND INFLAMMATION - The present invention provides compositions of saratin and methods of use thereof. One aspect of the invention is a method of prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Another aspect of the invention is a method for treatment of flexor tendon injuries.05-27-2010
20090162414Foamed ceramics - A method for the production of a macroporous ceramic foam, wherein: (a) forming a ceramic slip comprising a substantially homogeneous mixture of a ceramic particulate, an organic binder in a liquid carrier, and optionally one or more surfactants, wherein at least one surfactant is present if the organic binder does not function as a surfactant, and wherein the ceramic slip preferably has a viscosity in the range of from 15 to 200 mPas06-25-2009
20100247602METHOD OF REDUCING THE EFFECTS OF CYTOSTATIC DRUGS ON BONE MARROW DERIVED CELLS, AND METHODS OF SCREENING - A method of using an estrogen receptor agonist and antagonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system. The methods comprise contacting the cells with a therapeutically effective amount of an estrogen receptor agonist or antagonist, and contacting the cells with a cytostatic agent, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced. Agonists disclosed include 17-beta-estradiol. Antagonists disclosed include antisense nucleic acids and selective estrogen receptor modulators (SERMs). Furthermore, uses and medicaments comprising estrogen receptor agonists and antagonists are provided, as are screening methods for identifying therapeutic candidates for reducing the effect of cytostatic agents, and methods of using estrogen receptor agonists for increasing the proliferation of CD11709-30-2010
20100221302Delivery System For Heparin-Binding Growth Factors - A device comprising a scaffold coated with a protein having at least 83% identity to the amino acid sequence of the core protein of domain I of a mammalian perlecan, wherein at least one glycosaminoglycan is attached to the protein is described. The device may be used in vitro or in vivo to induce replication and/or differentiation of connective tissue cells and to repair tissue.09-02-2010
20100129415BONE REGENERATION DEVICE - This invention is directed to a bone regeneration device including fascia and demineralized bone matrix mixed at a temperature not exceeding about 40° C. and lyophilized into the bone regeneration device, methods of preparing such a bone regeneration device and methods of treating bone defects using such a bone regeneration device.05-27-2010
20100119578EXTRACELLULAR MATRIX MODULATING COATINGS FOR MEDICAL DEVICES - A unique method and coatings are provided to promote/allow early stage tissue encapsulation/endothelization of medical devices while effectively controlling excessive tissue buildup by eluting antiproliferative therapeutic agent within a body of a patient. The method involves using a therapeutic agent that suppresses excessive extracellular matrix proliferation and allows/promotes thin tissue healing/encapsulation/endothelization of the device. Optimized timing of onset of elution to match onset of excessive extracellular matrix proliferation for maximum effectiveness is achieved by delay barrier with biochemical switch.05-13-2010
20110129514Hygroscopic coating on a balloon device - The present invention provides a hygroscopic coating on a balloon for an implantable device and methods of making and using the same.06-02-2011
20100086579MACROCYCLIC LACTONE COMPOUNDS AND METHODS FOR THEIR USE - The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a compound myolimus, or a derivative thereof. Further included in the present invention is a method of treating an ophthalmic condition or disease by administering a therapeutically effective amount of a compound myolimus, or a derivative thereof.04-08-2010
20090285873IMPLANTABLE MEDICAL DEVICES AND COATINGS THEREFOR COMPRISING BLOCK COPOLYMERS OF POLY(ETHYLENE GLYCOL) AND A POLY(LACTIDE-GLYCOLIDE) - The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.11-19-2009
20090074835Human disc tissue - This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.03-19-2009
20090074836DIFFUSION-HARDENED MEDICAL IMPLANT - The present invention relates to a new composition and medical implant made therefrom, the composition comprising a thick diffusion hardened zone, and preferably further comprising a ceramic layer. The present invention relates to orthopedic implants comprising the new composition, methods of making the new composition, and methods of making orthopedic implants comprising the new composition.03-19-2009
20090074833BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a composition may be administered to a subject to control bone resorption, inflammation, and/or pain.03-19-2009
20090074832Medical Scaffold, Methods of Fabrication and Using Thereof - Articles of manufacturing comprising electrospun elements having continuous or stepwise gradients of porosity, average pore size, weight per volume and/or of agents for promoting cell colonization, differentiation, extravasation and/or migration are provided. Also provided are methods of manufacturing and using same for guiding tissue regeneration.03-19-2009
20090074831LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and atherosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.03-19-2009
20090074830ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE - The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.03-19-2009
20090232870APPARATUS AND METHOD OF RETAINING AND RELEASING MOLECULES FROM NANOSTRUCTURES BY AN EXTERNAL STIMULUS - An apparatus and method for using nanostructures, such as nanopores, nanofibers, nanowells, or nanocones as carriers for drugs, biomarkers and/or biomolecules. The apparatus and method for use on implant surfaces to retain and release drugs, biomarkers and/or biomolecules on command by an external stimulus.09-17-2009
20090246245SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME - Subcutaneous implants obtained by extrusion containing an active ingredient, and a hydrophilic excipient dispersed in a PLGA matrix so that the weight ratio: (Active Ingredient (AI)+Excipient (E))/PLGA is higher than 0.05 and lower than 1.10-01-2009
20110027336COATINGS FOR IMPLANTABLE DEVICES COMPRISING POLYMERS OF LACTIC ACID AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising polymers of lactic acid.02-03-2011
20090252777Method for formulating a controlled-release pharmaceutical formulation - Methods for making formulations of drugs and crystalline side chain polymers which formulations provide controlled and/or sustained release drug formulations.10-08-2009
20090246249COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE - The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.10-01-2009
20090246250COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE - The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.10-01-2009
20090246248COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE - The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.10-01-2009
20090246246PROCESSES FOR RELIEVING BLOCKED VESSELS AND PRODUCTS THEREBY - Select microbials, microbiologicals, biologics and related naturally occurring or engineered microbial solutions supplement existing device modalities. Likewise, librarying and mapping processes are disclosed by which novel enhanced processes for relieving blocked vessels can be discovered, generated or improved for intravascular usages.10-01-2009
20090246251COATING COMPOSITIONS HAVING IMPROVED PERFORMANCE - The presently disclosed subject matter provides compositions comprising a first substrate-binding domain (a peptide or a polymer) having binding affinity for a tissue or a medical device, a second substrate-binding domain having binding affinity for a target molecule, and the target molecule. In some embodiments, the first and second substrate-binding domains are covalently linked. The first and second substrate-binding domains are covalently coupled to at least one hydrophobic interaction tag, negatively charged interaction tag, or positively charged interaction tag. When the substrate-binding domains are combined and coated onto the tissue or medical device, the hydrophobic interaction tags interact with each other and the charged interaction tags interact with the oppositely charged interaction tags or the oppositely charged substrate binding polymers, to form a macromolecular network of non-covalently coupled substrate-binding domains to load the target molecule onto the tissue or medical device.10-01-2009
20090186063Preparation for regeneration of postoperative, post-traumatic bone defects and method for implantation of this preparation - According to the invention preparation for regeneration of bone defects is employed in many branches of medicine, especially in orthopedics, dental surgery, reconstructive surgery, periodonthology and implantology. The preparation has been developed on the basis of inorganic chemical compound naturally occurring, i.e. deproteinized human bone, and on the basis of at least one of inorganic chemical compounds synthetically occurring, i.e. bioglass in the form of granulated high calcium product (54% mol. CaO), obtained with the use of zol-gel method in the system CaO—SiO07-23-2009
20090110713Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices - The present invention is directed to polymeric materials (e.g., coatings) comprising biodegradable copolymers and implantable devices (e.g., drug-delivery stents) formed of such materials. The biodegradable copolymers are derived from at least two relatively polar monomers and at least one relatively nonpolar monomer. Incorporation of at least one relatively nonpolar monomer into the copolymer improves controlled release of a hydrophobic drug from the polymeric material by increasing the copolymer's miscibility with and permeability to the hydrophobic drug. The polymeric materials can also contain at least one biocompatible moiety, at least one non-fouling moiety, at least one biobeneficial material, at least one bioactive agent, or a combination thereof. The polymeric materials are designed to improve the mechanical, physical and biological properties of implantable devices formed thereof.04-30-2009
20080311172Programmed-release, nanostructured biological construct - A biologically engineered construct comprising of a polymeric biomatrix, designed with a nanophase texture, and a therapeutic agent for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent may be a therapeutic substance or a biological agent, such as antibodies, ligands, or living cells. The nanophase construct is designed to maximize lumen size, promote tissue remodeling, and ultimately make the implant more biologically compatible. The nano-textured polymeric biomatrix may comprise one or more layers containing therapeutic substances and/or beneficial biological agents for the purpose of controlled, differential substance/drug delivery into the luminal and abluminal surfaces of the vessel or lumen, and the attraction of target molecules/cells that will regenerate functional tissue. The topographic and biocompatible features of this layered biological construct provides an optimal environment for tissue regeneration along with a programmed-release, drug delivery system to improve physiological tolerance of the implant, and to maximize the cellular survival, migration, and integration within the implanted tissues.12-18-2008
20080274156Composition forstimulating bone growth and differentiation and method for isolating same - This invention relates to isolated heparan sulphate and use thereof to stimulate bone cell growth and differentiation. The invention also relates to use of heparan sulphate with implants, prosthesis and bioscaffolds to repair and regenerate bone. Such use may be for repair of damaged tissue including bone tissue, for example damage resulting from injury or defect.11-06-2008
20080274157Cartilage implant plug with fibrin glue and method for implantation - The invention is directed toward a cartilage repair assembly comprising a shaped structure of subchondral bone with an integral overlying cartilage cap which is treated to remove cellular debris and proteoglycans and milled cartilage in a bioabsorbable carrier. The shaped structure is dimensioned to fit in a drilled bore in a cartilage defect area so that said shaped bone and cartilage cap when centered in the bore does not engage the side wall of the bore and is positioned from the side wall of the bone a distance ranging from 10 microns to 1000 microns and is surrounded by milled cartilage and a fibrin thrombin glue. A method for inserting the assembly into a cartilage defect area is disclosed.11-06-2008
20080268015Methods and compositions for promoting localization of pharmaceutically active agents to bone - Compositions are provided comprising a family of peptides having binding specificity for bone, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to bone, and are used in methods related to bone implants, bone repair, and bone-related diseases.10-30-2008
20090110712Methods and systems for use of photolyzable nitric oxide donors - The present disclosure relates to methods and systems for use of photolyzable nitric oxide donors for the treatment of sexual dysfunction.04-30-2009
20100297211BIOBENEFICIAL POLYAMIDE/POLYETHYLENE GLYCOL POLYMERS FOR USE WITH DRUG ELUTING STENTS - This disclosure provides a medical device and a method of forming the medical device. The medical device comprises a coating comprising a type-one polymer and a type-two polymer. The type-one polymer comprises at least two different blocks, at least one L1 block with the formula11-25-2010
20110212154Biodegradable Implantable Drug Delivery Device - The invention relates to biodegradable and implantable devices for the in situ delivery of a pharmaceutical composition to a human or animal that comprise a generally discoid body, having at least one aperture through which the body is anchorable by suture, and that are formed from biodegradable polymeric compositions. The invention relates to methods of manufacturing devices for the in situ delivery of a pharmaceutical composition to a human or animal that comprise a generally discoid body, having at least one aperture through which the body is anchorable by suture, and that are formed from biodegradable polymeric compositions. The invention relates to a therapeutic method that comprises inserting a biodegradable and implantable device that comprises a generally discoid body, having at least one aperture through which the body is anchorable by suture, and that is formed from a biodegradable polymeric composition, into a body cavity of a human or animal.09-01-2011
20090047323Medical Devices Containing Rapamycin Analogs - A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to Formula (I). This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.02-19-2009
20100297212SCAFFOLD FOR CELL GROWTH AND DIFFERENTIATION - The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.11-25-2010
20110117169METHODS AND COMPOSITIONS FOR CAPTURE OF CELLS - Compositions and methods are provided for capturing cells. Cell binding peptides are provided that bind to one or more of stem cells, fibroblasts, or endothelial cells. In the methods, a sample containing cells is contacted with a cell binding peptide attached to a substrate, and the cells present in the sample are captured onto the substrate through binding to the cell binding peptide.05-19-2011
20110117168METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.05-19-2011
20110117167METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.05-19-2011
20110117165IMPLANTABLE BONE GRAFT MATERIALS - Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached BMP binding peptide. In addition, an implantable bone graft material is provided consisting essentially of a resorbable β-TCP and a resorbable polymer, wherein the β-TCP has a total porosity of about 50% or greater and wherein the β-TCP has a particle size ranging from about 100 micron to about 300 micron. The implantable bone graft materials are useful for promoting bone growth in a subject.05-19-2011
20110117163BIOACTIVE COATING FOR AN IMPLANTABLE DEVICE OR BIOPROSTHESIS - For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration.05-19-2011
20110123594Implantable or Insertable Medical Devices For Controlled Delivery of a Therapeutic Agent - The present invention is directed to novel implantable or insertable medical devices that provide controlled release of a therapeutic agent. According to an embodiment of the present invention, a therapeutic-agent-releasing medical device is provided, which comprises: (a) an implantable or insertable medical device; (b) a release layer disposed over at least a portion of the implantable or insertable medical device; and (c) a therapeutic agent. The release layer comprises a styrene copolymer and at least one additional polymer. The release layer regulates the rate of release of the therapeutic agent from the medical device upon implantation or insertion of the device into a patient. The present invention is also directed to methods of forming the above implantable or insertable medical devices, methods of administering a therapeutic agent to a patient using such devices, and methods of modulating the release of therapeutic agent from such devices.05-26-2011
20090258054Heparin Prodrugs and Drug Delivery Stents Formed Therefrom - A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.10-15-2009
20100303884GROWTH FACTOR COMPLEXES AND MODULATION OF CELL MIGRATION AND GROWTH - Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.12-02-2010
20100303881Therapeutic Electrospun Fiber Compositions - The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits.12-02-2010
20100303880Tissue scaffolding comprising surface folds for tissue engineering - The invention is directed to solid gradient scaffolds, methods of producing the same, and therapeutic applications arising from their utilization. Specifically, the gradient scaffolding includes, inter-alia, surface folds of various configuration for increasing surface area to volume of the scaffold.12-02-2010
20100303886GRAFT MATERIALS AND METHODS FOR STAGED DELIVERY OF BIOACTIVE COMPONENTS - Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).12-02-2010
20100303885METHOD FOR PRODUCING AN IMPLANTABLE BONE COMPOSITION - Disclosed are methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for use in graft implantation obtainable by said methods.12-02-2010
20100303882Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.12-02-2010
20110014261SCAFFOLD FOR TISSUE REGENERATION IN MAMMALS - A three-dimensional scaffold with interconnected pores for repair of tissue comprising a scaffold body for structural support of the tissue scaffold, where the scaffold body comprises scaffold body components bonded to each other and made from component materials comprising about 40 to about 90 wt % B01-20-2011
20100330145BIOBENEFICIAL COATING COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF - A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.12-30-2010
20090068249 METAL ALLOYS FOR MEDICAL DEVICES - A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device.03-12-2009
20090068248POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME - The present invention provides compound of the formula (I):03-12-2009
20090068244Polymeric/carbon composite materials for use in medical devices - The invention provides implantable or insertable medical devices, which contain one or more composite regions. These composite regions, in turn, contain polymer and carbon particles. Also, the invention provides composite materials for use in a medical device containing styrene-isobutylene copolymer and carbon nanotubes.03-12-2009
20110008405Hollow Tubular Drug Eluting Medical Devices - A method of a forming a hollow, drug-eluting medical device includes providing composite member having an outer member and a core member disposed within a lumen of the outer member. The composite member is shaped into a pattern. Openings are formed through the outer member of the composite member. The composite member is processed to remove the core member from the lumen of the outer member without harming the outer member, leaving a hollow tubular member already formed into the desired pattern. The lumen of the outer member is filled with a therapeutic substance.01-13-2011
20100189762TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.07-29-2010
20110014265Implant Improving Local Bone Formation - A bone implant comprises an active agent on at least a portion thereof. The active agent is locally deliverable to bone proximate the implant in at least a two-phased release scheme. A first phase rapidly releases a first quantity of the active agent, and at least a second phase gradually releases a second quantity of the active agent, whereby bone formation stimulated by the active agent is modulated. In one embodiment, a porous implant comprises a porous portion coated with a calcium phosphate compound and which is contacted with a bisphosphonate compound to form a bisphosphonate layer chemically bound to the calcium phosphate at the surface of the porous portion and to form bisphosphonate molecules being non-chemically attached inside the pores of the porous portion. The non-chemically attached bisphosphonate molecules are released in the subject at a rate greater than that of the chemically bound bisphosphonate layer.01-20-2011
20110014264Medical Devices Having Nanostructured Regions For Controlled Tissue Biocompatibility And Drug Delivery - According to certain aspects of the invention, implantable or insertable medical devices are provided that contain one or more nanoporous regions, which may further comprise interconnected nanopores. Other aspects of the invention are directed to implantable or insertable medical devices that contain one or more nanostructured regions, which are formed by a variety of methods. Still other aspects of the invention are directed to implantable or insertable medical devices having nanotextured surface regions, in which cell-adhesion-promoting biomolecules (e.g., glycosaminoglycans, proteoglycans, cell adhesion peptides, and adhesive proteins) are provided on, within or beneath the nanotextured surface regions.01-20-2011
20110014262CONTROLLING VESSEL GROWTH AND DIRECTIONALITY IN MAMMALS AND IMPLANTABLE MATERIAL - A method for directing vessel growth toward a blood-deficient site in a mammal comprising implanting into the mammal an assembly of at glass fibers to form a vascular bridge with a first end of the vascular bridge in contact with the blood-deficient site and a second end of the vascular bridge remote from the blood-deficient site. Over time the bridge biodegrades and promotes vascularity in the direction of the bridge.01-20-2011
20110111005BIOCOMPATIBLE MATERIAL AND USES THEREOF - The present invention relates to a biocompatible ceramic material comprising Sr, Mg or Ba doped Hardystonite (Ca05-12-2011
20090035349Composite scaffolds and methods using same for generating complex tissue grafts - A composite scaffold for engineering a heterogeneous tissue is provided. The composite scaffold includes: (a) a first scaffold being capable of supporting formation of a first tissue type thereupon; and (b) a second scaffold being capable of supporting formation of a second tissue type thereupon; wherein the first scaffold and the second scaffold are arranged with respect to each other such that when the first scaffold supports the first tissue type and the second scaffold supports the second tissue type, a distance between any cell of the second tissue type and the first tissue type does not exceed 200 μm.02-05-2009
20090035347ISOLATED STROMAL CELLS AND METHODS OF USING THE SAME - Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed. The methods comprise introducing into such individuals, stromal cells that are administered in a manner that physically isolates them from the recipient's immune system and that comprise a gene construct that comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells.02-05-2009
20100178311IMPLANT AND METHOD FOR ITS MANUFACTURE - The invention is directed to an implant (07-15-2010
20110033518PEPTIDES PROMOTING LIPID EFFLUX VIA ABCA1 AND ACTIVATING A LIPOPROTEIN LIPASE - Disclosed herein are peptides and peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway, as well as peptides that activate lipoprotein lipase, and compositions comprising such peptides or combinations thereof. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells and activate lipoprotein lipase within cells are also disclosed herein.02-10-2011
20100150982DEPOSITION OF NANOCRYSTALLINE CALCITE ON SURFACES BY A TISSUE AND CELLULAR BIOMINERALIZATION - Disclosed are articles comprising layered nanocrystalline calcite and methods for forming nanocrystalline calcite layers and compositions comprising nanocrystalline calcite layers.06-17-2010
20110150963BIOACTIVE ANTIBACTERIAL BONE GRAFT MATERIALS - The present invention generally relates to bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety of clinical applications including spine and orthopaedic procedures.06-23-2011
20100143440UL97 INHIBITORS FOR TREATMENT OF PROLIFERATIVE DISORDERS - Methods and compositions related to treating or preventing a proliferative disease in a subject comprising administering an inhibitor of a UL97 or a UL97 homolog to the subject are described.06-10-2010
20110038914CORAL-DERIVED COLLAGEN AND METHODS OF FARMING SAME - An isolated collagen fiber is disclosed, wherein a length of the fiber prior to stretching by about 15%, is identical to a length of the fiber following said stretching by about 15%. The fiber comprises a Nuclear Magnetic Resonance (NMR) spectroscopic profile as shown in FIG. 02-17-2011
20110244015IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.10-06-2011
20090068246COLLAGEN-RELATED PEPTIDES AND USES THEREOF - The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof.03-12-2009
20090098181TRIAZOLOPYRIDAZINES AS KINASE MODULATORS - The invention is directed to triazolopyridazine compounds of Formula I:04-16-2009
20100255057Device for actively removing a target cell from blood or lymph of a vertebrate subject - Devices, systems, and methods are described herein for controlling the level of one or more target cell types in the blood fluid and/or lymph fluid of a vertebrate subject. Devices and systems are provided that include a body defining at least one lumen configured for fluid flow; at least one controllable flow barrier to the at least one lumen; one or more sensor configured to detect one or more target cell types in blood fluid or lymph fluid of a vertebrate subject; at least one treatment region disposed within the at least one lumen; at least one reactive component disposed in the at least one treatment region, the at least one reactive component configured to modulate a physiological effect of the one or more target cell types in the vertebrate subject; and at least one controller in communication with the one or more sensor and in communication with the at least one controllable flow barrier to the at least one lumen; wherein the at least one controller is configured to open or close the at least one controllable flow barrier in response to the one or more sensor.10-07-2010
20100226956Production of moldable bone substitute - Composites and methods of producing a mouldable bone substitute are described. A scaffold for bone growth comprises nanocrystalline hydroxyapatite (HA), a bioresorbable plasticizer, and a biodegradable polymer. Plasticizers of the invention include oleic acid, tocopherol, eugenol, 1,2,3-triacetoxypropane, monoolein, and octyl-beta-D-glucopyranoside. Polymers of the invention include poly(caprolactone), poly(D,L-Lactic acid), and poly(glycolide-co lactide). Methods of regulating porosity, hardening speed, and shapeability are also described. Composites and methods are described using nanocrystalline HA produced with and without amino acids. The scaffold for bone growth described herein displays increased strength and shapeability.09-09-2010
20100221304Bionanocomposite Materials and Methods For Producing and Using the Same - The present invention provides bionanocomposite materials comprising at least two coaxial layers of bionanocomposites, and methods for producing and using the same. The bionanocomposite materials of the present invention comprise a core structure and a shell structure encapsulating the core structure, where one of the core structure or the shell structure comprises a porous biocompatible natural-derived material and the other comprises a biocompatible biomimetic nanostructure.09-02-2010
20110086080EX-VIVO PRODUCTION OF HUMAN DEMINERALIZED BONE MATRIX - The present disclosure provides ex vivo-derived human demineralized bone matrix. The bone matrix is produced using mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating bioreactor, such as a High Aspect Ratio Vessel (HARV) culture system. The ex vivo-derived human demineralized bone matrix of the disclosure can be used in, for example, orthopedic and periodontal procedures.04-14-2011
20100062038Markers, Antibodies and Recombinant scFvs for Mesenchymal Stem Cell Sub-populations and Osteoclasts - Abstract Markers, antibodies and recombinant scFvs for Mesenchymal Stem Cell sub-populations and osteoclasts. The present invention relates to specific epitopes of surface membrane bound glycoproteins expressed by mesenchymal stem cells and pre-osteoclasts and relates to antibodies such as monoclonal antibodies and recombinant scFv or fragments thereof, raised to the particular epitope and their use in identifying, isolating, and characterization of mesenchymal stem cell sub-populations such as that termed “Stromal Progenitor Cells” (SPCs) in bone marrow and identifying, isolating, and characterization of pre-osteoclasts in peripheral blood. By binding to a specific epitope on the cell surface, limbin/EVC-2 detection and separation by conventional cell sorting methodologies are facilitated.03-11-2010
20090226503ADHESION INHIBITING MATERIAL FOR VERTEBRAL/SPINAL OPERATION - It is to provide a material to inhibit spine/spinal cord adhesion in the form of a sponge, a film or a suspension to be used for the purpose of assisting/accelerating the tissue healing. An adhesion inhibiting material for a spine/spinal cord surgery in the form of a sponge, a film or a suspension to be used for reducing the degree of adhesion or for inhibiting adhesion caused by a spine/spinal cord surgery, which contains a crosslinked acid polysaccharide.09-10-2009
20100015202CANCELLOUS CONSTRUCT WITH SUPPORT RING FOR REPAIR OF OSTEOCHONDRAL DEFECTS - The invention is directed toward an osteochondral repair assembly comprising a shaped allograft construct comprising an unbalanced barbell-shaped cylindrical cancellous bone primary member formed with a mineralized cylindrical base section having a smaller diameter cylindrical stem leading to a second cylindrical section which is demineralized. A mineralized ring-shaped support member is forced over the compressed demineralized second demineralized the aperture of the ring-shaped member to fit around the stem with one ring surface being adjacent the bottom surface to the second cylindrical section and the opposite ring surface being adjacent the upper surface of the mineralized cylindrical base section.01-21-2010
20090317440ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS - Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.12-24-2009
20090324681Vascularization Enhanced Graft Constructs - A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of liver basement membrane and extracts and hydrolysates thereof, and processed collagen from vertebrate non-submucosal sources, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance the initiation of vessel-like structures in the grant. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired. Methods for enhancing the vascularization in vivo of these tissue graft constructs and for preparing these graft constructs are also provided.12-31-2009
20100062037SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME - Subcutaneous implants obtained by extrusion containing an active ingredient dispersed in a PLGA matrix obtained by grinding an extruded product consisting of a blend of: at least two PLGA having different lactic acid/glycolic acid molar ratios and different weight average molecular weights, or a PLGA and PLA having different weight average molecular weight.03-11-2010
20100015197AMPHIPHILIC PEPTIDES AND HYDROGEL MATRICES THEREOF FOR BONE REPAIR - The present invention relates to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.01-21-2010
20100047310Bio-acceptable conduits and method providing the same - Disclosed is a bio-electrospinning technique for preparing a cell-containing, oriented, continuous tubular scaffold, made of biodegradable polymer, designed for use as a nerve guide conduit (NGC) in nerve regeneration. With a coaxial spinneret, the PC-12 cell medium solution was co-electrospun into a core of tubular fibers, with PLA on the outer shell. The resulted fibers' morphology was characterized via SEM and optical microscopy, and following structural characteristics were found: 1. the larger, hollow fibers had diameters in tenth of microns and wall thicknesses around few microns, 2. an orientation in a preferred direction with the aid of a high-rotating collection device. The fluorescent PC12 cells embedded within the scaffold were cultured and nerve growth factor was added. We observed cells could not only survive the process, but also sustain their viability by undergoing differentiation process, extending neurite along the micro tubular scaffold in the desired direction. All these results demonstrate its potential application for advanced NGC.02-25-2010
20100062035Biocompatible Antimicrobial Filament Material - The invention provides a biocompatible filament material having an antimicrobial finish, in particular in the form of a surficial layer, the finish comprising polyhexamethylenebiguanide (PHMB) as a nonspecifically antimicrobially active component, and also a process for producing the filament material, comprising the steps of: 03-11-2010
20100055148Biological artificial nerve guide and method of making - A biological nerve guide for implantation into a human body is made by providing a natural animal tissue membrane, crosslinking and fixing the membrane, minimizing the antigens from the membrane, tanning the membrane, coupling an active layer to an inner surface of the membrane, cutting the membrane into a desired shape and size, positioning the cut membrane onto a rod-shaped mold so that the cut membrane assumes a cylindrical configuration, and attaching a spiral support to the outer surface of the cut membrane.03-04-2010
20100055144High aspect ratio template and method for producing same - Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing process begins with a first polymer fiber arranged in a matrix formed by a second polymer fiber. End caps may be attached to provide structural support and the polymer fiber matrix selectively dissolved away leaving only the long polymer fibers. These may be exposed to another product, such as a biocompatible gel to form a biocompatible matrix. The polymer fibers may then be selectively dissolved leaving only a biocompatible gel scaffold with the pores formed by the dissolved polymer fibers.03-04-2010
20110097378DECELLULARIZED LIVER FOR REPAIR OF TISSUE AND TREATMENT OF ORGAN DEFICIENCY - The present invention provides a liver-derived devitalized mammalian parenchymatous tissue composition which includes an interstitial structure of connective tissue which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.04-28-2011
20110097374Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws - A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. The screw has a cannulated internal reservoir that contains a chondrocyte growth-inducing pharmaceutical (such as a growth factor or small molecule) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate.04-28-2011
20110086082COMPOSITION, SYSTEM, AND METHOD FOR MODULATING RELEASE KINETICS IN IMPLANTABLE DRUG DELIVERY DEVICES BY MODIFYING DRUG SOLUBILITY - An implantable drug delivery device loaded with a beneficial agent is provided, wherein the beneficial agent is in two different forms, a first form having a higher solubility and a second form having a lower solubility, and wherein the two different forms are present in a proportion which is selected to achieve a desired release rate.04-14-2011
20090028919SYSTEMS AND METHODS OF PROMOTING ENGRAFTMENT OF A HYBRID LOWER LIMB ARTERY BYPASS VASCULAR GRAFT IN A MAMMAL - Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop subsystem is capable of adjusting at least two dynamic conditions in the specimen holder or a diameter of a specimen in the specimen holder. Embodiments of methods can promote engraftment of a hybrid lower limb artery bypass vascular graft following implantation into a mammal's body by placing the hybrid lower limb artery bypass vascular graft in a system embodiment according to the invention prior to implantation of the hybrid lower limb artery bypass vascular graft into the mammal's body.01-29-2009
20090028920UROLOGICAL DEVICES INCORPORATING COLLAGEN INHIBITORS - Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is a urethral, ureteral, or nephroureteral catheter or stent. Kits comprising the same are also provided.01-29-2009
20110177152Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease - A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.07-21-2011
20100136084RESPONSIVE POLYMERIC SYSTEM - A novel environmentally responsive polymeric system is provided for biomedical applications, comprising silicon-containing reactive groups which undergo a hydrolysis-condensation reaction at a predetermined body site and thereby change rheological and mechanical properties of the polymeric system. The polymeric system is useful, for example, as a sealant, as a matrix for drug delivery, in the prevention of post-surgical adhesions, and in gene therapy.06-03-2010
20110081395ULTRA-NANOCRYSTALLINE DIAMOND AS A BIOMATERIAL FOR ENHANCING PROLIFERATION AND DIFFERENTIATION OF NEURAL STEM CELLS - Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film may comprise a hydrogen-terminated or an oxygen-terminated surface. The hydrogen-terminated surface promotes proliferation and differentiation of a neural stem cell into neurons, and the oxygen-terminated surface promotes a neural stem cell to proliferate and differentiate into oligodendrocytes.04-07-2011
20080274158Hydrazide Compounds with Angiogenic Activity - Compounds exhibiting angiogenic properties incorporating the structure of Formula I:11-06-2008
20110150962THERAPEUTIC AGENT CAPSULE FOR IMPLANTS - The present invention discloses a system for releasing one or more therapeutic agents contained within a capsule onto or into an implant. At least one capsule is inserted in a recess preferably located along a longitudinal axis of the implant. The at least one adhesive capsule may be inserted in the recess and held in place therein by a holder. A plurality of adhesive capsules and holders may be inserted in one or more recesses located substantially along the longitudinal axis of the implant. The at least one capsule preferably has a casing housing one or more therapeutic agents, wherein the capsule is configured to be pierced by the at least one fastener to release the one or more therapeutic agents. The casing of the capsule may form an annular passageway to receive a guide wire for aiding the insertion of the capsule in an implant having a longitudinal bore along at least a portion thereof.06-23-2011
20100068241RECONSTITUTED MINERALIZED CARTILAGE TISSUE - A biological material comprising a continuous layer of cartilaginous tissue reconstituted in vitro which contains components associated with cartilage mineralization. The biological material may be cultured with a mineralizing agent to form a mineralized biological material. The mineralized biological material is characterized by having a biochemical composition and physiological organization substantially similar to the deep and contiguous calcified cartilage zones of articular cartilage found in animals in vivo. Methods for preparing the biological materials and methods of using the biological materials are described.03-18-2010
20110104229Bone Xenograft - The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft (X) for the implantation into a defect (D) located in a bone portion (05-05-2011
20110104231BIOCERAMIC AND BIOPOLYMER COMPOSITE - The invention provides a high performance porous bioceramic composite that has a high compression strength resulting from the ability to compression form a bioceramic precursor material and a pore forming agent under a high pressure load prior to sintering and/or removing the pore forming agent. Methods of making and using the same are also provided. Optionally, a biopolymer and/or therapeutic agent may be infused into the pores thereby forming the bioceramic composite.05-05-2011
20090214616BIOMATERIALS HAVING NANOSCALE LAYERS AND COATINGS - The invention generally relates to substrates and surfaces having substrates. Generally speaking, the substrates may be thinly layered substrates, and the surfaces may comprise thinly layered substrates. Additionally, the substrates may comprise a multifunctional water soluble polymer and a lipoprotein and the surfaces may comprise a multifunctional water soluble polymer and a lipoprotein.08-27-2009
20090214614Method for Cell Implantation - The present invention provides for a method for tissue engineering by cell implantation that involves the use of a scaffold in situ at the site of a defect, where the therapeutic cells are fixed in place into the scaffold only once the scaffold is inserted at the site of the tissue defect, thereby locking not only the cells to the scaffold, but also the scaffold to the tissue defect. The invention also provides a kit of parts suitable for performing the method of the invention.08-27-2009
20090214613Endothelized Artificial Matrix Comprising a Fibrin Gel, Which Is a Superproducer of Proangiogenic Factors - The invention relates to an endothelized artificial matrix comprising a fibrin gel, which is a superproducer of proantiogenic factors. The inventive matrix comprises a fibrin gel containing embedded endothelial cells which have been transfected in vitro with at least one adenoviral vector containing the sequence encoding at least one proangiogenic factor, which is inserted such that it can be overexpressed in said endothelial cells. The insertion of the aforementioned matrix between a flap and the receptor site thereof during a transplant procedure improves the survival rates of said flap, since the endothelized matrix can induce angiogenesis both in the flap and in the receptor site and, in this way, improve the vascularization of the transplanted area.08-27-2009
20110081397Mesh Implant - The present disclosure relates to implants including a porous substrate, a first hydrogel precursor, a second hydrogel precursor and a mesh. The first and second hydrogel precursors are applied to the porous substrate. The mesh has a first portion in contact with the porous substrate and a second portion exposed for tissue contact.04-07-2011
20110070282Materials and Methods for Treating Skeletal System Damage and Promoting Skeletal System Repair and Regeneration - Disclosed herein are materials and methods suitable for treating injured, damaged or diseased mineralized and non-mineralized skeletal tissues, including bones, joints, tendons, ligaments, cartilage and/or other non-mineralized skeletal tissues. The affected structure can be treated by contacting a surface of the skeletal element at or adjacent to or in the vicinity of an area of injury, damage or disease with an implantable material. The implantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected structure. A composition comprising a biocompatible matrix and cells engrafted therein or thereon can be used to treat the affected structure. The composition can be a flexible planar material or a flowable composition.03-24-2011
20110070283Coating For Implantable Devices And A Method Of Forming The Same - Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.03-24-2011
20110150965MEDICAL DEVICES HAVING ADHERENT POLYMERIC LAYERS WITH DEPTH-DEPENDENT PROPERTIES - According to one aspect of the invention, a method of forming a medical device is provided, which includes: (a) contacting a substrate with a solution that contains (i) one or more types of polymers, (ii) a solvent that contains one or more types of solvent species, and (iii) one or more optional agents, for example, one or more therapeutic agents, among others; and (b) removing the solvent from the solution, thereby forming a polymeric layer on the substrate. The composition of the solution is changed over the course of forming the polymeric layer. In another aspect of the invention, a medical device is provided, which includes a substrate and a polymeric layer over the substrate. The polymeric layer contains a copolymer that contains differing first and second monomers. The lower surface of the polymeric layer contacting the substrate has a surface concentration of the first monomer relative to the second monomer that is higher than that of the upper surface of the polymeric layer opposite the substrate.06-23-2011
20080254092Acellularized Biomaterial from Embryonic Stem Cells - Compositions containing acellularized biomaterial derived from differentiating pluripotent cells, for example, embryonic stem cells are provided. The acellularized biomaterial can be used to promote wound healing, promote tissue regeneration, or inhibit scarring. Methods for using the acellularized biomaterial for treating degenerative diseases are also provided.10-16-2008
20100310623Synergetic functionalized spiral-in-tubular bone scaffolds - An integrated scaffold for bone tissue engineering has a tubular outer shell and a spiral scaffold made of a porous sheet. The spiral scaffold is formed such that the porous sheet defines a series of spiral coils with gaps of controlled width between the coils to provide an open geometry for enhanced cell growth. The spiral scaffold resides within the bore of the shell and is integrated with the shell to fix the geometry of the spiral scaffold. Nanofibers may be deposited on the porous sheet to enhance cell penetration into the spiral scaffold. The spiral scaffold may have alternating layers of polymer and ceramic on the porous sheet that have been built up using a layer-by-layer method. The spiral scaffold may be seeded with cells by growing a cell sheet and placing the cell sheet on the porous sheet before it is rolled.12-09-2010
20100310625METHODS FOR PURIFYING INSOLUBLE BONE GELATIN - The present invention provides methods for purifying insoluble bone gelatin and uses for insoluble bone gelatin. The process for isolating insoluble bone gelatin from bone tissue includes grinding the bone tissue into bone powder; washing the bone powder with saline; demineralizing the bone tissue; contacting the bone powder with a neutral salt; and contacting the bone powder with a stabilizer. The present invention also discloses an insoluble bone gelatin including about 10 percent growth factor. Insoluble bone gelatin is useful, for example, in preparing impaction bone grafts.12-09-2010
20100310624CROSSLINKED BIOABSORBABLE MEDICAL DEVICES - The present invention is directed to bioabsorbable medical devices which are introduced into the body of a subject in a first configuration and deformed in the subject's body to a second configuration. The devices generally include at least one bioabsorbable expandable device component that comprises at least one type of biodegradable polymer. In accordance with an aspect of the invention, the expandable device component is crosslinked while in an expanded configuration. The crosslinked device component is then heated to a temperature above the glass transition temperature (Tg) of the material forming the device component. Upon heating to this temperature, the device component is compressed into a contracted configuration and cooled to below the Tg of the material to maintain the contracted configuration.12-09-2010
20110033517COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING HYDROPHILIC SUBSTANCES AND METHODS FOR FABRICATING THE SAME - A segmented polyurethane and an amphiphilic random or block copolymer are disclosed. The segmented polyurethane and the amphiphilic random or block copolymer can be used for fabricating a coating for an implantable medical device such as a stent.02-10-2011
20100291174BIOLOGICALLY ACTIVE DEVICE AND METHOD FOR ITS PRODUCTION - The present invention is directed to a biologically active device with a main body made from a polymer, in which bioactive nanoparticles of one or several materials are embedded, wherein the nanoparticles of at least one material proliferatively act on a biological material contacted by the device, and wherein nanoparticles of a different material act in an anti-proliferative manner on biological material in the ambience of the device. The invention is also directed to a method of manufacturing a biologically active device with a main body made from a polymer, wherein nanoparticles of several different materials are dispersed in an injection-moldable fluid, and the fluid is shaped into the polymer main body by means of injection molding and curing, such that the nanoparticles are dispersed in the bulk of the polymer main body. According to the invention, the nanoparticles are generated by arranging at least two substrates of different material in a vessel filled with a fluid material, and by generating the nanoparticles by abrasion from the surface of the substrates in the fluid with laser radiation.11-18-2010
20110045048BONE GRAFT AND SCAFFOLDING MATERIALS IMMOBILIZED WITH TYPE I COLLAGEN BINDING PEPTIDES - The present invention relates to a pharmaceutical composition comprising a bone graft material, a scaffold for tissue engineering applications and type I collagen Binding Peptides which have bone calcification-promoting peptides immobilized on the surface, and more particularly, to a bone graft material and a scaffold for tissue engineering applications (hereinafter, referred to as scaffold), which have peptides specifically binding with type I collagen immobilized on the surface, and pharmaceutical composition for recovering tissue regeneration containing type I collagen binding-inducing peptide. In the inventive bone graft material and scaffold for tissue engineering applications, the cells related to regeneration by collagen binding-inducing peptide adhered to the surface, promote an adhesion of type I collagen binding-inducing peptide (main ingredients of extracellular matrix) to increase differentiation rate into bone tissues, and promote a calcification which is last step of bone regeneration to maximize a tissue regeneration finally.02-24-2011
20110150964APTAMER-COATED IMPLANT, PROCESS OF PRODUCTION, AND USES - One embodiment of the present invention is an implant with an aptamer coating, wherein the aptamer has an activating effect on the α06-23-2011
20090022775POLYMER BACKBONE FOR PRODUCING ARTIFICIAL TISSUE - The invention relates to polymer scaffolds suitable for producing artificial tissues, in particular polysaccharide scaffolds, to processes for their preparation, to their use for producing artificial tissues, and to artificial tissues produced on the basis of such polymer scaffolds.01-22-2009
20090022770Chitosan Compositions - This invention relates to an orthopaedic composition comprising porous chitosan particles suspended in a liquid medium wherein the liquid medium further comprises a biocompatible polymer. The invention also provides a process for preparing a solid or semi-solid orthopaedic material by drying the orthopaedic composition. The resulting solid or semi-solid orthopaedic material finds use as a bone-replacement material, a bone cement and a tissue scaffold. A process for preparing suitable porous chitosan particles for the present invention by incorporating a porogen capable of including crystallinity is also described.01-22-2009
20100015198TRANSPLANTS ENCAPSULATED WITH SELF-ELASTIC CARTILAGE AND METHOD OF PREPARING THE SAME - Disclosed is an implantable microparticle in which a transplant is encapsulated with elastic cartilage derived from the subject receiving the transplant. Also disclosed is a method of preparing an implantable microparticle, comprising (1) isolating elastic cartilage from a subject receiving a transplant; (2) multiplying the elastic cartilage through subculture; (3) mixing the elastic cartilage and the transplant, and subjecting a resultant mixture to shaking culture in order to allow the elastic cartilage to become attached around the transplant; and (4) isolating microparticles in which the transplant is encapsulated with the elastic cartilage.01-21-2010
20100003302VASCULAR RESTENOSIS PREVENTING AGENT AND IMPLANTABLE INTRAVASCULAR DEVICE COATED THEREWITH - A drug for preventing vascular restenosis comprises a compound that inactivates α1-protease inhibitor and α2-macroglobulin as active constituents, which are associated with occurrence of vascular restenosis after coronary artery intervention. Preferably, the drug is coated on a surface of an implantable intravascular device and locally administered to the affected area by application of the implantable intravascular device to a narrowed area.01-07-2010
20100003303POLYMERS OF FLUORINATED MONOMERS AND HYDROCARBON MONOMERS - It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.01-07-2010
20100003301Bone Defect Filler, Release-Controlled Carrier, And Their Production Methods - A bone filling material having controlled release of a pharmaceutical agent such as a growth factor, and a drug release controlling carrier having controlled release of a pharmaceutical agent is provided by inactivating a functional group which can strongly bind to the pharmaceutical agent of the bone filling material with a blocking agent. The bone filling material and the drug release controlling carrier of the present invention comprises: a calcium-based material such as hydroxyapatite, carbonate apatite, fluorapatite, chlorapatite, β-TCP, and α-TCP; a blocking agent of the calcium-based material such as serine and dextran; and a pharmaceutical agent.01-07-2010
20100003298SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDER PERIOD OF TIME - Subcutaneous implants obtained by extrusion containing (01-07-2010
20080248081METHOD OF TREATING CHRONIC DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to cardiac muscle for treatment of chronic dysfunction of cardiac muscle is disclosed.10-09-2008
20080248078SYSTEMS AND METHODS OF PROMOTING ENDOTHELIALIZATION OF A HYBRID HEMODIALYSIS ACCESS GRAFT OR A HYBRID FEMORAL ARTERY BYPASS GRAFT IN A MAMMAL - Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop subsystem is capable of adjusting at least two dynamic conditions in the specimen holder or a diameter of a specimen in the specimen holder. Embodiments of methods can promote endothelialization of a hybrid hemodialysis access graft or a hybrid femoral artery bypass graft by placing the hybrid hemodialysis access graft or the hybrid femoral artery bypass graft in a system embodiment according to tie invention under conditions effective to promote stem cells to differentiate into endothelial cells on a surface of the hybrid graft.10-09-2008
20080248080Decelluarlized Tissue Engineered Constructs and Tissues - New methods for producing tissue engineered constructs and engineered native tissues are disclosed. The methods include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for production of the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. The methods also include producing an engineered native tissue by harvesting tissue from an animal or human, performing one or more tissue engineering steps on the tissue, and subjecting the tissue to decellularization. The decellularized, engineered native tissue may then be subjected to further tissue engineering steps.10-09-2008
20080206299Method for Recovering Minerals From Bone and Use of Same - Systems and methods for recovering bone minerals from bone are provided in which bone minerals are separated from bone, and the separated bone minerals with natural bone mineral inorganic moieties are isolated. Also provided are implantable hydroxyapatite materials that are at least partially derived from bone and include natural bone mineral inorganic moieties.08-28-2008
20090317445DRUG DELIVERY SYSTEM WITH THERMOSWITCHABLE MEMBRANES - The present invention provides a device for controlled release of molecules. The device is particularly suitable for controlled release of therapeutic drugs to a patient. The device includes a housing with an opening for release of the molecules from the housing. The housing also comprises a reservoir for containing the molecules, in particular therapeutic drugs. The reservoir is arranged in the housing to allow release of the molecules through the opening. The device also comprises at least one thermoswitchable membrane and at least one heating element for at least partially heating the membrane. The device is configured for modulating the release of the molecules at the opening by heating the membrane, using the heating element. Optionally, the device further comprises a pressure element for providing pressurized release of the molecules from the device. In this way, the drug can be delivered to a patient in a pulsatile fashion. The present invention also provides a method for modulating the release of molecules, using such a device.12-24-2009
20090317443COATED IMPLANT - A method forming a coated implant is described. The implant comprises a surface which is first coated with a primer and subsequently with a biocompatible polymer capable of forming a covalent bond to the primer. The polymer coating is then crosslinked. The invention also relates to implants, in particular, stents, coated with such a coating.12-24-2009
20090317442Super Elastic Epoxy Hydrogel - Described is a super elastic epoxy hydrogel that is easy to manufacture and can be engineered for various performance enhancements of the polymer. Also described are methods of enhancing the performance of this hydrogel and other hydrogels. Various polymer hydrogel composites, structures, and their uses are included, such as the actuator element comprising the hydrogel of the invention depicted in FIG. 12-24-2009
20090291115Superporous hydrogel with cells encapsulated therein and method for producing the same - The present invention is a superporous hydrogel with cells encapsulated within the hydrogel matrix, and a method for producing the same.11-26-2009
20080248084METHOD OF TREATING ACUTE DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat acute dysfunction of cardiac muscle (heart attack) is disclosed.10-09-2008
20110256202IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.10-20-2011
20090136557Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots - It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.05-28-2009
20090110710DEVICES AND METHODS FOR TREATING DEFECTS IN THE TISSUE OF A LIVING BEING - An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may be “matched” to provide the implant with similar physical and/or chemical properties as the host tissue.04-30-2009
20080279908Hydroxyapatite-Binding Peptides for Bone Growth and Inhibition - Hydroxyapatite (HA)-binding peptides are selected using combinatorial phage library display. Pseudo-repetitive consensus amino acid sequences possessing periodic hydroxyl side chains in every two or three amino acid sequences are obtained. These sequences resemble the (Gly-Pro-Hyp)11-13-2008
20080279909Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization - The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.11-13-2008
20090220564METHODS OF TREATING AND PREVENTING ACUTE MYOCARDIAL INFARCTION - The present disclosure provides methods and compositions for treating coronary tissue damaged as a result of a cardiac disorder such as ischemia, acute myocardial infarction, vulnerable plaques, or reperfusion injury. Specifically, the cardiac disorder is treated using a multivalent molecule that is specific for a marker located, in or near the damaged coronary tissue and a marker located on a target cell (e.g., a stem cell). The multivalent molecule may be administered by intravenous injection, intra-arterial catheter, intramyocardial injection, or implantable device (e.g, stent).09-03-2009
20080241207Methods and materials relating to novel stem cell growth factor-like polypeptides and polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.10-02-2008
20110256204RAPID PREPARATION AND USE OF ENGINEERED TISSUE AND SCAFFOLDS AS INDIVIDUAL IMPLANTS - Methods, technical apparatus and compositions to achieve short term processing for the manufacture of a graft or a transplant in the form of a scaffold that can be used to treat or to heal injuries and traumas of a great diversity of tissues and organs in a central or peripheral location of the human or an animal body. Tissue regeneration by way of stem cells and different specific tissue and organ repair promoting factors that activate the endogenous or exogenous stem cells to differentiate to specific tissue cells thus reconstituting the original microenvironment of the cell damaged by the injury.10-20-2011
20080305144High Strength Devices and Composites - An oriented implantable, biodegradable device is disclosed. The oriented implantable, biodegradable device is formed from a homogeneous polymer blend comprising a polylactic acid in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive which both plasticises polymer draw and is a degradation accelerant. The polymer comprised within the blend may be a uniaxial, biaxial or triaxial orientation. Also disclosed is a composite thereof, processes for the preparation thereof, and The implantable biodegradable device may be used as a high strength trauma fixation device suitable for implantation into the human or animal body. As examples, the high strength trauma fixation device may take the form of plates, screws, pins, rods, anchors or scaffolds.12-11-2008
20080268017METHOD OF PRODUCING TISSUE BY PLACING A MOLDING SUPPORT WITHIN A BODY CAVITY - A method of producing a tissue includes placing a molding support within a body cavity for a time and under conditions sufficient for non-vascularized tissue comprising myofibroblasts to form on the molding support. In some embodiments, the tissue produced by this method is particularly useful as vascular tissue for the treatment or prophylaxis of diseased or damaged blood vessels such as in atherosclerosis.10-30-2008
20080268016Engineered Renal Tissue - Biocompatible tissue repair implant devices and their methods of use are provided for repairing a diseased kidney tissue. The present invention relates to methods of removing a portion of kidney tissue from a host or donor, mincing it, placing it on a bioresorbable scaffold, and implanting the scaffold into a defect site in a kidney of a host or patient for use in the treatment of degenerative kidney diseases. The compositions and methods provide a pluripotent milieu for the de-novo generation of renal tubular structures in the replacement of diseased kidney tissue. The processes and devices are useful in the treatment of medical conditions and diseases relating to the kidneys such as trauma, necrosis, and both acute and chronic forms of renal failure.10-30-2008
20080268011Antimicrobial Implant with a Flexible Porous Structure - The invention relates to an antimicrobial implant with a flexible porous structure composed of a biocompatible synthetic material which comprises particles of at least one antimicrobial agent.10-30-2008
20080220043Repair of larynx, trachea, and other fibrocartilaginous tissues - Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues in a mammal.09-11-2008
20080220040Nitric Oxide Donating Medical Devices and Methods of Making Same - Disclosed are implantable medical devices comprising nitric oxide (NO) donating polymers comprising polymer backbones having at least one cyclic amine disposed thereon. Methods are further disclosed for providing nitric oxide-donating polymers.09-11-2008
20110165218Therapeutic Bone Growth and Regeneration - The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.07-07-2011
20080254093COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is described.10-16-2008
20080254090Porcine Islets Cultured With Porcine Sertoli Cells For Xenotransplantation - Aggregates and their method of preparation suitable for implantation into a recipient in order to produce insulin in vivo. The methods involve culturing islet cells isolated from the pancreas of donor piglets with isolated Sertoli cells from the testes of donor piglets. A preferred period of culturing is 5 days and may be followed by a purification procedure.10-16-2008
20080241206CALCIUM PHOSPHATE CEMENTS COMPRISING AUTOLOGOUS BONE - Aspects of the invention include methods for producing flowable compositions, e.g. pastes, that set into calcium phosphate containing products, where the products include autologous bone. Aspects of the invention further include compositions produced by the methods, as well as kits for preparing the same. The subject methods and compositions produced thereby find use in a variety of applications, including hard tissue repair applications.10-02-2008
20110165217SCAFFOLDS WITH TRACE ELEMENT FOR TISSUE REGENERATION IN MAMMALS - A scaffold for implantation into a mammal to facilitate vessel growth in repair, regeneration, and/or proliferation of bodily tissue, where the scaffold is based on a borate, silicate, or phosphate, glass-former and is biodegradable upon implantation in mammals. The scaffold includes one or more trace elements from the group consisting of Cu, F, Fe, Mn, Mo, Ni, Sr, and Zn which are released into the host to support vessel growth. A method involves implantation of such scaffolds.07-07-2011
20110020421Biodegradable polyphosphazenes containing pyrrolidone side groups - Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.01-27-2011
20110020420Variable Density Tissue Graft Composition and Methods of Making and Using the Same - Disclosed are tissue graft compositions made of materials having different densities, methods of making, and methods of treatment for restoring tissues in a patient.01-27-2011
20110027338BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.02-03-2011
20110027332PLIABLE MEDICAL DEVICE AND METHOD OF USE - A firm but pliable medical device for use as a bone graft substitute or bone graft extender retains its shape without the requirement of a containment device, such as a syringe. Because the device is solid, it is easy to locate or position in-vivo and, in the moist environment of the body, it will hold its shape well, for an extended time. Because the lyophilized pliable medical device is porous, it adsorbs blood and other beneficial cells containing body fluids, such as bone marrow, contributing to its superior bone repair efficacy in comparison to an analogous putty that has not been lyophilized. In addition these lyophilized pliable medical devices are easier to terminally steam sterilize than the analogous putty because there is no moisture present to boil and “blow-out” of the containment device (syringe). The glycerin that is present in the formulation lends pliability but has a low vapor pressure.02-03-2011
20110027337PROTEASE INHIBITOR - The present invention relates to a polypeptide exhibiting a protease inhibitory activity and uses of said polypeptide in methods for inhibiting, directly or indirectly, one or more proteases of the blood clotting cascade. The invention also relates to use of said polypeptide as a pharmaceutical e.g. for prophylactic or ameliorating treatment of blood clots. In addition the invention comprises methods for production of said polypeptide.02-03-2011
20110027335COATED MEDICAL DEVICES - An implantable medical device carries on at least part of its external surface a coating. The coating consists essentially of a terpolymer of vinyl pyrrolidone, acrylic acid and activated acrylic acid, and optionally a colouring agent.02-03-2011
20110027334MULTILAYER MEDICAL DEVICES HAVING AN ENCAPSULATED EDGE AND METHODS THEREOF - The present disclosure describes a medical which includes a body defining a conduit. The body includes a multilayer wall having at least one edge. The wall including a core layer positioned between an inner layer and an outer layer, wherein at least one of the inner and outer layers encapsulates the core layer along the edge.02-03-2011
20110027333STEM CELL-DERIVED RETIN RETINAL PIGMENT EPITHELIAL CELLS - The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGFβ superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGFβ superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.02-03-2011
20100285084Antimicrobial coatings for medical devices and methods for making and using them - Embodiments of the invention provide methods for using compositions to inhibit microbial growth on a surface of a medical device having the composition applied thereto, to medical devices having the composition applied to a surface thereof and to methods for using the compositions to coat medical devices.11-11-2010
20100285089Medical Devices, Drug Coatings And Methods For Maintaining The Drug Coatings Thereon - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In particular, disclosed herein is a drug delivery device comprising a balloon-expandable intraluminal stent, and a pharmaceutical agent-containing coating, wherein the coating comprises a biocompatible polyfluoro copolymer that comprises about eighty-five weight percent vinylidinefluoride copolymerized with about fifteen weight percent hexafluoropropylene and a pharmaceutical agent intermixed with said polyfluoro copolymer.11-11-2010
20100285088Tissue Adhesives and Sealants and Method for Their Use - Compositions provided by mixing a biotin-containing component and an avidin-containing component are useful as an adhesive or sealant for medical/surgical uses.11-11-2010
20100285085BALLOON COATING WITH DRUG TRANSFER CONTROL VIA COATING THICKNESS - A coated medical device, such a balloon or stent. The coating includes a therapeutic agent having a thickness of the coating is between about 1.5 to 10 μm and less than 30% of the coating remains on the balloon post delivery to a vessel.11-11-2010
20100285087SINGLE PHENOTHIAZINE ENANTIOMERS AS AGENTS FOR THE PREVENTION OF BONE LOSS - Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution.11-11-2010
20110256203POROUS CERAMIC SCAFFOLD HAVING AN ORGANIC/INORGANIC HYBRID COATING LAYER CONTAINING BIOACTIVE FACTOR AND METHOD THEREOF - A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid composite coating layer containing a bioactive factor is disclosed. The method includes; forming a porous ceramic scaffold, mixing a silica xerogel and a physiologically active organic substance to prepare an organic/inorganic hybrid composite, adding a bioactive factor to the organic/inorganic hybrid composite, and filling the organic/inorganic composite containing the bioactive factor into a pore structure of the porous ceramic scaffold, thereby coating the porous ceramic scaffold. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time.10-20-2011
20110135706NERVE TREATMENT DEVICES AND METHODS - Devices and methods for treating defects in peripheral nerves are provided. The devices can include acellular arterial tissue matrices that facilitate regrowth of nerve tissue across a gap or defect in a peripheral nerve.06-09-2011
20110135707POLYHYDROXYALKANOATES FOR IN VIVO APPLICATIONS - Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.06-09-2011
20110135705METHODS AND COMPOSITIONS FOR TISSUE AUGMENTATION - Methods and compositions for use in tissue volume replacement are provided. The present invention comprises compositions comprising a combination of materials, comprising preferably a solid polymer particle phase and a gel phase, and also comprises single phase compositions. More particularly, preferred embodiments comprise a solid polymer particle phase made of materials comprising Gore-Tex (micronized e-PTFE), PDS II (polydioxanone, a monofilament), NUROLON (a long chain aliphatic polymer Nylon 6 or Nylon 6,6) ETHILON (a long chain aliphatic polymer Nylon 6 and Nylon 6,6), PROLENE (Polypropylene, isotactic crystalline stereoisomer of polypropylene, a synthetic linear polyolefin.), VICRYL (copolymer made from 90% glycolide and 10% L-lactide), silk, MONACRYL (poly ε-caprolactone.), polylactide, polyglycolide, poly lactide-co-glycolide, and BIOPOL (polyhydroxyvalerate), MEDPOR (biocompatible (micronized) polyethylene), BIOGLASS (bioactive glass particulate), NOVABONE and NOVABONE-CM, and the gel phase comprises polyvinylpyrrolidone (PVP). Preferred single phase compositions comprise PVP. Methods of the present invention comprising injection of such compositions for tissue augmentation.06-09-2011
20110135704Infection Control for Surgical and Trauma Patients - Apparatus and methods for disrupting the colonization of 06-09-2011
20110262518Treatment for cardiac injuries created by myocardial infarction - An injectable, high potency (high capillary force) composite comprised of bioceramic spheres having a smooth porous macroarchitecture and porous microarchitecture with interconnected pores and may be combined with various electrospun polymer fibers, thus achieving a biphasic composite implant device whereby a primary phase stabilizes, reinforces, restricts and constricts the expansion of dysfunctional and diseased cardiac muscle tissue, and a secondary phase providing a matrix structure within the bioceramic composite for the regeneration of dysfunctional and diseased cardiac tissue; an injectable composite implant material containing pharmaceutical agents or may contain stem cells, and other DNA materials; an injectable, high potency, bioceramic composite material providing a specific means to alter cardiac muscle geometry so as to normalize cardiac wall stress, aid in the reduction of local stresses in the border zone or in the actual infarct as well as multiple peri-infarct border zone modifications that have been implicated in pathological remodeling.10-27-2011
20110052658MK2 INHIBITOR COMPOSITIONS AND METHODS TO ENHANCE NEURITE OUTGROWTH, NEUROPROTECTION, AND NERVE REGENERATION - The described invention provides compositions comprising at least one peptide of formula I for enhancing neurite outgrowth, neuroprotection, and nerve regeneration, and methods of use thereof.03-03-2011
20100322992Anti-Proliferative And Anti-Inflammatory Agent Combination For Treatment Of Vascular Disorders With An Implantable Medical Device - Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque12-23-2010
20100322993INJECTABLE BIOCOMPATIBLE COMPOSITION - The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.12-23-2010
20090208553Monomers and Polymers with Covalently - Attached Active Ingredients - Methods to form an active agent modified monomer comprising a ring opening cyclic monomer linked to an active agent via a degradable covalent linkage. Methods to form a polymer or copolymer comprising an active agent modified monomer. Methods to form an active agent modified monomer comprising combining a ring opening cyclic monomer with a first functional group (X) and an active agent with a second functional group (Y) to form an active agent modified monomer, wherein the first (X) and second (Y) functional groups are complementary functional groups that form a degradable linkage. The active agent modified monomer can also comprise a non-degradable linkage. The method can form a ring opening cyclic monomer that includes a cyclic carbonate, cyclic epoxide, lactam, lactone, lactide anhydride, cyclic carbamate, cyclic phosphoester, or siloxane. Apparatus that includes a medical device that comprises a polymer or copolymer that comprises an active agent modified monomer.08-20-2009
20110142903CONTROLLED-RELEASE, INTRA-ARTICULAR THERAPEUTIC AGENT DELIVERY COMPOUND, AND A METHODOLOGY FOR THE CONTROLLED-RELEASE OF AN INTRA-ARTICULAR THERAPEUTIC AGENT DELIVERY COMPOUND - An intra-articular therapeutic agent delivery compound for controlled delivery of an intra-articular therapeutic agent to an intra-articular site. An intra-articular therapeutic agent. A substrate configured to bind with the intra-articular therapeutic agent, to be delivered to the intra-articular site, and to be distributed over a period of time thus releasing the intra-articular therapeutic agent.06-16-2011
20110165216Hydrogen Sulfide Generating Polymers - Described herein are hydrogen sulfide (H07-07-2011
20110086081COATING SYSTEM AND METHOD FOR DRUG ELUTION MANAGEMENT - The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional endothelium over a surface of the medical device.04-14-2011
20100119579DECELLULARIZED LIVER FOR REPAIR OF TISSUE AND TREATMENT OF ORGAN DEFICIENCY - The present invention provides a liver-derived devitalized mammalian parenchymatous tissue composition which includes an interstitial structure of connective tissue which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.05-13-2010
20110097376RADIOPAQUE INJECTABLE NUCLEUS HYDROGEL COMPOSITIONS - A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising: 04-28-2011
20110097379DIRECTED STEM CELL RECRUITMENT - The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.04-28-2011
20110097377Methods and Devices for Correcting Spinal Deformity With Pharmaceutical-Eluting Pedicle Screws - A method of correcting spinal deformity, which includes locating pharmaceutical-loaded implants adjacent to targeted spinal growth plates, and then eluting the pharmaceutical onto the growth plates. Preferably, the method involves correcting spinal deformity by simply inserting a pharmaceutical-eluting pedicle screw onto the concave side of a scoliotic curve. In some embodiments, the screw has a cannulated internal reservoir that contains a growth-inhibiting pharmaceutical (such as a tetracycline) and at least one fenestration that allows the pharmaceutical to elute onto the vertebral body growth plate.04-28-2011
20110097375FORMULATION FOR PREVENTING OR REDUCING BLEEDING AT A SURGICAL SITE - An implantable drug depot useful for preventing, reducing or treating bleeding at a surgical site beneath the skin in a patient is provided. The implantable drug depot comprises a therapeutically effective amount of clonidine or a pharmaceutically acceptable salt thereof, and at least one biodegradable polymer. The drug depot is capable of releasing clonidine or a pharmaceutically acceptable salt thereof over a period of at least three days.04-28-2011
20100166825TREATING AND/OR PREVENTING URINARY INCONTINENCE USING PRODRUGS OF GABA ANALOGS - Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary incontinence.07-01-2010
20100166823BIOPOLYMERIC MEMBRANE FOR WOUND PROTECTION AND REPAIR - The present invention relates to a conformable and semi-permeable biopolymeric membrane suitable for tissue repair and protection. This membrane contains a first layer made from randomly oriented, reconstituted biopolymer fibers and, on top of the first layer, a coating layer made from biopolymer fibers.07-01-2010
20100166822Adhesive cartilage implant - A method of producing a cartilage implant which may include coating a substrate with a thermo-sensitive polymer, seeding the polymer with a cell suspension comprising cells that may differentiate into chrondocyte-like cells, wherein the seeding may be conducted at a first temperature, culturing the cell suspension at an increased temperature, whereby cells in the suspension may adhere to the polymer and differentiate into chrondrocyte-like cells, which may form a cartilagenous implant, and decreasing the temperature of the polymer which may allow detachment of the implant from the polymer. The present invention may also include an implant based on this method. The invention may further include a cartilage implant for use in a patient in need thereof, which may include a random three-dimensional configuration of differentiated cells, which may have a natural adhesion surface on at least a portion of the outer surface of the three-dimensional configuration.07-01-2010
20100158973THERAPEUTIC USES OF CANNABIDIOL COMPOUNDS - The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as preventing the formation of heart scars.06-24-2010
20100158977PROGENITOR CELLS FROM URINE AND METHODS FOR USING THE SAME - Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and/or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use.06-24-2010
20100158976COLLAGEN/HYDROXYAPATITE COMPOSITE SCAFFOLD, AND PROCESS FOR THE PRODUCTION THEREOF - A process for producing a collagen/hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilising the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w/w). Also provided is a collagen/hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w/w). Suitably, the composite scaffold has a porosity of at least 99% (v/v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants.06-24-2010
20100158975EXTRACELLULAR MATRIX COMPOSITIONS - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.06-24-2010
20100158979TEMPORAL RELEASE OF GROWTH FACTORS FROM 3D MICRO ROD SCAFFOLDS FOR TISSUE REGENERATION - The present invention relates to the use of three-dimensional microrod scaffolds for the temporal release of growth factors useful in tissue regeneration, engineering and treatment of disorders.06-24-2010
20100196438METHODS INCLUDING MEDICAL DEVICES HAVING A SURFACE INCLUDING A BIOLOGICALLY ACTIVE AGENT THEREIN - The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.08-05-2010
20100196437MEDICAL DEVICES HAVING A SURFACE INCLUDING A BIOLOGICALLY ACTIVE AGENT THEREIN - The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.08-05-2010
20100196436IMPLANTS CONTAINING DISULFIRAM AND AN ANTI-INFLAMMATORY AGENT - The present invention provides an implantable composition which contains disulfiram, an anti-inflammatory agent, and optionally a pharmaceutically acceptable carrier. Methods of making the implants, and methods of using the implants to treat alcoholism and opioid dependency are also disclosed.08-05-2010
20100119575OSTEOGENIC COMPOSITE MATRIX, METHOD FOR THE PRODUCTION THEREOF AND IMPLANT AND SCAFFOLD FOR TISSUE ENGINEERING PROVIDED WITH A COATING FORMED BY SAID OSTEOGENIC COMPOSITE MATRIX - The invention relates to an osteogenic composite matrix consisting of collagen and non-collagen components of an extracellular matrix (ECM-components), to a method for producing said matrix, to a method for producing an implant or a scaffold for tissue engineering which is provided with a coating formed by said osteogenic composite matrix and is used for stimulating and accelerating a hard tissue formation such as, for example. The implant osseointegration in bones. The inventive osteogenic composite matrix comprises a collagen and at least one non-collagen ECM component or the derivatives thereof, wherein the collagen component consists of non-crosslinked collagen fibres produced by fibrillogenesis and the non-collagen ECM component or the derivatives thereof are integrated into said collagen fibres.05-13-2010
20100196434COMBINED FIBNRINOLYTIC AND ANTIMICROBIAL CATHETHER AND USES THETHEROF - Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.08-05-2010
20100068238Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis - The present invention relates to implantable medical devices, such as stents, that comprise a composition for controlled delivery of flavonoids or a derivative thereof. The flavonoids are aimed at preventing or reducing secondary complications which can occur following implantation of the device such as e.g. occlusive and catastrophic vascular phenomena. The invention further relates to the inclusion of additional therapeutic agents in the system that may have antiproliferative, antimitotic, antimicrobial, anticoagulant, fibrinolytic, anti-inflammatory, immunosurpressive, and anti-angiogenic activities. The composition comprising the flavanoids and optional further therapeutic agents may be used in methods for treating or preventing narrowing or obstruction of the body passageway. In particular the devices and compositions of the invention are useful in methods for treating or preventing restenosis, e.g. subsequent to angioplasty and/or for preventing or reducing acute, subacute and chronic secondary complications associated with angioplasty, such as e.g. thrombus.03-18-2010
20100068242Medical Devices for Localized Drug Delivery - In certain embodiments, the invention relates to an implantable medical device that includes a body having an internal cavity. Receptor sites in the internal cavity may be adapted to repeatedly bind to, temporarily hold, and release an active agent. An opening may extend through the body and into the internal cavity to allow the active agent into and out of the internal cavity. This opening may be sized and shaped to prevent blood cells from entering the internal cavity through the opening while allowing the active agent to enter and/or exit the cavity via the opening. A polymeric structure may be located in the internal cavity. This polymeric structure may include artificial receptor site mimics for the active agent.03-18-2010
20100068239Osteogenic Device for Inducing Bone Formation in Clinical Contexts - This invention relates to an osteogenic device for the de novo induction of bone formation in a mammal. The device contains a at least one transforming growth factor—&bgr;3 isoform and a retention matrix. The device is introduced by direct injection or surgical implantation into an area where de novo bone formation is desired and, once implanted, the retention matrix acts to retain the TGF-&bgr;3 isoform at its place of introduction and forms a scaffold for generated bone, the induction of which is promoted by the TGF-&bgr;3 isoform. The device may be used to induce bone growth where bone has been debrided in a surgical procedure and it may also be used to transform neoplastic primary and/or metastatic secondary masses into bone thus facilitating surgical debridement thereof.03-18-2010
20080299170Medical Devices and Coatings Therefor - A coating for a medical device, the device generally being of the type which is to be used internally in a subject, includes a transglutaminase (TGase) inhibitor. The Tgase inhibitor effectively prevents the activity of any Tgase involved in clot formation or clot stability. Preferably, the transglutaminase inhibitor is a factor XIIIa inhibitor. The coating may be prepared by suitable processes such as esterification. The coating may be immobilized on a suitable medical device in a number of ways and is preferably included in a TGase inhibitor containing polymer. The coating may also include a suitable antimicrobial agent.12-04-2008
20110182962 RESORBABLE MATRIX HAVING ELONGATED PARTICLES - Compression resistant matrices and methods are provided that have elongated particles embedded therein. The compression resistant matrices provide improved stability and mechanical strength and resists shifting, extrusion and rotation after implantation. In some embodiments, the matrices provided reduce or prevent surface compression of the implantable matrix which will cause unwanted increased amounts of growth factor (e.g., bone morphogenic protein) to leak from the matrix.07-28-2011
20090202606Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor - The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood vessel two or more isoforms of hepatocyte growth factor (HGF). In one embodiment the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms.08-13-2009
20090202605HIGH ASPECT RATIO TEMPLATE AND METHOD FOR PRODUCING SAME FOR CENTRAL AND PERIPHERAL NERVE REPAIR - Millimeter to nano-scale structures manufactured using a multi-component polymer fiber matrix are disclosed. The use of dissimilar polymers allows the selective dissolution of the polymers at various stages of the manufacturing process. In one application, biocompatible matrixes may be formed with long pore length and small pore size. The manufacturing process begins with a first polymer fiber arranged in a matrix formed by a second polymer fiber. End caps may be attached to provide structural support and the polymer fiber matrix selectively dissolved away leaving only the long polymer fibers. These may be exposed to another product, such as a biocompatible gel to form a biocompatible matrix. The polymer fibers may then be selectively dissolved leaving only a biocompatible gel scaffold with the pores formed by the dissolved polymer fibers. The scaffolds may be used in, among other applications, the repair of central and peripheral nerves. Scaffolds for the repair of peripheral nerves may include a reservoir for the sustained release of nerve growth factor. The scaffolds may also include a multifunctional polyelectrolyte layer for the sustained release of nerve growth factor and enhance biocompatibility.08-13-2009
20090196901Tissue Engineering Methods and Compositions - The presently disclosed subject matter generally relates to methods and systems for facilitating the growth and differentiation of adipose-derived stem cells for laboratory and therapeutic applications. The cells can be employed alone or in conjunction with unique biologically-compatible scaffold structures to generate differentiated tissues and structures, both in vitro and in vivo. The presently disclosed subject matter further relates to methods of forming and using improved tissue engineered scaffolds that can be used as substrates to facilitate the growth and differentiation of cells.08-06-2009
20090175919CHEMICAL COMPOSITION OF HYDROGELS FOR USE AS ARTICULATING SURFACES - The present invention provides a hydrogel composition comprising at least one polymer with functional groups including alcohol groups, acid groups, and amide groups and where the ratio of the functional alcohol groups to functional acid groups in the hydrogel composition ranges from about 16:1 to about 3:2. The present invention also provides a method of repairing an articulating surface in a body using the inventive composition. The inventive hydrogel composition is created by blending two or more polymers to achieve the desired ratio of functional groups, reacting at least one polymer with a reagent that results in the formation of alcohol, acid, and/or amide functional groups of the desired ratio, and/or polymerizing at least one monomer to achieve the desired ratio of functional groups.07-09-2009
20090175924COATED STENT - A method of implanting a stent whereby the risk of restenosis is reduced, the method including the step of implanting into a patient susceptible to post-implant restenosis a stent coated with a therapeutically effective amount of a compound for reducing the onset or severity of restenosis, the compound containing a high density, negatively charged domain of at least three vicinally oriented phosphorus-containing radicals.07-09-2009
20090175922THREE DIMENSIONAL PURIFIED COLLAGEN MATRICES - Cell culture scaffolds presenting a more biologically relevant microenvironment are disclosed. More particularly, these cell culture scaffolds comprise three-dimensional matrices/biomaterials that are created from solubilized collagen compositions using controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can be used alone or in combination with cells as a tissue graft construct to enhance the repair of damaged or diseased tissues.07-09-2009
20090175923HUMANIZED ANTI-AMYLOID BETA ANTIBODIES - Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.07-09-2009
20090175920Biomaterial for osteosynthesis - The present invention relates to a biomaterial for the manufacture of osteosynthesis articles with dynamic mechanical properties analogous to calcified tissue, comprising a semi-aromatic polyamide matrix and at least one reinforcing means.07-09-2009
20110189253BIOMATERIAL COMPOSITION AND METHOD - The disclosure is directed to a composition includes a macromer having a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure and at least two pendant chains bearing crosslinkable groups, an amphiphilic comonomer, and a crosslinking initiator, wherein the composition has a setting time of less than about 3 minutes. The disclosure is further directed to a kit and a method of making the above-mentioned composition.08-04-2011
20100189760Synthetic Cell Platforms and Methods of Use Thereof - The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.07-29-2010
20110189255DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION - Drug eluting stents (DES) useful for the treatment of restenosis are described. The stents comprise biocompatible polymers and adenosine receptor modulators.08-04-2011
20110189254SURGICAL GRAFTS FOR REPAIRING CHONDRAL DEFECTS - An implant containing a collagen matrix embedded with chondrocyte-like cells, its use in repairing a chondral defect, and a method of preparing the implant.08-04-2011
20100028403MEDICAL DEVICES FOR THERAPEUTIC AGENT DELIVERY - In various aspects, the present invention relates to implantable or insertable medical devices which release therapeutic agent into the body of a patient.02-04-2010
20100028404Compound and device for treating bone and/or cartilage defects - The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.02-04-2010
20100028401STEM CELL SOURCE FOR PROMOTING NEOVASCULARISATION - The Eph (erythropoietin-producing hepatocellular carcinoma) receptors and their cell surface anchored ligands, the Ephrins, comprise the largest of the receptor tyrosine kinases families with 14 receptors and 8 ligands. The receptors are subdivided into Eph-A and Eph-B categories and have known actions in the development of the vascular and nervous system. The present invention relates to an isolated mesenchymal stem cell selected from the group consisting of an isolated mesenchymal stem cell that expresses Ephrin-B2, an isolated mesenchymal stem cell that over-expresses Ephrin-B2, and an isolated mesenchymal stem cell that is genetically modified to increase Ephrin-B2 expression. The invention further relates to the various applications of the isolated mesenchymal stem cells of the present invention.02-04-2010
20100028405MATRIX, CELL IMPLANTATION AND METHOD FOR THEIR PRODUCTION AND USE - The invention relates to porous matrices based on a biologically compatible polymer or polymer mixture, to a cell implantation that is established on said matrices and to additional cell implantation based on cell mixtures of hepatocytes and islets of Langerhans. The invention also relates to a method for producing porous matrices, to matrices obtained according to said method and to a special method for obtaining cells for the inoculation of an implantable matrix.02-04-2010
20100028402NANOPARTICLE-BASED ANTICOAGULANT - A method for preventing or treating a blood clotting disorder is disclosed. The method includes administering a therapeutic effective amount of at least one nanoparticle-based anticoagulant to a subject afflicted with blood clotting disorder or potentially afflicted with a blood clotting disorder, wherein the at least one nanoparticle-based anticoagulant is a substituted fullerene, polyamidoamine (PAMAM) dendrimer or combination thereof.02-04-2010
20120308633NANOSTRUCTURED MATERIAL FORMULATED WITH BONE CEMENT FOR EFFECTIVE ANTIBIOTIC DELIVERY - This invention uses mesoporous silica nanoparticles and other nanostructured materials to formulate polyacrylate-based bone cement for achieving an enhanced and controlled elution of active ingredients such as antibiotics. This invention overcomes the limitation of low antibiotic release from commercial polyacrylate-based bone cements using for example, PMMA. In certain aspects, the formulation enables a sustained release of antibiotics from the bone cement over a period of 80 days and achieves 70% of total drug release, whereas the commercial antibiotic bone cement (e.g., SmartSet GHV) only releases about 5% of the antibiotics on the first day and subsequently an almost negligible amount. In addition, the mechanical properties of our formulated bone cements are well retained. The inventive bone cement exhibits good antibacterial properties and has very low cytotoxicity to mouse fibroblast cells.12-06-2012
20100021518FOAM CARRIER FOR BONE GRAFTING - An improved osteogenic composition is provided. The composition comprises a foam that contains polymer beads having one or more growth factors such as bone morphogenic protein. Through use of this composition, bone, collagen and/or other tissue growth may be facilitated.01-28-2010
20100021523Medical Devices Having Inorganic Barrier Coatings - Medical devices having a barrier layer comprising an inorganic material. The medical device has a reservoir containing a therapeutic agent and the barrier layer is disposed over the reservoir. In one aspect, the barrier layer has one permeability to the therapeutic agent at one portion of the medical device and a different permeability at another portion of the medical device. In another aspect, the dosage amount of the therapeutic agent in the reservoir at one portion of the medical device is different from the dosage amount of the therapeutic agent in the reservoir at another portion of the medical device. In another aspect, a bioresorbable layer is disposed over the barrier layer at one or more portions of the medical device, wherein the bioresorbable layer comprises a bioresorbable material. Also, methods of coating a medical device are disclosed, in which a barrier layer over a medical device is formed using a lithographic etching process where a plurality of particles serve as an etch mask.01-28-2010
20100021522SUSTAINED DELIVERY OF EXENATIDE AND OTHER PEPTIDES - Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.01-28-2010
20100021521Prosthesis for joint cartilage repair and method of manufacture - A cartilage prosthesis is made according to a method that includes the steps of collecting animal material from a bovine, ovine or porcine source, the animal material being a cartilage, shaping the animal material to provide a desired shape for the cartilage implant, removing cells from the animal material, crosslinking the animal material, removing antigens from the animal material, subjecting the animal material to an alkaline treatment, coupling into the animal material active substances which are capable of adhering growth factor and stem cell, and packing the animal material in a container that contains a sterilization solution.01-28-2010
20100021519Compositions and Methods for Treating or Preventing Diseases of Body Passageways - The present invention provides compositions and methods for treating or preventing diseases associated with vascular and non-vascular body passageways, the method comprising the step of delivering to a body passageway a therapeutic agent delivered locally through a polymer matrix from an implanted stent or other structure.01-28-2010
20090263447Crosslinked hyaluronic acid and process for the preparation thereof - The present invention relates to a crosslinked hyaluronic acid that can be obtained according to a process comprising: (a) activation of a hyaluronic acid, (b) reaction of the activated hyaluronic acid with an oligopeptide- or polypeptide-based crosslinking agent, in a reaction medium adjusted to a pH of from 8 to 12, so as to obtain a crosslinked hyaluronic acid, (c) adjustment of the pH of the reaction medium to a value ranging from 5 to 7, and (d) precipitation of the crosslinked hyaluronic acid from an organic solvent.10-22-2009
20100092536IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS - Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.04-15-2010
20090169597TREATMENT OF INTERVERTEBRAL DISC DEGENERATION USING HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.07-02-2009
20080220041Medical devices having improved performance - In accordance with various aspects of the invention, implantable and insertable medical devices are provided, which contain one or more polymeric regions. In one aspect, the polymeric regions comprise (a) a block copolymer that comprises a polyaromatic block and a polyalkene block admixed with (b) a sulfonated high Tg polymer. In another aspect, the polymeric regions comprise a block copolymer that comprises (a) a sulfonated polymer block and (b) fluorinated polymer block.09-11-2008
20090110711IMPLANTABLE DEVICE HAVING A SLOW DISSOLVING POLYMER - The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same.04-30-2009
20090060973COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS - Medical implants are provided which release a fluoropyrimidine or an analog thereof, thereby inhibiting or reducing the incidence of infection associated with the implant.03-05-2009
20100239632DRUG DEPOTS FOR TREATMENT OF PAIN AND INFLAMMATION IN SINUS AND NASAL CAVITIES OR CARDIAC TISSUE - Effective treatments of pain and/or inflammation are provided. Through the administration of a biodegradable drug depot film, patch, strip or sponge being implantable at or near a cardiac tissue or within a nasal or sinus cavity, one can reduce, prevent or treat pain and/or inflammation.09-23-2010
20100196435MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES - This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics.08-05-2010
20090022772BIOABSORBABLE ELASTOMERIC ARTERIAL SUPPORT DEVICE AND METHODS OF USE - The invention provides bioabsorbable elastomeric arterial support devices fabricated using elastomeric polymer networks and semi-interpenetrating networks in which a linear polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. The invention devices are designed for implant into curved segments of artery and can be expanded during arterial implant and cross-linked in vivo in the expanded state to restore a clogged artery to extended function. The invention devices are useful for in vivo implant in diseased arteries and for delivery of a variety of therapeutic molecules in a time release fashion to surrounding tissues to reduce or eliminate arterial response to implant of the device.01-22-2009
20100189761Methods for Prevention and/or Treatment of Capsular Contracture - Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.07-29-2010
20080241212Biodegradable, Polymer Coverings for Breast Implants - A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.10-02-2008
20110117162Isolated Renal Cells and Uses Thereof - The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.05-19-2011
20110117166IMPLANTABLE BONE GRAFT MATERIALS - Compositions and methods are provided for promoting bone growth. An implantable bone graft material is provided comprising a resorbable ceramic and a resorbable polymer, wherein the polymer comprises a covalently attached BMP binding peptide. In addition, an implantable bone graft material is provided consisting essentially of a resorbable β-TCP and a resorbable polymer, wherein the β-TCP has a total porosity of about 50% or greater and wherein the β-TCP has a particle size ranging from about 100 micron to about 300 micron. The implantable bone graft materials are useful for promoting bone growth in a subject.05-19-2011
20110117161BIOLOGICALLY ABSORBABLE COATINGS FOR IMPLANTABLE DEVICES AND METHODS FOR FABRICATING THE SAME - Coatings for an implantable medical device and a method of fabricating thereof are disclosed, the coatings comprising a biologically degradable, biologically erodable, and/or biologically resorbable ABA or AB block copolymer. A biologically active agent can be conjugated to the block copolymer.05-19-2011
20110117164Use of Additive Sites to Control Nitric Oxide Release from Nitric Oxide Donors Contained within Polymers - A method for increasing, prolonging, and/or controlling the release rates of nitric oxide (NO) from polymeric materials containing NO adducts. Such NO-containing polymeric materials may find use in devices such as blood contacting devices, and biocompatible devices utilizing the same. The method and device utilizes anionic site additives, acidic site additives and/or acidic producing site additives in a polymer that contains NO-adducts to generate higher fluxes of NO to exceed NO threshold levels desirable to substantially prevent and/or minimize reactions such as platelet activation or adhesion.05-19-2011
20100255056Fibronectin Type III Domain Based Scaffold Compositions, Methods And Uses - A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG based on the consensus sequence have been identified as useful for diagnostic and/or therapeutic applications.10-07-2010
20090297579Control of Cells and Cell Multipotentiality in Three Dimensional Matrices - Methods for wound healing or tissue regeneration by means of cell and tissue engineering, including using three-dimensional matrices with cells therein. A three-dimensional matrix, optionally containing cells such as fibroblasts, is inserted Into the wound of a subject. An anti-inflammatory factor may also be used to reduce or suppress the immune response. The wound may be covered to limit exposure to gaseous oxygen, for example, using a membrane. An anticoagulant may also be applied. In addition, cells, such as fibroblasts or stem cells, when cultured within a three-dimensional matrix, under certain conditions, can be induced to form non-fibroblast multipotent cells. When stem cells are cultured in the three-dimensional matrix, at least some of the stem cells remain as stem cells and do not differentiate. Kits for promoting the control of cells within three-dimensional matrices are also disclosed.12-03-2009
20100172952Electrospun Scaffolds And Methods Of Generating And Using Same - A porous scaffold is disclosed, the porous scaffold comprising electrospun polymeric nanofibers, wherein an average diameter of a pore of the porous scaffold is about 300 μm is disclosed. An average diameter of the polymeric nanofibers ranges from about 100 to 400 nm. The scaffold may comprise a plurality of particles, the particles being greater than about 1 μm in diameter. Methods of fabricating scaffolds, methods for generating tissue and methods of using scaffolds for tissue reconstruction are also disclosed.07-08-2010
20110081396GLASS CERAMIC SCAFFOLDS WITH COMPLEX TOPOGRAPHY - A bioactive and bioresorbable scaffold including a glass-ceramic material including fluoroapatite and hydroxyapatite doped with about 1-5 wt.% niobium oxide that is shaped into a scaffold is described. The glass-ceramic material has high crystallinity and a complex topography which provide it with greater structural strength and bioresorbability. Methods of preparing the bioactive and bioresorbable scaffold and methods of using the scaffold for musculoskeletal engineering are also provided.04-07-2011
20090246244MALLEABLE MULTI-COMPONENT IMPLANTS AND MATERIALS THEREFOR - Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials.10-01-2009
20100068240IMPLANTABLE NERVE REGENERATION CONDUIT - Implantable nerve regeneration conduits and methods of making the same are disclosed. The implantable nerve regeneration conduits mainly comprise a biodegradable polymer and a metal. Moreover, the conduits may also comprise one or more nerve regeneration enhancing elements, which comprise bioactive molecules or cells. The inner surface of the conduits may be micropatterned photolithographic processes to form microgrooves for facilitating cell alignment.03-18-2010
20080274160Implant material - An implant material includes a base material that includes, as a main component, a partially stabilized zirconia having an average crystal particle diameter of 0.3 μm or less and a porous covering layer that includes ceramic as a main component and has a center pore diameter within a range of 10-100 μm. The covering layer 11-06-2008
20090297580SPINAL NUCLEUS PULPOSUS IMPLANT - The present invention relates to a spinal nucleus pulposus implant for use in the treatment of the intervertebral disc and in particular, to the use of a CD-RAP protein therefore.12-03-2009
20110305741Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis - A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.12-15-2011
20080260799BIOACTIVE IMPLANT AND METHOD OF USE - The invention relates to a method for producing bioactive implant surfaces consisting of metallic or ceramic materials, to be used for implants such as artificial joints or very small implants such as so-called stents. The invention also relates to implants produced according to this method and methods of using the implants.10-23-2008
20090087473Osteoinductive bone graft material and manufacturing method - In order to promote a bone regeneration, atelocollagen, collagen or metal to be utilized as a biomaterial is immersed in an organic solvent solution containing dissolved silanol polyhedral oligomeric silsesquioxane or silanol, then the immersed material is taken out of the solution and dried, and the dried silanol polyhedral oligomeric silsesquioxane or silanol is coated on the atelocollagen, collagen or metal, then the resultant compound is embedded in the bone defect.04-02-2009
20100215716COMPOSITIONS AND METHODS FOR COATING ORTHOPEDIC IMPLANTS - An orthopedic implant suitable for insertion into the body of a subject, the implant comprising: a metal substrate having one or more surfaces operable to contact a bone tissue or soft tissue when implanted into the subject; a coating comprising a resorbable polymer impregnated with an admixture of a rifamycin antibiotic and a second antibiotic selected from the group consisting of tetracyclines, penicillin, ampicillin, cefazolin, clindamycin, erythromycin, levofloxacin, or vancomycin. The adhered coating layer present on the one or more surfaces is capable of releasing the rifamycin and second antibiotics in an antimicrobially effective amount. Method for making an antibiotic coated implant by mixing a resorbable polymer mixture with an antibiotic solution forming a coating solution, applying the coating solution to a surface of the implant and evaporating the solvent from the coated layer.08-26-2010
20090136558Anti-Restenosis Coatings and Uses Thereof - The present invention provides coatings or coating compositions for implantable or insertable medical devices containing one or more polymers and a combination of an immunosuppressant agent and an anti-neoplastic agent. In some embodiments, the coatings or coating compositions of the invention control sustained-release of the immunosuppressant agent and the anti-neoplastic agent for at least about 4 weeks. The present invention also provides implantable or insertable medical devices and other drug delivery or eluting systems containing a coating or coating composition of the invention and uses thereof.05-28-2009
20090022776COMPOSITION AND METHOD FOR TREATMENT AND PREVENTION OF RESTENOSIS - Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.01-22-2009
20110111004OSTEOINDUCTIVE NANOCOMPOSITES - The present invention relates porous osteoinductive nanocomposites and for the methods to prepare osteoinductive nanocomposites. The osteoinductive composites consist of biocompatible polymers and non-heated (or non-sintered), needle-shaped or plate-like calcium phosphate nanocrystals and the methods comprise the steps of: a. adding phosphate to a calcium solution thereby evoking precipitation of calcium phosphate nanocrystals; b. washing the nanocrystals with water and suspending them in an organic solvent or getting dry calcium phosphate nanocrystals after evaporating organic solvent; c. adding polymers (previously dissolved in an organic solvent) to calcium phosphate nanocrystal suspension, rotational mixing of the components using beads, mixing with porogenic agents, moulding the composite material and evaporating of the organic solvent; or mixing polymers (not dissolved in an organic solvent but raw powder), dry calcium phosphate nanocrystals and porogenic agents with melting intrusion and moulding the composites; d. leaching porogenic agents in water.05-12-2011
20100247597Biocompatible Polymers for Coating or Fabricating Implantable Medical Devices - The present disclosure generally relates to biocompatible polymers for coating or fabricating implantable medical devices and to implantable medical devices having the present biocompatible polymers. The disclosed biocompatible polymers exhibit superior biocompatibility and therefore minimize unwanted immune reaction from a patient into whom a medical device is implanted.09-30-2010
20110081399SURFACE MODIFICATION OF NITINOL - Disclosed herein are methods of modifying a nitinol surface by using abrasive blasting techniques. The surface modification can be performed by abrasively blasting the surface and delivering at least one dopant from one or more fluid jets to cause the at least one dopant to impregnate and/or coat the nitinol surface. The nitinol surface can form a portion or all of a medical device, such as an implantable medical device, e.g., a stent.04-07-2011
20120177716Methods for Making Controlled Delivery Devices Having Zero Order Kinetics - A method of making an injectable or implantable active agent delivery device capable of delivering a diagnostic, therapeutic, and/or prophylactic agent to a desired targeted site having orifice(s) on the surface is disclosed herein providing unidirectional release of the agent at a controlled desirable rate. The agent may include, but is not limited to, drugs, proteins, peptides, biomarkers, bioanalytes, and/or genetic material. The technology of the invention is based on parallel processing to fabricate micro-holes on tubes employing photo-lithography and reactive ion etching techniques and also incorporates a simple molding method to form the micro-holes on flexible polymer tubes, including bio-degradable tubes. The parallel processing method of the instant invention is fast, economical and well suited for mass production. The developed device, due to its composite structure, has the ability to combine several release mechanisms, leading to zero-order release kinetics for most of the time.07-12-2012
20090175921Chain Extenders - The present invention relates to chain extenders, processes for their preparation and their use in the preparation of biocompatible biodegradable polyurethanes and polyurethane ureas for biomedical applications such as stents, scaffolds for tissue engineering. The chain extenders comprise a compound of formula (I)07-09-2009
20110008406Silk Fibroin Hydrogels and Uses Thereof - The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.01-13-2011
20080220044CANCELLOUS CONSTRUCT WITH SUPPORT RING FOR REPAIR OF OSTEOCHONDRAL DEFECTS - The invention is directed toward an osteochondral repair assembly comprising a shaped allograft construct comprising an unbalanced barbell-shaped cylindrical cancellous bone primary member formed with a mineralized cylindrical base section having a smaller diameter cylindrical stem leading to a second cylindrical section which is demineralized. A mineralized ring-shaped support member is forced over the compressed demineralized second demineralized the aperture of the ring-shaped member to fit around the stem with one ring surface being adjacent the bottom surface to the second cylindrical section and the opposite ring surface being adjacent the upper surface of the mineralized cylindrical base section.09-11-2008
20080220042Biomolecule-linked biomimetic scaffolds - The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from an extracellular matrix component, a growth factor, and combinations thereof. The invention also provides methods of making the composition and methods of using the compositions to add new tissue to a subject, such as a human.09-11-2008
20110045053ISOLATED POPULATION OF LUMINAL STEM CELLS THAT GIVE RISE TO PROSTATE CANCER AND METHODS OF USING SAME - The present invention is directed to an isolated population of luminal stem cells obtained from the prostate epithelium that express Nkx3.1. The invention is also directed to methods for diagnosing whether a patient is at risk of developing prostate cancer.02-24-2011
20090136559Chondrocyte Differentiation from Human Embryonic Stem Cells and Their Use in Tissue Engineering - Methods for inducing differentiation of human embryonic stem cells into chondrocytes for use in tissue engineering applications are provided. One example of a method is a method for inducing differentiation of human embryonic stem cells into chondrocytes comprising aggregating undifferentiated human embryonic stem cells to form embryoid bodies; and culturing the embryoid bodies in culture medium in the presence of growth factors that induce chondrogenic differentiation of the embryoid bodies.05-28-2009
20110064781NOVEL HEPARIN ENTITIES AND METHODS OF USE - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.03-17-2011
20110064782METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - A decellularised collagen-containing matrix for guided tissue regeneration, wherein the matrix is derived from a natural tissue material and is substantially free of non-fibrous tissue proteins, cellular elements and lipids or lipid residues and wherein the matrix displays the original collagen fibre architecture and molecular ultrastructure of the natural tissue material from which it is derived. The decellularised collagen-containing matrix is useful as an implant for guided tissue regeneration, having a capacity to induce guided regeneration of host tissue.03-17-2011
20110318402TRICALCIUM PHOSPHATES, THEIR COMPOSITES, IMPLANTS INCORPORATING THEM, AND METHODS FOR THEIR PRODUCTION - Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.12-29-2011
20100247601REPAIR AND TREATMENT OF BONE DEFECT USING CELLS INDUCED BY AGENT PRODUCED BY CHONDROCYTES CAPABLE OF HYPERTROPHICATION AND SCAFFOLD - The present invention provides a method of inducing undifferentiated cells into induced osteoblasts. The method includes: A) a step of providing an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a step of culturing the undifferentiated cells in an undifferentiated cell culture medium containing the induced osteoblast differentiation inducing agent and a medium component, to differentiate the undifferentiated cells into the induced osteoblasts.09-30-2010
20090148489BIOABSORBABLE MATERIAL - A bioabsorbable material suitable for implanting within a human body, the material including fibers of a composite of a synthetic bioabsorbable polymer such as poly-lactic acid, and a particulate bioactive filler such as calcium phosphate powder. The fibers are discontinuous with non-uniform cross-sections and non-uniform cross-sectional areas. The surface topography provided by the fibers provides a substrate which is more amenable to cellular colonization than prior materials.06-11-2009
20120114731MULTILAYER PROTEIN FILMS, METHODS OF MAKING, AND DRUG DELIVERY DEVICES AND BIOMEDICAL IMPLANTS EMPLOYING THE FILMS - A multilayer protein film has a mass of greater than 0.5 μg/cm05-10-2012
20120114732ELASTIN STABILIZATION OF CONNECTIVE TISSUE - A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.05-10-2012
20080292677Engineered lung tissue, hydrogel/somatic lung progenitor cell constructs to support tissue growth, and method for making and using same - Somatic lung progenitor cell/polymer constructs are disclosed along with methods for isolating somatic lung progenitor cells from adult mammals, seeding the cells onto or into polymeric scaffolds and allowing the cells to differentiate and proliferate into functional lung tissue/polymer implants. A method for treating lung disease, disorders or injuries is also disclosed.11-27-2008
20100015201IMPLANT WITH COATING - The present invention concerns an implant with a molecularly imprinted polymer coating, a process for its synthesis, a molecularly imprinted polymer, as well as a process for its synthesis and its use as well as a process for the treatment or prophylaxis of certain disease conditions by implantation of an implant in accordance with the invention according to the respective independent claims.01-21-2010
20090035345Nuclear Receptors Agonists for Treatment of Atherosclerosis and/or Related Cardiovascular Disease - The invention relates to the use of an agonist of one or more of the nuclear receptors TR3, MINOR and NOT for the preparation of a medicament for the treatment of cardiovascular disease, in particular in-stent restenosis and/or vein-graft disease. The invention further relates to medical devices, such as stents and cuffs, that are coated with the agonist, or in which the agonist is incorporated and which are for use in the treatment of in-stent restenosis or vein-graft disease.02-05-2009
20100316689Implant Filling Material and Method - Compositions of cross-linked polyvinylpyrrolidone (PVP) are disclosed that are generally in the form of an elastic, hydrophilic, water-insoluble viscous cohesive mass of material that has many important medical uses including uses as a filler for implants. The present invention also involves a process for producing such compositions.12-16-2010
20090035348DISSOLUTION OF ARTERIAL PLAQUE - Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation.02-05-2009
20090258050Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid - The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The disclosure further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.10-15-2009
20090196900Use of Phosphodiesterase Inhibitor as a Component of Implantable Medical Devices - Implantable medical devices having coatings comprising phosphodiesterase inhibitors are disclosed. Specifically, coatings comprising phosphodiesterase-5 inhibitors are disclosed. The phosphodiesterase-5 inhibitors include sildenafil, tadalafil, vardenafil or pharmaceutically acceptable derivatives thereof. The medical devices can include stents, catheters, micro-particles, probes and grafts08-06-2009
20100021520BIOMATERIAL IMPLANTS - A biomaterial implant includes a mineralized collagen fibril scaffold. The collagen fibrils are formed from type I collagen monomers and display native-D band periodicity. The implant has load bearing capabilities and can be resorbed when implanted in a mammal's body.01-28-2010
20090291111COATING COMPRISING AN AMORPHOUS PRIMER LAYER AND A SEMI-CRYSTALLINE RESERVOIR LAYER - The present invention provides a coating comprising a reservoir layer comprising a semi-crystalline polymer and a primer layer comprising an amorphous polymer on an implantable device and methods of making and using the same.11-26-2009
20110038912COMPOSITIONS AND METHODS FOR DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS TO MEDICAL DEVICE SURFACES - The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to the peptide having binding affinity for glycopeptide antibiotic. Also provided are methods of applying the peptide compositions to a medical device by contacting the peptide compositions with a surface of the medical device. In addition, kits are provided comprising the peptide compositions.02-17-2011
20090022774Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances for treatment of vascular disorder - A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to,01-22-2009
20090148490Preparation of Therapeutic Foam - A device is described for facilitating the preparation of therapeutic foam e.g. for the treatment of varicose veins. A pressurised vial contains a sclerosant liquid, e.g., polidocanol solution, and a sterile gas which is readily absorbed by the body, e.g., carbon dioxide, oxygen or a mixture of these gases. The vial is provided either with a specialised stopper/seal into which a syringe nozzle may be inserted or alternatively a septum seal which may be penetrated by a hypodermic needle. The quantities of gas and liquid and the pressure in the vial are pre-set so that, on connection of a syringe to the vial, a predetermined volume of both gas and liquid is transferred to the syringe, with the intention that the syringe is then used to make a foam by known means. The use of the vial ensures that the ratio of gas to liquid in the foam is standardized, and also provides a convenient way of packaging the gas and liquid and of filling the syringe in a sterile manner.06-11-2009
20120064142POLYMERIC PHARMACEUTICAL DOSAGE FORM IN SUSTAINED RELEASE - This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers.03-15-2012
20100183699COMPOSITIONS AND METHODS TO CROSS LINK POLYMER FIBERS - Novel compositions comprising genipin for cross-linking polymer fibers, are provided. In aspects of the invention the compositions further comprise a solvent system, wherein said solvent system comprises alcohol solvent and water. The genipin-based compositions are useful in methods for promoting the stabilization of fibers in an aqueous environment, and in tissue engineering. The novel genipin-based composition is also useful in methods of treating dermatological conditions.07-22-2010
20090280154Biodegradable Scaffold with ECM Material - We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration is equally distributed in the dressing hence avoiding unnecessary high concentrations of ECM. In addition to the effect of the ECM, the porous structure of the base material provides the cells with a structure for in-growth.11-12-2009
20090317444PROCESS FOR CELL PROLIFERATION - In vitro process for the proliferation or culture of conjunctive tissue cells selected from the group consisting of chondrocytes, osteoblasts, chondroprogenitor cells, osteoprogenitor cells, tenocytes and ligament cells comprising the step of contacting said cells with an aminosugar selected from the group consisting of mannosamine, N-acetylmannosamine, mannosamine salts and their mixtures. The present invention also relates to compositions which comprise the aminosugar in combination with the cells. These compositions are useful for the treatment of cartilage, bone, tendon and ligament lesions or defects, bone mass losses and osteochondral defects or lesions.12-24-2009
20120121682cRGD PEPTIDE DERIVATIVE AND ITS MANUFACTURE, AND IMPLANT HAVING A COATING CONTAINING A cRGD PEPTIDE DERIVATIVE - Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1):05-17-2012
20110091517BIOCOMPATIBLE SCAFFOLDS WITH TISSUE FRAGMENTS - A biocompatible tissue repair implant or scaffold device is provided for use in repairing a variety of tissue injuries, particularly injuries to cartilage, ligaments, tendons, and nerves. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair. The biocompatible tissue repair implants include a biocompatible scaffold and particles of living tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.04-21-2011
20100209470DEMINERALIZED BONE MATRIX DEVICES - The invention relates to a sheet-form demineralized bone matrix (DBM) composition comprising an aqueous admixture of DBM particles, starch and gelatin, wherein the DBM particles are present in an amount of between about 30% and about 70% by weight, the gelatin is present in an amount between about 10 and about 40% by weight and the starch is present in an amount between about 5% and about 20% by weight, wherein the DBM particles are retained in the form of the resilient sheet.08-19-2010
20100291179COMPOSITE BIOMATERIAL FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS - The present invention relates to a composite biomaterial and a process for producing a composite biomaterial with controlled release of active ingredients, comprising a three-dimensional polymer-based support structure, and a polymer-based matrix structure. The active ingredients are in this case incorporated into the composite biomaterial via the matrix structure, and the composite biomaterial is obtainable by introducing the matrix structure into the support structure. The active ingredients may in this case be incorporated for example adhesively, via specific binder molecules or via enzyme-labile linker molecules via the matrix structure into the composite biomaterial.11-18-2010
20100291177PREVENTION OF STAPHYLOCOCCUS BIOFILM FORMATION - The present application discloses antibodies directed to protein SE2232 (SesC) of 11-18-2010
20100291175POLYMERS COMPRISING AMORPHOUS TERPOLYMERS AND SEMICRYSTALLINE BLOCKS - The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.11-18-2010
20100291173METHOD OF IMPROVING RENAL FUNCTION - A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1/Bone Morphogenic Protein-7 (OP-1/BMP-7) polypeptide in the renal tissue.11-18-2010
20110104232Sustained Release Systems of Ascorbic Acid Phosphate - A novel method of preparing a controlled release composition is disclosed. Specifically, the present invention relates to a method of preparing controlled release compositions of ascorbic acid phosphate and absorbable polymers. Also disclosed is a novel controlled release composition of ascorbic acid phosphate made by the method of the present invention.05-05-2011
20110104228SELF-ELIMINATING COATINGS - The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to enhance biocompatibility and to control the local delivery of biologically active agents.05-05-2011
20110104230COMPOSITIONS OF NOVEL BONE PATCH IN BONE AND VASCULAR REGENERATION - A bone patch and method for treating a bone condition of an animal. The bone patch includes a composition of ingredients. The composition of ingredients include: stem cells; signaling molecules for osteoblast/endothelial differentiation; and scaffold material. The method for treating a bone condition includes: applying the bone patch to the animal for bone regeneration, treatment of a fractured bone, and/or treatment of a bone disorder.05-05-2011
20100092535Nanoporous Drug Delivery System - Disclosed herein are controlled release drug delivery systems. The systems comprise a medical device at least one nonoporous surface, at least one bioactive agent and optionally a biodegradable polymer. The nanoporous surfaces of the medical devices contain nanopores capable of acting as reservoirs for drugs that are controllably released.04-15-2010
20100092540DRUG DELIVERY COMPOSITIONS AND MEDICAL DEVICES CONTAINING BLOCK COPOLYMER - A composition for delivery of a therapeutic agent is provided. The composition comprises: (a) a biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks and (b) a therapeutic agent, wherein the block copolymer is loaded with the therapeutic agent. The block copolymer is preferably of the formula X-(AB)04-15-2010
20100092534Combination Local Delivery Using a Stent - Described herein are implantable medical devices useful in treating vascular conditions such as restenosis. In one embodiment, stents are described in which a combination of bioactive agents is described for local delivery in the vasculature. The combination of bioactive agents comprises at least one compound capable of inhibiting smooth muscle cell proliferation and at least one compound capable of mitigating MCP- and/or TF induction. For example, a compound capable of inhibiting smooth muscle cell proliferation is a mTOR inhibitor and a compound capable of mitigating MCP-1 and/or TF induction is a corticosteroid.04-15-2010
20100015196Drug Depot Implantable Within a Joint - Methods and compositions for treating a tissue within a synovial joint in a patient in need of such treatment are provided. The methods and compositions involve inserting a drug depot through the synovial joint and attaching the drug depot to the inside of the synovial joint capsule so that the drug depot does not substantially interfere with movement of the joint, wherein said depot comprises a polymer and at least one pharmaceutical agent.01-21-2010
20100247599DRUG-RELEASING POLYELECTROLYTE COATING, METHOD FOR FORMING A DRUG-RELEASING POLYELECTROLYTE COATING, AND IMPLANTABLE DEVICE - A drug-releasing polyelectrolyte coating includes: (a) at least two oppositely charged polyelectrolyte layers; (b) at least one pharmaceutical active drug which is covalently coupled to polyelectrolytes of at least one of the polyelectrolyte layers; (c) wherein the drug exhibits a release rate from the polyelectrolyte coating of less than 50% in 3 days.09-30-2010
20100247596ELEMENT FOR IMPLANTATION WITH MEDICAL DEVICE - A therapeutic agent eluting element includes an elongate body member and one or more therapeutic agents elutable from the body member. The elongate body member is configured to be implanted subcutaneously along side of a therapy delivery element. The elongate body member may be formed from a polymeric material, and the agent eluting element may consist essentially of the body member and the one or more therapeutic agents. The therapeutic agent eluting element may be a part of a system or kit that includes a therapy delivery element and a tunneling tool, such as a dilator, sheath, catheter passer, or the like.09-30-2010
20100247600THERAPEUTIC DRUG ELUTING IMPLANT COVER AND METHOD OF MAKING THE SAME - A drug-eluting implant cover fabricated from a drug-eluting biocompatible matrix containing at least one elutable drug, a drug-eluting implant cover kit containing at least one drug-eluting implant cover, and a method of manufacturing the same.09-30-2010
20100247604METHOD OF TREATMENT OF CONNECTIVE TISSUES AND ORGANS AND USES OF SAID TISSUES AND ORGANS - A method of treatment of connective tissue includes the steps of providing a biological tissue or organ, coating the tissue or organ with an enzymatic solution capable of phagocytizing at least partly fibroblasts, macrophages, mast cells and other cells responsible for immune and rejection reactions in homologous and heterologous transplantations. The biological tissue or organ, after the treatment with the enzymatic solution is irradiated with ionizing electromagnetic radiations in order to obtain an acellular tissue which maintains its own extracellular matrix unchanged. Preferably, such radiations are gamma radiations having a frequency between 1009-30-2010
20100247598Thick foams for biomedical application and methods of making - A novel method of manufacturing thick foams, especially molded thick foams useful as tissue scaffolds and other medical devices. Also disclosed are novel thick foams made using the process of the present invention, wherein such thick foams may be used as medical devices or components of medical devices.09-30-2010
20090130171High concentration gentian violet containing medical devices and methods of making same - Implantable medical devices, such as catheters, treated with a high concentration of gentian violet, and methods of preparing these medical devices are provided.05-21-2009
20090130168CERAMIC/STRUCTURAL PROTEIN COMPOSITES AND METHOD OF PREPARATION THEREOF - Ceramic/structural protein composite scaffolds and their preparation in a simple one-step process are shown.05-21-2009
20090130170Agent eluting bioimplantable devices and polymer systems for their preparation - Bioimplantable devices comprising a polyetherurethane modified by admixture with siloxane surface modifying additive that may be loaded with a therapeutic agent are provided.05-21-2009
20090130167Drug Delivery Device and Method for Use with Prosthetic Device Implantation - Implantable drug delivery devices are provided which are adapted to be installed adjacent to at least a portion of an orthopedic prosthetic device implanted on a surgically prepared bone section of a patient. For example, the prosthetic device may be a hip joint replacement or knee joint replacement. The drug delivery device may include a body having a core formed from a non-biodegradable material formed in the shape of a sleeve and having an inner surface and an outwardly directed outer surface, wherein the outer surface has a drug formulation for release thereof into the body of the animal following implantation of the prosthetic device within the body of the animal. The outer surface may define one or more pockets for holding the drug formulation.05-21-2009
20090130165MIF Inhibitors - The present invention relates to the use of specific benzimidazolone analogues and derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated. Novel benzimidazole analogues and derivatives are also provided.05-21-2009
20090130166SYSTEM FOR PROVIDING IMPLANT COMPATIBILITY WITH RECIPIENT - A system for providing or enhancing compatibility between an implant and a recipient. The system includes a recipient, typically a living biological organism, that further includes a target region; an implant having a first attraction means; and a plurality of cells. The cells are compatible with the target region and further include a second attraction means responsive to the first attraction means. The interaction between the first and second attraction means attaches the cells to the implant.05-21-2009
20090130164METHOD TO CONTROL CELL ADHESION AND GROWTH ON BIOPOLYMER SURFACES - Methods for treating surfaces of polymeric substrates (as used in medical implants) with inert plasmas to promote the growth of bioentities (such as cells) on these surfaces is disclosed. The treated surfaces are subsequently exposed to an environment to form functionalities associated with enhanced growth of the bioentity on the surface. For example, the substrate may be exposed to the ambient environment. The bioentity may then be deposited on the modified surface. This inert plasma treatment and exposure to a suitable environment does not degrade the implants, and thus improved implants are created. Also, due to the specific functional groups at the modified surface, high cell densities are achieved.05-21-2009
20090130163Drugs With Improved Hydrophobicity For Incorporation in Medical Devices - The invention provides a medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The invention also provides a method of treating a narrowing in a body passageway comprising placing an implantable medical device comprising a hydrophobic analog of a medicament known to inhibit cell proliferation and migration. The medicaments can be incorporated within or coated on the device. The invention further provides hydrophobic analogs of medicaments known to inhibit cell proliferation and migration.05-21-2009
20100226958METHOD FOR MODIFYING THE WETTABILITY AND/OR OTHER BIOCOMPATIBILITY CHARACTERISTICS OF A SURFACE OF A BIOLOGICAL MATERIAL BY THE APPLICATION OF GAS CLUSTER ION BEAM TECHNOLOGY AND BIOLOGICAL MATERIALS MADE THEREBY - The invention provides a method for preparing a biological material for implanting. The invention also provides a biological material for surgical implantation. The invention further provides a biological composition for surgical implantation.09-09-2010
20100209472DRUG RELEASING COATINGS FOR MEDICAL DEVICES - The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.08-19-2010
20110182964Vascular Stent Which Elutes Amino Acid-Methyl-Ester Derivatives for the Treatment of Vulnerable Plaque and Vascular Disease - This invention provides implantable medical devices that include delivery systems containing amino acid derivatives, and related methods for making and using. More specifically, this invention provides vascular stents with coatings containing methyl ester derivatives of amino acids, and related methods for making and using.07-28-2011
20110182963OSTEOIMPLANT AND METHODS FOR MAKING - An osteoimplant is disclosed and includes a plurality of partially demineralized fibers. Each fiber has an elongated, thin body having a length of about 1 centimeter to about 3 centimeters. Further, the plurality of fibers engages to establish a matrix of material. The disclosure is further directed to a method of making the above-mentioned osteoimplant.07-28-2011
20120213839HYDROPHOBIC CROSS-LINKED GELS FOR BIOABSORBABLE DRUG CARRIER COATINGS - Coatings for medical devices, methods of making the coatings, and methods of using them are described.08-23-2012
20090186062Method of Repairing Meniscal Tears - A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the fibrous face allowing cell growth thereon. The collagen is predominantly collagen I. The sheet of collagen membrane material is fixed over a meniscal tear so that the fibrous face is oriented toward the meniscal tear.07-23-2009
20100172954IRRADIATED IMPLANTABLE BONE MATERIAL - A method for making an implantable bone material. The method includes providing a bone composition consisting essentially of demineralized human bone, and irradiating the composition at a temperature less than about 0° C.07-08-2010
20100172951Enhanced Medical Implant - A medical implant comprising in combination a synthetic, biological, or autologous matrix (or scaffold) and pluripotent stem cells derived from human teeth. Stem cells are harvested from the dental pulp of extracted wisdom teeth. After the stem cells are removed, the hard tooth is ground into a base material for the manufacture of a porous matrix bone into which the stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.07-08-2010
20100172955BIODEGRADABLE MATERIAL COMPONENTS - A biodegradable material for use in making items usable in surgery and related fields of medicine. The material comprising a bioabsorbable thermoplastic polymer component and a bioactive filler material. In components made of the material particles of the filler material occur embedded within the surface of the components.07-08-2010
20120213837COMPOSITIONS AND METHODS FOR BIOACTIVE COATINGS TO IMPROVE ALLOGRAFT INCORPORATION - The invention provides compositions and methods useful for treating wounds and enhancing wound healing. The present invention discloses a continuous polymer coating system to provide sustained localized delivery of bioactive agents. The data demonstrate the efficacy of a bioactive coating comprising the polymer PLAGA and the agent FTY720, a selective agonist for sphingosine 1-phosphate receptors, and biologically active derivatives and analogs thereof, for use in wound healing. In vitro drug release studies validated 64% loading efficiency with complete release of compound following 14 days. Mechanical evaluation of healing bone showed significant enhancement of mechanical stability in FTY720 treatment groups. Superior osseous integration across the host-graft interface, significant enhancement in smooth muscle cell investment, and reduction in leukocyte recruitment were evident in FTY720 treated groups. The present invention is useful for enhancing angiogenesis for wound healing.08-23-2012
20110189256REDUCTION OF INFECTION ASSOCIATED WITH MEDICAL DEVICE - Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.08-04-2011
20120213838MEDICAL DEVICE FOR PLACEMENT INTO A LUMEN AND MANUFACTURING METHOD THEREOF - The present invention provides a medical device for placement into a lumen such as a stent and a catheter whose surface is uniformly and sufficiently coated with a drug, and a process thereof with easy way and with low cost. The medical device is coated with mixed particles of drug particles whose surface is modified with positive-charge and biocompatible nanoparticles. In the invention, a drug can be taken into a cell through the dissolution of the drug particle together with the biocompatible nanoparticle after a DES is placed in a biological body.08-23-2012
20120076847MEDICAL INSTRUMENT AND METHOD OF MANUFACTURING THE SAME - A medical instrument and a manufacturing method thereof are provided. The medical instrument includes a biomedical metal layer and a polymer film. The polymer film is a biodegradable polymer material. The manufacturing method includes the following steps: providing the biomedical metal layer, immersing the biomedical metal layer in a polymer solution, performing a baking process on the biomedical metal layer coated with a polymer film, forming the biomedical metal layer coated with the polymer film, taking out the biomedical metal layer coated with the polymer film to fabricate the medical instrument. The biodegradable polymer film and the biomedical metal layer are combined into the medical instrument, so that a physician performs a surgery more easily. In addition, decomposition time of the polymer film can be preset, so as to achieve efficacy of blocking soft tissue cells having a higher growth rate.03-29-2012
20100047313MEDICAL DEVICES HAVING A COATING FOR ELECTROMAGNETICALLY-CONTROLLED RELEASE OF THERAPEUTIC AGENTS - Medical devices having a coating comprising an ionic polymer for electromagnetically-controlled release of a therapeutic agent. Release of the therapeutic agent from the coating is facilitated or modulated by the application of an electromagnetic field to the medical device. Exposure to the electromagnetic field may cause the release of the therapeutic agent in various ways, including electrochemical changes in the ionic polymer, structural changes in the coating and/or ionic polymers, changes in the permeability of the coating, changes in the orientation of the ionic polymers, or motion of the ionic polymers. Also disclosed are methods for delivering a therapeutic agent using electromagnetic fields.02-25-2010
20100047312USE OF BIOACTIVE AND RADIOPAQUE MATERIAL FOR STENT COATING - The invention relates to a stent having a coating or cavity filling comprising or containing an organic Au complex.02-25-2010
20100047315Stent for Increasing Blood Flow to Ischemic Tissues and a Method of Using the Same - Stents and a method of using the stents to increase blood flow to ischemic tissues in a patient are disclosed.02-25-2010
20100047311PROTECTING ALGAE FROM BODY FLUIDS - Apparatus (02-25-2010
20100047309Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods - This application describes apparatuses and methods for musculoskeletal tissue engineering. Specifically, graft collar and scaffold apparatuses are provided for promoting fixation of musculoskeletal soft tissue to bone.02-25-2010
20100047308Production methods of virus inactivated and cell-free body implant - A method is provided for producing a virus-inactivated, acellular implant for the human body, featuring the use of TNBP in combination with a detergent selected from among deoxycholate, SDS, Tween 80, Triton X-100, sodium cholate and combinations thereof for removing cells and viruses simultaneously. Also disclosed are an acellular human body implant produced by the method and a wound healing agent comprising the acellular human body implant.02-25-2010
20100047307INJECTABLE DRUG CARRIER COMPRISING LAYERED DOUBLE HYDROXIDE - Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug.02-25-2010
20100047314FOLINIC ACID DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.02-25-2010
20100272776Device including bone cage and method for treatment of disease in a subject - Devices, methods, and systems are described for controlling pathogenic condition or disease in a subject. Devices are described that include one or more bone cages. The device including one or more bone cages can be configured to include one or more immunogens and one or more adjuvants. The device including one or more bone cages can be configured to, and/or structured to at least partially or completely surround one or more cells or tissues that produce one or more immunogens and/or one or more adjuvants. The device is useful in a method for treating a pathogenic condition or disease in the subject.10-28-2010
20100272778STENTS HAVING CONTROLLED ELUTION - Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.10-28-2010
20100272777OCULAR THERAPEUTIC AGENT DELIVERY DEVICES AND METHDOS FOR MAKING AND USING SUCH DEVICES - Ocular implant devices (10-28-2010
20100008967Bioactive scaffolds - Provided are tissue scaffolds colonized by vertebrate cells expressing a transgenic bioactive molecule, where the vertebrate cells are unable to undergo mitosis. Also provided are methods of growing tissue in a mammal and methods of delivering a transgenic bioactive molecule to a tissue of a mammal, using the tissue scaffolds. Additionally, methods of making the tissue scaffolds are provided.01-14-2010
20100008968METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.01-14-2010
20090169592Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects - Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.07-02-2009
20090068245Porous Laser Sintered Articles - The present invention provides selectively laser sintered porous polymeric articles and methods of making and using the same. In one embodiment, a method of the present invention comprises providing a first layer of particles of a first polymeric material, heating selected locations of the first layer to sinter particles of the first polymeric material to form a three-dimensional article, the three-dimensional article having a porosity of at least about 30 percent.03-12-2009
20090060976Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects - Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and defects resulting from degenerative diseases such as osteochondritis dessicans.03-05-2009
20090060975CONTAINMENT SYSTEM FOR DELIVERY OF BIOLOGICAL PRODUCTS AND METHOD OF SURGERY - Methods and systems for delivering biological products such as bone marrow aspirate (BMA) to different surgical sites during surgery (for example, arthroscopic surgery). The biological product is encapsulated or contained within a containment system comprising a carrier such as collagen carrier. The containment system may be formed of water soluble polymers, either natural, synthetic or semisynthetic, provided into films that may be made or molded into various shapes and sizes, and that may be manipulated to confer specific properties (such as solubility or degradation rates according to a specific environment, for example) of such films. The water soluble films may be processed into capsules, packets or other containers.03-05-2009
20090060974METHODS OF ARTHROSCOPIC OSTEOCHONDRAL RESURFACING - Methods of arthroscopic resurfacing of anatomical tissue utilizing a biological component strengthened with glue or similar material. The biological component is selected from the group consisting of blood, blood components, PRP, bone marrow aspirate (BMA) and autologous conditioned plasma (ACP). The biological component/glue composition may be inserted (by injection and/or by employing a biologic resurfacing mold, for example) into, or in the vicinity of, the anatomical tissue. Upon insertion within, or contact with, the anatomical tissue, the biological component/glue composition is designed to coagulate and solidify (or partially solidify) within minutes, to advance healing or tissue growth of the anatomical tissue. The biological component/glue composition may optionally comprise components such as growth factors, antiseptic chemicals and/or antibiotics and/or electrolytes, or hormones or site-specific hybrid proteins, among others.03-05-2009
20090060972DEVICE AND METHOD FOR CELL GRAFTING - A device for cell grafting is disclosed. The device comprises a compartment enclosed by a semipermeable envelope made at least in part of nonwoven polymer fibers, and at least one inlet port formed in the envelope. The inlet port(s) are accessible from the exterior of the envelope and configured for establishing fluid communication with the compartment.03-05-2009
20120258161IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF DOPAMINE AGONIST - The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.10-11-2012
20120258160CHEMICALLY MODIFIED CELLULOSE FIBROUS MESHES FOR USE AS TISSUE ENGINEERING SCAFFOLDS - Cellulose and sulfated cellulose fibrous meshes exhibiting robust structural and mechanical integrity in water were fabricated using a combination of electrospinning, thermal-mechanical annealing and chemical modifications. The sulfated fibrous mesh exhibited higher retention capacity for human recombinant bone morphogenetic protein-2 than the cellulose mesh, and the retained proteins remained biologically active for at least 7 days. The sulfated fibrous mesh also more readily supported the attachment and osteogenic differentiation of rat bone marrow stromal cells in the absence of osteogenic growth factors. These properties combined make the sulfated cellulose fibrous mesh a promising bone tissue engineering scaffold.10-11-2012
20120082713PHOTOCHROME- OR NEAR IR DYE-COUPLED POLYMERIC MATRICES FOR MEDICAL ARTICLES - The invention provides polymers comprising pendent photochrome or near IR dye groups, as well as polymeric matrices made from these polymers, which can be used as or in association with a medical article. The polymers can be synthesized using methods that facilitate the preparation of medical articles having good biocompatibility. Exemplary polymeric matrices are in the form of lubricious coatings on medical devices, such as catheters. Visualization by irradiation of the photochrome or near IR dye can improve detection of the polymeric matrix on a device or in the body. This, in turn can improve aspects of a medical procedure, such as device insertion or matrix formation, as well as being useful for assessing the quality of the matrix.04-05-2012
20120082712Implantable Polymeric Films - The present disclosure relates to implantable medical devices containing a polymeric film layer containing glycerol and at least one biopolymer.04-05-2012
20090035346Methods and Compositions for Enhancing Vascular Access - Disclosed is an implantable material comprising a biocompatible matrix and cells which, when provided to a vascular access structure, can promote functionality generally. For example, implantable material of the present invention can enhance maturation of an arteriovenous native fistula as well as prolong the fistula in a mature, functional state suitable for dialysis. Additionally, the present invention can promote formation of a functional arteriovenous graft suitable for dialysis as well as promote formation of a functional peripheral bypass graft. Implantable material can be configured as a flexible planar form or a flowable composition with shape-retaining properties suitable for implantation at, adjacent or in the vicinity of an anastomoses or arteriovenous graft. According to the methods disclosed herein, the implantable material is provided to an exterior surface of a blood vessel. Certain embodiments of the flexible planar form define a slot. The materials and methods of the present invention comprise cells, preferably endothelial cells or cells having an endothelial-like phenotype.02-05-2009
20090017090DEVICES AND METHODS FOR DELIVERING ACTIVE AGENTS TO THE OSTEOMEATAL COMPLEX - Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.01-15-2009
20090017091STERILE HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS - The present application provides sterile hyaluronic polymer compositions than are useful, e.g., as medical devices, biomedical adhesives, and sealants. Generally, provided are sterile dry compositions comprising a thiol-derivatized hyaluronic acid and one or more stabilizing excipients. Also provided are related kits and methods. The compositions described herein are particularly robust to sterilizing irradiation, and substantially maintain both their molecular weight and gelation parameters such as gelation time after sterilization, such that such sterile compositions are capable of hydrogel formation.01-15-2009
20090017089Multiple active agents such as anthelmintics sustained release delivery device - A method of treating animals characterised by the step of introducing to the animal a single delivery device containing two or more active agents, wherein the delivery device is configured to release an effective amount of active agents over a defined time period of 3-14 days.01-15-2009
20110123593SELF-FIXATING SCAFFOLDS - A self-fixating scaffold delivers therapeutic material to tissue for treating various diseases/conditions. A scaffold holds the therapeutic material and is implanted into the tissue. A fixation element anchors the scaffold in the tissue making the scaffold less likely to become dislodged.05-26-2011
20110123592Biomaterials - The invention relates to a biomaterial having a latent form of a growth factor immobilised thereon, and to a method of producing the biomaterial, comprising immobilising the latent form of the growth factor on the biomaterial. The biomaterial may be used in medicine, such as in tissue regeneration or repair.05-26-2011
20120231061LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE-BASED POLYMERS AND THEIR MANUFACTURE - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.09-13-2012
20100255052INTEGRATED IMPLANT SYSTEM (IIS) BIOCOMPATIBLE, BIODEGRADABLE AND BIOACTIVE, COMPRISING A BIOCOMPATIBLE STERILE POROUS POLYMERIC MATRIX AND A GEL, INTEGRATING IN SITU THE TRIDIMENSIONAL MATRIX STRUCTURE - The present invention refers to an Integrated Implant System constituted as a gel-matrix-cells integrated system, that allows providing implants in a brief time period, for covering a great skin extension to be treated, with a successful acceptance in patients with burns, chronic damage or wound skin, needing of a skin grafting.10-07-2010
20080299172TISSUE REPAIR IMPLANT - An implant is formed from a sheet material and a plurality of microparticles. The sheet may be coated with a mixture of collagen and PMMA beads. The implant may be used to treat many types of defects, including hernias, skin defects, tendon defects, and ulcers. A biocompatible alloplastic mesh implant is stronger and more resistant to infection than typical mesh implants.12-04-2008
20080299171GROWTH FACTOR MODIFIED EXTRACELLULAR MATRIX MATERIAL AND METHODS FOR PREPARATION AND USE THEREOF - Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients.12-04-2008
20080299169Topographical Templating of Polymeric Materials Using Cellular Morphology - Substrates for influencing the organization, spreading or adhesion of a selected cell to induce or stimulate growth, differentiation or regeneration of the cell or of tissue constituting the cells are provided as well as methods of making such substrates and methods of using such substrates.12-04-2008
20080299168Stabilized Polymeric Delivery System - The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent.12-04-2008
20080299167Vascular Endothelial Growth Factors And Methods Of Their Use - Vascular endothelial growth factor alternative splice variants and methods of their use are provided.12-04-2008
20120263778POLYURETHANE UREA FOR STENT COATINGS - The invention relates to a polyurethane urea comprising structural units of formula (I), not terminated by at least one copolymer unit of polyethylene oxide and polypropylene oxide, and that can particularly be used for producing stent coatings. The invention further relates to a substrate having a base coating made of a polyurethane urea according to the invention. The invention further relates to a coating structure comprising at least one layer comprising active substances and made of a polyurethane urea according to the invention, and at least one layer free of active substances, made of a polyurethane urea according to the invention. The invention finally relates to a method for coating a substrate, wherein at least one layer made of a polyurethane urea according to the invention is applied to the substrate.10-18-2012
20110002974RANDOM AND NON-RANDOM ALKYLENE OXIDE POLYMER ALLOY COMPOSITIONS - A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homopolymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.01-06-2011
20110002973MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITION - The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.01-06-2011
20120328686Pharmaceutical Composition Comprising miRNA-100 And Its Use in the Modulation Of Blood Vessel Growth and Endothelial Inflammation - Disclosed is a pharmaceutical composition comprising a miRNA-100 molecule or an antagomir thereof or a variant thereof for use as a medicament for the positive or negative modulation of blood vessel growth and vascular inflammation wherein the miRNA-100 or the miRNA antagomir has a homology of at least 85% to any of SEQ ID NO:1, 2, 3 and/or 9.12-27-2012
20100233230SOL-GEL NANOSTRUCTURED TITANIA RESERVOIRS FOR USE IN THE CONTROLLED RELEASE OF DRUGS IN THE CENTRAL NERVOUS SYSTEM AND METHOD OF SYNTHESIS - The invention is related to a sol-gel nanostructured titania reservoir and its synthesis which is biocompatible with brain tissue. The pore size distribution, crystallite size and the extent of the crystalline phase distribution of anatase, brookite and rutile can be fully controlled. This device may be used to contain neurological drugs. It may be inserted directly into brain tissue for the purpose of the controlled time release of drugs over a period of from 6 months to three years.09-16-2010
20100233232FATTY-ACID BASED PARTICLES - The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.09-16-2010
20110038911PROSTHETIC MATERIAL FOR LIVING ORGAN - It is an object of the invention to provide a prosthetic material for living organs, which can sufficiently withstand the arterial pressure and thereby can prevent leakage of blood or rupture of blood vessels, and which serves as a scaffold for vascular tissue regeneration, and does not necessitate repeated surgeries or the like.02-17-2011
20110038910ANTI-INFECTIVE ANTIMICROBIAL-CONTAINING BIOMATERIALS - Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of loading them with silver compounds are described. The silver-containing biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more anti-infective agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.02-17-2011
20110045054MATERIALS AND METHODS FOR TREATING AND MANAGING PLAQUE DISEASE - Disclosed herein are materials and methods suitable for treating and managing plaque disease, including vulnerable plaque. An implantable material comprising cells, such as but not limited to endothelial cells, and a biocompatible matrix can reduce progression or deterioration of a plaque-associated lesion situated on the interior lumen of said blood vessel. The implantable material is implanted directly on an exterior surface of a blood vessel at or adjacent or in the vicinity of the site of a lesion on an interior lumen. Alternatively, the implantable material is deposited on an exterior surface at or adjacent or in the vicinity of the site of a lesion on an interior lumen by an intraluminal delivery device which traverses or penetrates the vessel wall or by a percutaneous delivery device which enters the perivascular space. Both modes of administration can be preceded by or coincident with an imaging step. The present invention can treat hemorrhage, erosion, fissure, plaque-associated thrombosis and occlusion, rupture, displacement and/or dislodgement of a plaque lesion.02-24-2011
20110045051EXTRACELLULAR MATRIX COMPRISING PLATELET FACTORS - The present invention describes an extracellular matrix comprising human platelet derived growth factors, that permits the maximising of therapeutic efficacy, combining the benefits of both components, to result in a more efficient and rapid integration of the matrix up to the structurally organised reconstruction of the neoformed tissue “in vivo”02-24-2011
20110045050NANOEMULSION FORMULATIONS FOR DIRECT DELIVERY - A nanoemulsion and corresponding methods of making and using systems of single or blended high HLB value surfactant(s) for the emulsification of single or blended oils and vitamin E components in an aqueous phase are provided. The resulting nanoemulsions and methods of administering the nanoemulsions, including a corresponding kit, provide delivery of the nanoemulsions to a patient.02-24-2011
20110045049IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE - This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.02-24-2011
20090208552CROSS-LINKED FATTY ACID-BASED BIOMATERIALS - Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.08-20-2009
20110223232 DRUG-RELEASE COMPOSITION HAVING A THERAPEUTIC CARRIER - The invention is generally directed to a drug-release composition that contains drug-linker-drug compound that is combined with another therapeutic agent that can be an antirestenotic agent. The therapeutic agent can be partially bound to the drug-linker-drug compound, miscible with the drug-linker-drug compound, combined with the drug-linker-drug compound at various ratios, and tuned to control the release of drugs to a tissue in need thereof.09-15-2011
20100247605Three Dimensional Cell Protector/Pore Architecture Formation for Bone and Tissue Constructs - Living cellular material is encapsulated or placed in a protective material (cell protector) which is biocompatible, biodegradable and has a three-dimensional form. The three dimensional form is incorporated into a matrix that maybe implanted in vivo, ultimately degrade and thereby by replaced by living cell generated material.09-30-2010
20110236456IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs.09-29-2011
20110236455Novel Regulators of the Innate Immune System - The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H. In a further aspect, the present invention focuses on providing monoclonal antibodies which specifically detect CFHR proteins, and on the use thereof in methods of determining CFHR in body fluids. These methods are particularly suitable for diagnosing inflammatory diseases.09-29-2011
20100233239Templated islet cells and small islet cell clusters for diabetes treatment - A scaffold having islet cells or small islet cell clusters attached thereto in a multilayer, and a micro-mold having divots for culturing islets, wherein islet formation is influenced by the shape and dimensions of the divots are disclosed.09-16-2010
20100233238Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery - According to an aspect of the present invention, implantable or insertable medical devices are provided which contain (a) one or more depressions that contain at least one therapeutic agent, and (b) a nanoporous coating, disposed over the therapeutic-agent-containing depressions, which regulate transport of species between the therapeutic-agent-containing depressions and the exterior of the device. The implantable or insertable devices are configured to preform a role beyond mere drug delivery, for example, providing mechanical and/or electrical functions within the body, among other functions. An advantage of the present invention is that medical devices may be provided, which release therapeutic agents in quantities far exceeding the void volume within the nanoporous coating, while at the same time providing functionality that extends beyond drug delivery. Such release may further approach or achieve a zero order kinetic drug release profile.09-16-2010
20100233237METHOD AND DEVICE FOR ELECTROCHEMICAL FORMATION OF THERAPEUTIC SPECIES IN VIVO - A device and method are provided for spontaneous electrochemical production of therapeutic species, in vivo. An active metal is implanted in the tissue. The metal undergoes corrosion, thus acting as a reducing agent to constituents in the tissue, so as to cause these constituents to form the therapeutic agents.09-16-2010
20100233231USE OF CRYOGENIC PROCESSING TO OBTAIN A SUBSTANTIALLY-THICKENED FORMULATION - The present invention related to substantially-thickened therapeutic formulation comprising an oil-based composition and a therapeutic agent, wherein the therapeutic agent is of a reduced particle size.09-16-2010
20110250255DRUG COATED STENT WITH ENDOSOME-DISRUPTING CONJUGATE - A stent is provided with a drug-eluting layer disposed on at least a portion of its surface, wherein the drug-eluting layer comprises an endosome-disrupting agent and a pharmaceutical agent. In an embodiment, the endosome-disrupting agent, when taken up through endocytosis into living cells, causes lysis of endosomes containing the endosome-disrupting agent. The pharmaceutical agent can accompany the endosome-disrupting agent into the living cells.10-13-2011
20110293687HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.12-01-2011
20080220045Self-setting polymeric cyanoacrylate composites - Self-setting, absorbable bioactive polycyanoacrylate-based composites include at least one inorganic phosphate salt or a combination of at least one inorganic phosphate salt and calcium silicate in a cyanoacrylate matrix. The composites can be reinforced with single- or multicomponent absorbable, warp-knitted mesh, thus producing a broad range of absorbable, bioactive biomaterials suitable for use not only as preferred absorbable alternatives to the commercial non-absorbable polymethyl methacrylate bone cements, but also for repairing or replacing cranial and maxillofacial bone defects and other complex defects through guided bone regeneration.09-11-2008
20100215713SCAFFOLDS FOR FOLLICLE TRANSPLANTATION - The present invention provides for a device comprising a scaffold composition, a bioactive composition and a bio-in-hibiting composition, wherein said bioactive and bio-inhibiting compositions are incorporated into or coated onto said scaffold composition, wherein said scaffold composition temporally supports survival and growth of resident follicles, migration and multiplication of stroma cells and spreading and organization of endothelial cells and new vessels wherein said bioactive composition regulates development of a resident follicle, formation of new blood vessels and chemoattraction and proliferation of stroma cells and wherein the bio-inhibiting composition regulates inhibition of the development of a second resident follicle. The presence of the bio-inhibiting composition within the scaffold is involved in the quiescence of the follicles in the primordial stage, which is important to restore fertility.08-26-2010
20100215717ENDOTHELIAL SCAFFOLDS - Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy).08-26-2010
20100215715GEL DELIVERY SYSTEM FOR TISSUE REPAIR - The present invention discloses methods and compositions comprising a biocompatible gel that is used in tissue repair and regeneration. Once the gel is administered to a tissue site in need of repair or regeneration, the cells migrate from the gel into the tissue and repair or regenerate the tissue.08-26-2010
20100215714TREATMENT OF STROKE AND OTHER ACUTE NEURAL DEGENERATIVE DISORDERS USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.08-26-2010
20100215711STABILIZED ENZYME COMPOSITIONS - A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).08-26-2010
20100215710Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing - Methods for increasing rate of healing of wounds in epithelial tissues by administration of beta-2 adrenergic receptor antagonists to target patients are provided. Methods for decreasing cell growth around implanted devices and methods for decreasing wound contraction by administration of beta-2 adrenergic receptor agonists are also provided. Pharmaceutical compositions and kits including beta-2 adrenergic receptor agonists and antagonists are described, as are devices coated with beta-2 adrenergic receptor agonists.08-26-2010
20100215712BLOOD VESSEL STENT OF AMIDOGLUCOSAN POLYSACCHARIDE LOADED WITH CD133 ANTIBODY AND ITS PREPARATION METHOD - A blood vessel metal stent coating of amidoglucosan polysaccharide loaded with antibody comprises carrier material composed of chitosan and inartificial degradable acidic amidoglucosan polysaccharide and the effective dose of CD133 antibody loaded in the carrier material. The blood vessel metal stent coating is manufactured with self-assemble method to fix the CD133 antibody in the carrier material of the coating. The coating has good biocompatibility, water retention property, flexibility, flush resistance and bio-stability, and can specifically capture the vascular endothelial progenitor cells in human peripheral blood, and differentiate into vascular endothelial cells. The process would accelerate endothelialization to repair injured vessel caused and prevent restenosis and thrombosis efficiently.08-26-2010
20090220570Axon Regeneration with PKC Inhibitors - Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.09-03-2009
20090220567Pure Populations of Astrocyte Restricted Precursor Cells and Methods for Isolation and Use Thereof - An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided.09-03-2009
20120100200System And Method For Satellite Drug Delivery - The present disclosure is directed to an implantable repository including a housing comprising at least one bioactive agent and at least one attachment member coupled to the housing, the at least one attachment member configured to couple the implantable repository to at least one of a medical device and a tissue surface.04-26-2012
20100226957Protein-Based Artificial Retinas - Multilayer protein films are provided, which comprise native bacteriorhodopsin and/or specialized bacteriorhodopsin mutants as the photoactive element. Also provided are artificial subretinal and epiretinal implants carrying such bacteriorhodopsin films, as well as methods for making and using the same, for example, to treat retinal diseases and conditions.09-09-2010
20100221303Method for Preparing Porous Scaffold for Tissue Engineering, Cell Culture and Cell Delivery - The present invention relates to a method for preparing a porous scaffold for tissue engineering. It is another object of the present invention to provide a porous scaffold obtainable by the method as above described, and its use for tissue engineering, cell culture and cell delivery. The method of the invention comprises the steps consisting of: a) preparing an alkaline aqueous solution comprising an amount of at least one polysaccharide, an amount of a cross-linking agent and an amount of a porogen agent b) transforming the solution into a hydrogel by placing said solution at a temperature from about 4° C. to about 80° C. for a sufficient time to allow the cross-linking of said amount of polysaccharide and c) submerging said hydrogel into an aqueous solution d) washing the porous scaffold obtained at step c).09-02-2010
20100209471MEDICAL DEVICES HAVING POLYMERIC NANOPOROUS COATINGS FOR CONTROLLED THERAPEUTIC AGENT DELIVERY AND A NONPOLYMERIC MACROPOROUS PROTECTIVE LAYER - An implantable or insertable medical device is provided which contains the following: (a) a substrate, (b) a therapeutic agent-containable region disposed over the substrate, (c) a nanoporous polymeric layer disposed over the therapeutic agent-containable region and (d) a macroporous non-polymeric layer disposed over the nanoporous polymeric layer. The nanoporous polymeric layer largely regulates transport of species between the therapeutic agent-containable region and the exterior of the device. The macroporous non-polymeric layer has a larger pore size than the nanoporous polymeric layer and largely serves to isolate the polymeric material from surrounding tissue during in-situ delivery of the therapeutic agents.08-19-2010
20090081274MAST CELL-DERIVED RENIN - The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that involve inhibiting the synthesis and/or release of renin from mast cells and/or inhibiting the activity of renin after release from mast cells. The methods of the invention can also involve inhibiting elements of the local renin-angiotensin system (e.g. inhibiting ACE and angiotensin II receptors), thereby inhibiting angiotensin II produced locally from mast-cell-derived renin03-26-2009
20100203100ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE - An antimicrobial accessory may include a pressure sensitive adhesive and an antimicrobial mixed in the pressure sensitive adhesive. In some examples, an antimicrobial accessory may include at least one first domain comprising a pressure sensitive adhesive and a first antimicrobial and at least one second domain including a second polymer and a second antimicrobial. The antimicrobial accessory may be configured to be attached to a housing of an implantable medical device (IMD).08-12-2010
20090324680NANOFIBER-REINFORCED COMPOSITION FOR APPLICATION TO SURGICAL WOUNDS - A nanofiber-reinforced composition suited to applying to a wound site in a human body includes a carrier liquid and nanofibers dispersed therein. The viscosity of the composition is such that it is able to be applied through a tube yet adhere proximate the wound site to provide a barrier layer which assists in healing of the wound by spacing it from neighboring organs.12-31-2009
20110159071Isolation and Identification of Glycosaminoglycans - The isolation and identification of glycosaminoglycans capable of binding to proteins having a heparin-binding domain is disclosed, as well as the use of the glycosaminoglycans isolated in the growth and/or development of tissue.06-30-2011
20110159070BIOMATERIALS AND IMPLANTS FOR ENHANCED CARTILAGE FORMATION, AND METHODS FOR MAKING AND USING THEM - The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.06-30-2011
20110159069Medical Implants and Methods of Making Medical Implants - A medical implant device having a substrate with an oxidized surface and a silane derivative coating covalently bonded to the oxidized surface. A bioactive agent is covalently bonded to the silane derivative coating. An implantable stent device including a stent core having an oxidized surface with a layer of silane derivative covalently bonded thereto. A spacer layer comprising polyethylene glycol (PEG) is covalently bonded to the layer of silane derivative and a protein is covalently bonded to the PEG. A method of making a medical implant device including providing a substrate having a surface, oxidizing the surface and reacting with derivitized silane to form a silane coating covalently bonded to the surface. A bioactive agent is then covalently bonded to the silane coating. In particular instances, an additional coating of bio-absorbable polymer and/or pharmaceutical agent is deposited over the bioactive agent.06-30-2011
20130022660DRUG DELIVERY SYSTEM FOR THE PREVENTION OF CEREBRAL VASOSPASM - The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm.01-24-2013
20080254091Multi-Layered Antiadhesion Barrier - The present invention relates to a multi-layered anti-adhesion barrier, particularly to a multi-layered anti-adhesion barrier comprising a nanofibrous structured base layer electrospun from a hydrophobic, biodegradable, biocompatible polymer and a polymer layer formed by coating a hydrophilic, biooriginated polymer on the base layer, and a method for the preparing the same. The multi-layered anti-adhesion barrier of the present invention can solve the problems of the conventional gel, solution, sponge, film or nonwoven type anti-adhesion systems, including adhesion to tissues or organs, flexibility, physical strength, ease of handling (ease of folding and bending), etc., offers improved user convenience. With a nanofibrous structure, the multi-layered anti-adhesion barrier of the present invention effectively blocks the infiltration or migration of blood and cells and promotes the healing of wounds. It is not torn or broken when folded or rolled and can be easily handled using small surgical instruments. Thus, it can minimize a foreign body reaction when used in various surgical operations.10-16-2008
20080248082METHOD OF TREATING INJURED CARDIAC TISSUE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is disclosed.10-09-2008
20080248079TISSUE AUGMENTATION DEVICES AND METHODS - Tissue augmentation devices, as well as methods of manufacturing and using the same, are disclosed. In certain embodiments, a tissue augmentation device comprises an elongate tissue penetrating member and an amount of remodelable material, wherein at least a portion of the elongate member is cannulated, and at least a portion of the amount of material is received within at least a portion of the cannulated portion of the elongate member. The elongate tissue penetrating member may provide at least one deformation that is configured to constrict portions of the amount of remodelable material received within the elongate member. In alternate embodiments, a flexible covering over an implantable biomaterial provides protection and allows an easier delivery of the biomaterial to a tissue tract.10-09-2008
20080241214Hydrogel-metal assembly - A hydrogel-metal assembly is provided. An intervening polymer network is used to bond together a water-swollen hydrogel layer and a biocompatible surface-modified metallic layer. The hydrogel layer is a water-swollen hydrogel layer of at least two interpenetrating polymers. The surface of the biocompatible surface-modified metallic layer is surface-modified with an inorganic material. The intervening polymer network has been chemically grafted to the inorganic material of the biocompatible surface-modified metallic layer through bi-functional linker molecules. The intervening polymer network is further physically or chemically cross-linked with the polymers of the water-swollen hydrogel. The hydrogel-metal assembly can be adapted to form a medical device, medical implant, an artificial implant, an orthopedic implant, or at least as part of a joint. The hydrogel-metal assembly is attractive for use as such implants or devices due to its characteristics such as, for example, low coefficient of friction, impact-absorption capacity or strength, and/or biocompatibility.10-02-2008
20080241213METHOD OF PREPARATION OF BIOABSORBABLE POROUS REINFORCED TISSUE IMPLANTS AND IMPLANTS THEREOF - A biocompatible tissue implant. The tissue implant may be bioabsorbable, and is made from a biocompatible polymeric foam. The tissue implant also includes a biocompatible reinforcement member. The polymeric foam and the reinforcement member are soluble in a common solvent.10-02-2008
20080241210WOUND HEALING AGENT AND COMPOSITION - The present invention relates to a wound-treating agent and to a composition for the treatment of wounds comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or of a polypeptide having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:2.10-02-2008
20080233165Time release calcium sulfate and growth factor matrix for bone augmentation - A bone-growth stimulating composition for forming a resorbable implant, methods for making such a composition and a corresponding putty/paste material. In some embodiments of the invention, such a material includes a plurality of particles having a predetermined size and comprising a first calcium sulfate compound, a resorbable polymer in a predetermined weight ratio and a growth factor.09-25-2008
20080233164Polymer for Use in Conduits, Medical Devices and Biomedical Surface Modification - A copolymer comprising (a) one or more pendant group segments and (b) one or more polyol segments, each of said segments being linked to one or more further segments which may be the same or different,09-25-2008
20080226691BONE CEMENT COMPOSITIONS HAVING FIBER-REINFORCEMENT AND/OR INCREASED FLOWABILITY - The present invention relates in general to implantable compositions, and method for preparing same, containing a calcium salt-containing component, optionally demineralized bone, a plurality of discrete fibers, optionally a flow additive, and optionally continuous reinforcing fibers or an array of organized fibers in the form of mesh. Advantageously, the discrete fibers have a specific aspect ratio (length/diameter) from about 50:1 to about 1000:1. The addition of a small amount of discrete fibers and/or the continuous reinforcing fibers or fiber mesh can cause drastic increases in certain mechanical properties including flexural strength, flexural toughness, and/or screw pullout strength.09-18-2008
20080226690Heparosan-based biomaterials and coatings and methods of production and use thereof - The presently claimed and disclosed invention relates to biomaterial compositions that include an isolated heparosan polymer. The presently claimed and disclosed invention also relates to kits containing such biomaterial compositions, as well as to methods of producing such biomaterial compositions. The presently claimed and disclosed invention further relates to methods of using such biomaterial compositions as surface coatings for implants as well as for augmenting tissues.09-18-2008
20080226689Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×1009-18-2008
20080226688Ceramic composition for filling bone defects - The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35.09-18-2008
20090311299ANTITHROMBOTIC COATING FOR DRUG ELUTING MEDICAL DEVICES - Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.12-17-2009
20080220039Thin Film Medical Devices Manufactured on Application Specific Core Shapes - A method for creating three-dimensional, unitary, thin film medical devices for implantation within a human subject is provided, along with a method for creating pores within such thin film devices. Using known sputtering methods, a film material is implanted on a core or combination of cores having an advanced threedimensional geometry, then the core is removed from the finished thin film device. The core may be provided with raised features at portions which are to be removed from the thin film device. Once the film has formed on the core, the portions of the film overlying the raised portions may be removed using mechanical means, such as grinding. Additionally, a kit can be provided having a plurality of the described thin film devices which may be used together for advanced surgical procedures.09-11-2008
20120251609DEMINERALIZED CANCELLOUS BONE MATRIX - A demineralized cancellous bone matrix comprising a cancellous bone matrix that has been demineralized is described herein. The demineralized cancellous bone matrix is rigid and has certain dimensions, including a certain length. Implants comprising at least one demineralized cancellous bone matrix are also described. Also disclosed are methods for treating bone having a void or defect in a patient using at least one demineralized cancellous bone matrix. In addition, methods of making a demineralized cancellous bone matrix are disclosed.10-04-2012
20080213332Cells Isolated from Placenta, Device for Isolating Same, and Uses Thereof - A method of processing an organ is disclosed. The method comprises: (a) placing an organ in a sealable container; (b) disrupting the structure of said organ to yield a cell suspension; and (c) transferring said cell suspension to a sealable cell-suspension storage container, thereby isolating cells of said organ, wherein said sealable container, wherein said disrupting and said transferring are all performed substantially in a continuous vessel.09-04-2008
20130095164SOL-GEL NANOSTRUCTURED TITANIA RESERVOIRS FOR USE IN THE CONTROLLED RELEASE OF DRUGS IN THE CENTRAL NERVOUS SYSTEM AND METHOD OF SYNTHESIS - The invention is related to a method of administering a controlled release central nervous system drug by means of sol-gel nanostructured titania reservoir comprising silica, titania and silica-titania, and comprising partially hydrodyzed nano-materials. This reservoir may be in the form of a xerogel.04-18-2013
20130115264IMPLANTABLE RASAGILINE COMPOSITIONS AND METHODS OF TREATMENT THEREOF - A method of treating the symptoms of Parkinson's disease comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of rasagiline to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes rasagiline hemitartrate and optionally, a sorption enhancer.05-09-2013
20130171229IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE - The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.07-04-2013
20080206302Cell-Free Graft - The invention proposes a cell-free graft, comprising (i) a cohesive, structure-forming matrix with open porosity made from a biologically and pharmaceutically acceptable material and (ii) serum.08-28-2008
20110217351COATING FOR MEDICAL IMPLANTS - A medical implant for drug delivery comprising an inner layer of polymer material including a drug dispersed therein and an outer layer which may then mediate the release of the drug in a controllable manner. The outer layer may adhere and/or penetrate the underlying layer and offer a protective coating along with improved mechanical strength along with the ability to hydrate and become permeable to water and allow for drug release.09-08-2011
20090317441BIOENGINEERED TISSUE CONSTRUCTS AND CARDIAC USES THEREOF - Cultured tissue constructs comprising cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention are prepared in defined media, that is, without the addition of chemically undefined components. These tissue constructs are used to repair cardiac tissues.12-24-2009
20110212153COMPOSITE COATINGS AND DEPOSITION METHODS - Provided in part herein are methods for preparing coated support materials and medical implants. Also provided in part herein are coated support materials and medical implants. Provided also in part herein are methods for treating injuries using coated support materials and medical implants.09-01-2011
20080199509Methods and Compositions for the Disruption of Biofilms - The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.08-21-2008
20080199508Immobilized Bioactive Hydrogel Matrices as Surface Coatings - The present invention is directed to a stabilized bioactive hydrogel matrix coating for substrates, such as medical devices. The invention provides a coated substrate comprising a substrate having a surface, and a bioactive hydrogel matrix layer overlying the surface of the medical device, the hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component, the first and second high molecular weight components each being selected from the group consisting of polyglycans and polypeptides, wherein at least one of the first and second high molecular weight components is immobilized (e.g., by covalent cross-linking) to the surface of the substrate.08-21-2008
20080199507Therapeutic Polymeric Pouch - An implantable or surface-applied device comprising a porous polymeric pouch containing a therapeutic polymer sealed in the pouch, to provide a localized therapeutic effect at the site of the application. The pores in the polymeric pouch being smaller than the therapeutic polymer, allowing body fluid to enter and exit the pouch and interact with the therapeutic polymer in the pouch in use, but not permitting the therapeutic polymer to leave the pouch.08-21-2008
20080199506Coating of the Entire Surface of Endoprostheses - The present invention relates to methods for coating the entire surface of lattice-like or mesh-like endoprostheses, wherein the endoprostheses initially are being provided with a thin layer covering the material surface of the endoprosthesis and subsequently, the surface of the entire endoprosthesis is being coated, wherein said coating of the entire surface covers the struts as well as the interstices between the individual struts.08-21-2008
20080199505Local Gene Therapy with an Eluting Stent for Vascular Injury - The present invention relates to a method for preventing or treating stenosis or restenosis in subjects by placement of a polymerized support delivering a recombinant adeno or adeno-associated vector with a mutant Ras nucleic acid encoding a mutant Ras protein which inhibits Ras-mediated phosphorylation, and blocking the Ras signal transduction pathway in vascular smooth muscle cells (VSMCs).08-21-2008
20080199504Dynamers for therapeutic agent delivery applications - Dynamers for use in therapeutic agent delivery systems are disclosed.08-21-2008
20110229547PROCESS FOR PRODUCING INORGANIC INTERCONNECTED 3D OPEN CELL BONE SUBSTITUTES - The present invention relates to a process of using a heat responsive mixture to produce inorganic interconnected 3D open-cell bone substitutes which can be applied in the orthopedic or dental field for treatment of bone damage. The invention provides a simple and easily-controlled process of preparing porous inorganic bone substitute materials.09-22-2011
20100062036Multiblock Copolymers with Shape-Memory Properties - The invention is directed to a multiblock copolymer with shape memory properties and a synthetic precursor of the multiblock copolymer 1. The multiblock copolymer contains: (i) a poly(depsipeptide) segment with an average molecular weight M03-11-2010
20100015199METHOD FOR SUPPRESSING GENERATION OF A TERATOMA - The present invention provides a method for suppressing generation of a teratoma of an undifferentiated cell, preferably an ES cell. A biological material obtainable by the method and a therapeutic method for transplanting the biological material into a subject are also provided.01-21-2010
20100297210REPAIR AND TREATMENT OF BONE DEFECT USING AGENT PRODUCED BY CHONDROCYTES CAPABLE OF HYPERTROPHICATION AND SCAFFOLD - The present invention provides a composite material for promoting or inducing osteogenesis in a biological organism. The composite material includes: A) an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a biocompatible scaffold. The present invention also provides a method of producing this composite material and a method of promoting or inducing osteogenesis in a biological organism.11-25-2010
20100285086Biomimetic Extracellular Matrices - The present invention is directed to hydrogel compositions for biotechnology applications. Specifically, the invention provides hydrogels mimicking the ECM and uses thereof.11-11-2010
20090297576Local Delivery of PAR-1 Antagonists to Treat Vascular Complications - Described herein are methods and medical devices used to deliver bioactive agents locally to patients in need of treatment and/or prevention of cardiovascular conditions Local delivery of protease-activated receptor 1 (PAR-1) antagonists are described herein from implantable medical devices including, but not limited to, stents.12-03-2009
20100303883POLYMERIC DRUG DELIVERY SYSTEMS AND THERMOPLASTIC EXTRUSION PROCESSES FOR PRODUCING SUCH SYSTEMS - Implants are disclosed for delivery of therapeutic agents such as opioids and the manufacture and uses of such implants.12-02-2010
20100310626ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION - A method of promoting bone regeneration in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of Erythropoietin and Fibronectin, thereby promoting bone regeneration in the subject, (i) wherein the therapeutically effective amount of the Erythropoietin is selected from the group consisting of: about 1-50 mg/Kg for systemic administration; and about 0.1-50 mg/ml for local administration, and (ii) wherein the therapeutically effective amount of the Fibronectin is selected from the group consisting of: about 100-1000 mg/ml for systemic administration; and about 50-500 mg/ml for local administration.12-09-2010
20100316688METHODS FOR CULTURING STEM AND PROGENITOR CELLS - The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells.12-16-2010
20110274738FUNCTIONALIZED CHEMICALLY INERT POLYMERS FOR COATINGS - Provided herein are methods for functionalizing a polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.11-10-2011
20110274737IMPLANTABLE MATERIALS HAVING ENGINEERED SURFACES AND METHOD OF MAKING SAME - An implantable biocompatible material includes one or more vacuum deposited layers of biocompatible materials deposited upon a biocompatible base material. At least a top most vacuum deposited layer includes a homogeneous molecular pattern of distribution along the surface thereof and comprises a patterned array of geometric physiologically functional features.11-10-2011
20130156840IMPLANTABLE INTRAOCULAR DRUG DELIVERY APPARATUS, SYSTEM AND METHOD - The present invention relates to an apparatus, system and method for, and for providing, intraocular delivery of an active agent. The apparatus, system and method may include an implantable scaffold and an active agent associated with the implantable scaffold. The implantable scaffold and the active agent may be configured to be completely contained within the eye upon implantation. The implantable scaffold may be a mechanical scaffold, or the implantable scaffold may be a chemical scaffold.06-20-2013
20080317813Nanobead releasing medical devices - Medical devices comprising nanobeads encapsulating one or more bioactive agents and methods of use thereof are provided.12-25-2008
20110311605Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings - Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.12-22-2011
20130189340NITRIC OXIDE DELIVERY SYSTEM USING THERMOSENSITIVE SYNTHETIC POLYMERS - A donor capable of controlled release of nitric monoxide and a prosthetic implant whose surface is coated with this donor are disclosed. The donor comprises a main chain of an organic polymer and a side chain that is covalently linked to the main chain and has a diazeniumdiolate functional group. The donor for controlled release of nitric monoxide exists in a fluid state such as liquid at room temperature and undergoes a sol-to-gel phase transition at a physiological pH as the temperature increases above the critical temperature. The critical temperature of the phase transition is in the range of 25 to 35° C., and the gel is a hydrogel without chemical cross-links.07-25-2013
20090041823Agent-releasing Vascular Prosthesis - The invention relates to a prosthesis comprising a proximal and a distal end and a hollow space that extends there-between. Said prosthesis is provided with a support structure and at least one biologically active compound.02-12-2009
20120027834METHODS OF TREATMENT WITH SYK INHIBITORS - The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.02-02-2012
20090117169Methods and compositions for regulating proliferation and migration of vascular smooth muscle cells - Provided is an extracellular domain of a mammalian Fat1 (Fat105-07-2009
20120093909Ceramic Coatings and Applications Thereof - In one aspect, the present invention provides coated metal substrates which, in some embodiments, demonstrate one or more advantageous chemical and/or mechanical properties.04-19-2012
20130209537CONTROLLED-RELEASE ANTIBIOTIC NANOPARTICLES FOR IMPLANTS AND BONE GRAFTS - The present invention relates to the preparation and use of antibiotic-containing nanoparticles for coating an implant including cranial implants and bone graft sites to provide for the extended release of antibiotics to treat infection.08-15-2013